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Chapter 1 
 
 
 
GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General Introduction 
 
 
Outline  
 
The main focus of this thesis is about the use of engineered bacterial P450 mutants as 
biocatalytic tools for regio-and stereoselective hydroxylation of fine chemicals, 
steroids and drugs as well as a bioactivation system for the generation of reactive 
metabolites. The present chapter gives a general introduction to the various scientific 
aspects covered in this thesis as outlined below. 
 
 
 Regio-and stereoselective hydroxylation 
 Oxidizing enzymes in biocatalysis 
 Cytochrome P450 Monooxygenases (classification and catalytic cycle) 
o Human cytochrome P450s  
o Microbial cytochrome P450s  
 Protein engineering methods 
 Engineering substrate specificity and selectivity of P450 BM3 
 In vitro and in vivo product formation 
 Microbial steroid oxidation 
 Enzymatic drug metabolite synthesis 
 Bioactivation of drugs and role in adverse drug reactions 
o Generation and characterization of reactive metabolites 
 Role of glutathione-S-transferases in the detoxification of reactive drug 
metabolites 
 Aim and scope of this thesis 
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Regio-and stereoselective hydroxylation 
 
Selective oxidation of unactivated C-H bonds poses as one of the most challenging 
reactions in organic chemistry (1, 2). During the past two decades, considerable 
progress has been witnessed in the development of chemical strategies for 
  Ϋ bonds involving the use of oxidizing agents, biomimetic 
supramolecular complexes or transitions metal catalysts. The combined use of 
directing groups and transition metal catalysts, for example, has provided a way to 
favor the oxidation of sp3 Ϋs located in proximity of a directing functionality 
(3-7).  In spite of these advances, the control of oxidation selectivity by chemical 
means is still challenging.  
 
An overview of the use of redox biocatalysts in industrial applications (Figure 1) 
showed that enantioselective oxyfunctionalizations such as hydroxylation and 
epoxidation reactions comprise an important part of the enzymatic processes, 
underscoring the importance for the need of robust catalysts (8). The use of 
biocatalysts for regio- and/or stereoselective oxyfunctionalization has proved be an 
attractive alternative to chemical methods (9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Distribution of oxidation reactions amongst industrial biocatalytic oxidations. Adapted from (8). 
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Oxidizing enzymes as biocatalysts  
  
Over the years, the use of enzymes as biocatalysts for diverse applications has grown 
steadily. Biocatalysis in industrial synthetic applications has become indispensible 
particularly in specialty and bulk chemical processes (10, 11). Enzymes are able to 
catalyze a wide variety of reactions with high selectivity and specific activity under 
mild conditions of temperature and pressure. 
 
There is a high demand for the use of oxidative biocatalysts especially in view of 
certain unsolved problems of oxidation reactions such as lack of control and 
predictability of product structures and the high costs of oxidizing reagents in 
conventional chemical catalysis (12). On the other hand, oxidizing enzymes confer 
some key advantages as the oxidation reactions can be readily controlled with high 
degree of regio- and/or stereoselectivity (13, 14). Oxidizing enzymes are broadly 
classified into three categories which in turn have different subcategories based on 
the range of their different activities (Figure 2). 
 
 
 
 
Figure 2.Classification of oxidizing enzymes. Adapted from (12).  
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Cytochrome P450 monooxygenases 
 
Monooxygenases are a group of oxidizing enzymes which may be metal, haem or 
flavin dependent and  catalyze the introduction of one atom of oxygen into a substrate 
molecule using cofactors like NADH or NADPH (15). Cytochrome P450s (P450s) 
constitute a superfamily of heme dependent monooxygenases (most of the 11000 
CYPs are not all characterized) that catalyze oxyfunctionalization of a vast variety of 
chemical compounds (16). P450s have the ability to catalyze different reactions 
including some unusual reactions like nitration of tryptophan and the more recently 
reported cycloproponation and intramolecular C-H amination (17-22). 
 
Depending on the nature of  the redox partners, P450s are classified as three-, two-, or 
single component systems (Figure 3) (5). The prokaryotic P450s are typically three 
component systems which are depending on a NAD(P)H-dependent FAD-containing 
reductase and a [2Fe-2S] ferredoxin or a FMN-dependent flavodoxin that shuttle 
electrons from the cofactor NAP(P)H to the monooxygenase protein (Figure 3a). 
Eukaryotic P450s such as drug-metabolizing human liver P450s and many plant and 
fungal P450s are two component systems in which electrons are delivered by a FAD 
 
 
 
 
 
Figure 3. Different types of P450 systems: (a) bacterial, class I P450 system (e.g., P450cam); (b) eukaryotic, 
membrane-bound class II P450 systems (e.g., human liver P450s); (c) P450-CPR fusion system (e.g., 
P450BM3); (d) P450RhF-type fusion system. FeS = ironΫsulfur cluster, FMN = flavin mononucleotide, FAD = 
flavin adenine dinucleotide. Adapted from (5). 
 
13
General Introduction 
 
and FMN containing P450 reductase (CPR) to the membrane bound P450 (Figure 3b) 
(23, 24). Figure 3c-d illustrate the single component P450 systems that can operate as 
redox self sufficient enzymes in contrast to the other multi-component P450s. An 
excellent example of this single component system is P450 BM3 (CYP102A1) in which 
the heme and reductase domain are fused into a single polypeptide (Figure 3c) 
thereby making electron transfer highly efficient (25) . Genome analysis has led to the 
identification of other self sufficient P450s like CYP102A2 and CYP102A3 similar in 
architecture to that of P450 BM3. Yet another novel class of self sufficient P450s is 
P450 RhF from Rhodococcus sp. NCIMB 9784 in which electrons are supplied by a 
FMN- and Fe/S-containing reductase partner in a fused arrangement (Figure 3d) (26, 
27). 
 
Cytochrome P450 catalytic cycle 
 
Most P450s are considered to function by a similar catalytic cycle. In the resting state 
of the P450 enzyme, the ferric iron atom is six-coordinated, and a water  ligand 
occupies the axial position trans to the proximal thiolato ligand (1). 
 
 
 
 
Figure 4: P450 cataltytic cycle. Adapted from (28). 
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The catalytic cycle of P450 is initiated by binding of substrate to the enzyme (2) 
resulting in the displacement of water from heme distal face with simultaneous shift 
in the heme spin state from low spin to high spin (28). This spin transition can be 
monitored spectrophotometrically since the Soret band undergoes a blue or ‘‘type I’’ 
shift from ca. 418 nm to ca. 390 nm. A single electron supplied by a reduced pyridine 
nucleotide (NADH or NADPH) is shuttled to the haem iron via electron transfer 
partners, reducing it to the ferrous state (3). Oxygen binding leads to an oxy-complex 
(4). Subsequently, a second electron is transferred creating a ferric-peroxo 
intermediate (5a). This intermediate is protonated to form ferric hydroperoxy adduct 
(Compound 0) (5b). A second protonation triggers water loss via the heterolytic 
cleavage of the O–O bond  to give ‘‘Compound  I’’ (6), which has recently been 
characterized (29). The catalytic cycle ends with the oxygenation of the substrate to 
form a product complex (7) followed by release of product (Figure 4). 
 
During the P450 catalytic cycle, three major non-productive reactions collectively 
termed as “uncoupling” can occur. These are: 
(i) autoxidation of the oxy-ferrous enzyme (4) resulting in the production of 
a superoxide anion and return of the enzyme to its resting state (2),  
(ii) dissociation of hydrogen  peroxide or hydroperoxide anion (5a,b) from 
the iron forming hydrogen peroxide  
(iii) an oxidase uncoupling wherein the ferryl-oxo intermediate (6) is 
oxidized to water instead of oxygenation of the substrate (28, 30) . 
Human P450 monooxygenases 
 
Human P450s are involved in the Phase I metabolism of approximately 75 % of 
marketed drugs, numerous dietery constituents as well as endogenous chemicals. The 
human genome contains 57 functional P450 genes arranged into 18 families and 42 
subfamilies (31, 32). The general characteristics of different active human cytochrome 
P450 enzymes are listed in Table 1. Human P450s are known to be polymorphic in 
nature with clinically most important polymorphisms observed with CY2C9, CYP2C19 
and CYP2D6 (33). A study of Shimada et al., 1994 reported that CYP1A2, CYP2A6, 
CYP2B6, CYP2C, CYP2D6, CYP2E1, and CYP3A accounted for approximately 70% of 
the total human liver P450 content; the remaining 30% consisted of then unknown 
enzymes (34) . In a recent study it was shown that the CYP4F family of enzymes also 
represents about 15 % of the overall human liver P450 pie (35) (Figure 5).   
 
 
 
15
General Introduction 
 
Table 1. General characteristics of human cytochrome P450 enzymes (33). 
 
Enzyme Marker substrate reaction Substrate specificity Main tissue 
localization 
CYP1A1 Ethoxyresorufin O-deethylation Pre-carcinogens, PAHs Extrahepatic 
CYP1A2 Phenacetin O-deethylation. 
ethoxyresorufin O-deethylation 
Aromatic, amines, PAHs Liver 
CYP1B1 Estradiol-4-hydroxylation DMBA, oestradiol Extrahepatic 
CYP2A6 Coumarin 7-hydroxylation Nicotine Liver 
CYP2A13 Coumarin 7-hydroxylation Olfactory mucosa 
CYP2C8 Taxol hydroxylation Liver 
CYP2C9 Tolbutamide methylhydroxylation, 
losartan hydroxylation, S-warfarin 7-
hydroxylation 
Drugs Liver 
CYP2C18  Some drugs Extrahepatic 
CYP2C19 S-mephenytoin 4-hydroxylation, 
omeprazole 5-hydroxylation
Drugs Liver 
CYP2D6 Dextromethorphan O-deethylation, 
bufuralol 1’-hydroxylation, debrisoquine 
4-hydrohylation 
Drugs Liver 
CYP2E1 Chlorzoxazone 6-hydroxylation Solvents, drugs, pre-
carcinogens 
Liver 
CYP2F1 Lung 
CYP2J2 Arachidonic acid hydroxylation Fatty acids Extrahepatic 
CYP2R1 Vitamin D25 hydroxylase Vitamin D Extrahepatic 
CYP2S1 Trans-retinol oxidation Small aromatic 
hydrocarbons 
Extrahepatic 
CYP3A4 ͸Ⱦ-hydroxylation, 
midazolam 1’-hydroxylation, 
erythromycin N-demethylase 
Drugs, pre-carcinogens, 
dietary components 
Liver, intestine 
CYP3A5 Same as CYP3A4 Similar as CYP3A4 Liver, intestine 
 
 
 
 
Figure 5 . Revised human liver P450 pie. The inset figure depicts the percentage contributions of individual 
P450 enzymes based on the immunoquantification performed by Shimada et al. (1994). The larger figure 
shows the revised P450 pie with CYP4F contributing to 15% of the total hepatic P450s. Adapted from (35). 
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Microbial P450 monoxygenases 
 
The P450 enzymes from microbes are enormously diverse and are involved in 
primary and secondary metabolism as well as act as potential drug targets (36, 37). 
Some examples of bacterial and fungal CYPs is shown in Table 2 with a selection of 
their respective activity/function. CYPs in bacteria are generally soluble proteins 
requiring ferredoxin and ferredoxin reductase for the two electrons needed in the 
catalytic cycle.  CYPs in eukaryotic organisms are typically located in the endoplasmic 
reticulum with an associated NADPH-CPR providing the necessary reducing 
equivalents (38). Of the bacterial P450s, the most extensively studied are CYP101 
(P450cam and CYP102A1 (P450 BM3) from Pseudomonas putida and Bacillus 
megaterium which have been structurally characterized extensively using X-ray 
crystallography and numerous other biophysical techniques (39). 
 
Table 2. Examples of bacterial and fungal CYPs with identified activity/function (36). 
 
Microbe CYP activity/function 
 
Microbial eukaryotes 
  
Saccharomyces cerevisiae CYP51 sterol biosynthesis (14-demethylation) 
Candida tropicalis CYP52A1 alkane and fatty acid catabolism 
Fusarium oxysporum CYP55A1 denitrification 
Saccharomyces cerevisiae CYP56A1 dityrosine formation for spore wall 
Nectria haematococca CYP57A1 phytoalexin detoxification 
Aspergillus nidulans CYP59A1, CYP60A2, 
CYP60B1,CYP62A1 
sterigmatocystin biosynthesis/mycotoxin 
Rhizopus oryzae CYP509C1 ͳͳȽ-hydroxylase 
Chlamydomonas rheinhard 
 
CYP710 (CYP61) sterol biosynthesis (22-desaturation) 
Bacteria   
Pseudomas putida CYP101A1 catabolism of camphor 
Bacillus megaterium CYP102A1 fatty acid catabolism 
Streptomyces avermitils CYP105P1, CYP105D6 filipin biosynthesis/antifungal 
Saccharopolyspora erythrea CYP107A1 erythromycin biosynthesis/antibacterial 
Streptomyces lavendulae CYP107N1, CYP160A1 mitomycin c biosynthesis/antitumour 
Streptomyces hygroscopius CYP122A2 rapamycin 
biosynthesis/immunosuppressant 
Mycobacterium tuberculosis CYP125A1 catabolism of cholesterol 
Jeotgalicoccussp. ATCC 8456 CYP152A3 decarboxylation of fatty acid 
Streptomyces fradiae CYP105L, CYP113B1 tylosin biosynthesis/veterinary 
antibacterial 
Streptomyces noursei CYP105H1, CYP161A1 nystatin biosynthesis/antifungal 
Streptomyces spheroides CYP163A1 novobiocin biosynthesis/antibacterial 
Sorangium cellulosum CYP167A1 epothilone biosynthesis/antitumour 
Streptomyces avermitils CYP171A1 avermectin biosynthesis/anthelmintic 
and insecticide 
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Protein engineering approaches to alter substrate selectivity 
 
Although P450s exhibit very high activity towards their natural substrates, their 
applicability towards unnatural substrates is generally limited. This can be overcome 
by various protein engineering strategies using both rational and evolutionary 
approaches (40, 41) (Figure 6). Rational approaches are characterized by the 
deliberate mutation of one or more amino acids based on mechanistic or structural 
information using molecular modeling and site directed mutagenesis. In the case of a 
semi-rational approach, mutations are introduced, for example, by simultaneous site-
saturation mutagenesis at important active site residues. The resulting mutant P450s 
are subsequently screened for enhancement of desired property (42). Alternatively, 
directed evolution achieved by rounds of error prone PCR has also become a powerful 
tool in P450 engineering (43). Although most random mutations are either neutral or 
deleterious, a small percentage may be advantageous. The mutagenesis rounds are 
repeated in an iterative process until the desired catalytic activity or selectivity is 
achieved. Because large numbers of mutants need to be screened for the desired 
activity, the success of directed evolution is highly dependent on suitable high-
throughput screening methodologies. 
 
 
 
 
Figure 6. Protein engineering strategies. Adapted from (40). 
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Table 3. Examples of P450 protein engineering (5, 42). 
 
Substrate Protein engineering goal P450 Reference 
Linear and cyclic terpenes Hydroxylation CYP102A1 (44) 
 
Dopamine Improved binding CYP102A1 (45) 
 
Amorphadiene Epoxidation CYP102A1 (46) 
 
Propylbenzene, 3-
methylpentane, fluorene 
Increased coupling efficiency 
and activity   
CYP102A1 (47) 
Protected cyclohexanol Selective hydroxylation CYP101A1 (48) 
 
Vitamin D3 
 
Increased activity for two 
sequential hydroxylations 
CYP105A1 
(49, 50) 
 
 
Progesterone 
 Altered regioselectivity CYP106A2 (51) 
Butane High rates of 1-butanol 
production 
CYP153A6 
(52) 
 
 
Deoxyaureothin  Catalysis of second oxygenation-
hetereocyclization step 
CYP151A 
family 
(53) 
 
 
 
The appropriate method for protein engineering of enzymes should be decided case-
by-case on the basis of the availability and quality of the structural and mechanistic 
information and the feasibility of a high-throughput screening (HTS) system for 
screening or selection (40, 54). Some examples illustrating protein engineering of 
microbial P450s is shown in Table 3. 
 
Engineered cytochrome P450 BM3 as biocatalysts 
 
Cytochrome P450 BM3 (CYP102A1) from Bacillus megaterium was identified as a 
medium to long chain fatty acid hydroxylase in the 1970s in the Fulco lab. 
Characterization of the 119 kDa protein revealed that the 55 kDa heme domain was 
fused to a 65 kDa reductase domain in a single polypeptide containing equimolar ratio 
of flavin groups FAD and FMN (55-57). P450 BM3 has the highest activity ever 
reported for a P450 of 17000 min-1 with arachidonic acid and exhibits a 100 to 1000 
fold more efficient catalytic efficiency kcat/km when compared to that of the eukaryotic 
fatty acid hydroxylating CYP4 enzymes. In spite of this high native substrate activity, 
the wild type protein has a considerably narrow substrate scope. For potential use as 
biocatalysts for various applications, its substrate scope has been widened by the 
various protein engineering methods as discussed above. 
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Figure 7. Schematic representation of the active site of wild-type cytochrome P450 BM3 (PDB 
structure1BU7). Important amino acid residues are depicted in stick format, as well as the catalytically 
active moiety. 
 
 
Substrate free crystal structures revealed that P450BM3 features a long hydrophobic, 
largely non-aromatic, substrate channel connecting the protein surface to the heme 
pocket (58, 59). The structure of the palmitoleate-bound form of P450 BM3 provided 
clear insights into the binding mode for long-chain fatty acids and the key amino acids that 
are involved in substrate binding and recognition (60, 61). Important residues are 
shown in Figure 7. These residues have been targets for mutagenesis to modulate the 
substrate profile and regioselectivity of the enzyme. Computational techniques can be 
used to rationalize experimentally observed selectivity as well as to identify important 
substrate binding interactions by using molecular dynamics (MD) simulations based 
on crystal structure data (62-66). 
  
The most widely studied residue in P450 BM3 shown to affect selectivity and activity 
is F87. In the substrate free structure, F87 lies perpendicular to the porphyrin system, 
but in substrate bound form it is rotated by 90 degrees and occupies a position 
between iron centre and substrate tail (61). Modifications at F87, which is most 
proximal to the heme has led to an altered substrate selectivity as illustrated for a  
variety of substrates such as arenes, hetereoarenes, 2-aryl acetic acid esters, 
cycloalkanes, ionone, steroids (67-71).  Apart from the F87 residue, other residues such 
as R47, A82, L437, S72 and A74 have also been shown to affect the substrate selectivity 
(72-74). Specifically, mutation at A82 position to a more bulky phenylalanine or 
tryptophan, increased the regioselectivity and coupling efficiency for hydroxylation of 
steroids and other drugs (75-77). S72 is the first residue of the B’ helix and modeling 
studies have revealed that fatty acids may tether to S72 when binding close to heme iron 
(78). Mutations at S72 have been shown to affect regio-and stereoselectivity of the 
substrate oxidation (79, 80).  
20
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Combinatorial active site mutations have shown to have synergistic effects resulting in 
much higher selectivity and or activity. Mutations at positions 87 and 328 have greatly 
increased the selectivity of terpene oxidation (44), whereas mutations at 72 and 82 have 
been shown to affect stereoselectivity of steroid hydroxylation (80). Furthermore, 87 
and 82 position mutations have been shown to affect stereoselectivity of styrene 
epoxidation (81). Thus, protein engineering approaches have led to the development 
of several mutants of cytochrome P450 BM3 capable of accepting non-natural 
substrates (Figure 8). In addition to conventional methods, efforts have also been 
made to control the substrate specificity of wildtype P450 BM3 without mutagenesis by 
using small decoy molecules (82). Recently, an activator-based strategy was applied to 
wild-type P450 BM3 in which the P450 BM3 catalytic cycle was triggered by long-
chain perfluorocarboxylic acids (PFs), which mimic P450BM3 preferred substrates 
but contain non-oxidizable CΫF bonds in their side chains, resulting in the oxidation of 
various aliphatic substrates, such as cyclohexane, acyclic C6 and gaseous (C1ΫC4) 
alkanes (78, 83). 
 
 
 
 
Figure 8 . Spectrum of compounds that have been used as substrates for engineered P450 BM3 variants. 
 
Apart from improving the substrate scope and selectivity, efforts have been made to 
improve the robustness of P450 BM3 as a biocatalyst for biotechnological applications 
(24, 42, 84). Extensive work has been done to improve the thermostability and solvent 
tolerance of BM3 variants (85-87). Improving total turnover numbers was shown to 
positively affect coupling efficiency (42, 88). Novel methods of incorporation of non- 
 
Engineered 
P450 BM3 
Flavor, 
fragnance 
compounds
Pharmaceuticals
Aliphatic 
hydrocarbons
Steroids and 
other 
compounds
Aromatics
Indole
Testosterone
n-alkanes
Naphthalene
Anthracene
Alpha-ionone
Alpha-pinene
Propanolol
Dextromethorphan
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canonical amino acids have proven to be effective to increase total turnover numbers 
to more than 30000 for non-natural substrates like ibuprofen methyl ester and 
nootkatone (89). 
 
In vitro and in vivo product formation 
 
For non-cellular in vitro P450 catalysis, enzymatic regeneration systems are usually 
employed for regeneration of the cofactor NADPH (15, 57). The most commonly used 
systems with their advantages and disadvantages are presented in Table 4. By 
mutations at residue W1046, P450 BM3 has been engineered to accept NADH as co-
factor in place of the more expensive NADPH (90). Alternative methods which 
circumvent the use of NAD(P)H as electron donor include light driven catalysis, 
peroxide driven catalysis and the use of zinc and cobalt sepulchrate system (91-93). 
 
 Table 4. Examples of NAD(P)+-dependent (de)hydrogenases that can be applied for coenzyme 
regeneration (15). 
 
Enzyme Organism Advantages/Disadvantages 
Alcohol 
dehydrogenase 
Thermoanaerobium brockii + Thermostable 
+ Commercially available 
Ϋ Only selective for NADP+ 
ΫUnfavorable thermodynamic 
    equilibrium 
Ϋ High [substrate] required 
Formate 
dehydrogenase 
Candida boidinii + Ƥ 
+ Favorable thermodynamic 
     equilibrium 
+ Thermostable 
+ Selective for NAD(P)+ 
Ϋ Low activity 
Glucose 
dehydrogenase 
Bacillus cereus + Commercially available 
ΪƤ 
+ Thermostable 
+ Selective for NAD(P)+ 
Ϋ Product may complicate 
    workup procedure 
Glucose-6-phosphate 
dehydrogenase 
 
Leuconostoc mesenteroides + Commercially available 
ΪƤ 
+ Selective for NAD(P)+ 
Ϋ Ƥ 
    substrate 
Ϋ Product may complicate 
workup procedure 
Phosphite 
dehydrogenase 
Pseudomonas stutzeri ΪƤ 
+ Favourable thermodynamic 
   equilibrium 
+ Thermostable 
+ Selective for NAD(P)+ 
Ϋ Low activity 
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P450 catalysis using whole cellular systems has gained considerable importance as a 
more cost effect way of product formation (16). Several different host organisms like 
E. coli (94) , B. megaterium (95), R. erythropolis (96), Y. lipolytica (97), S. cervisiae (98), 
S. pombe(99), P. pastoris (100) have been employed for P450 whole cell biocatalysis. 
Although the effective intrinsic NADPH concentration can sometimes be rate limiting 
even in whole cell systems, this has been easily addressed by co-expression of NADPH 
regenerating enzymes (101, 102). One of the most often encountered problems with 
whole cell biocatalysis is the inefficient cellular uptake of substrates (103). Many P450 
substrates are highly hydrophobic and do not readily cross cell membranes (104). In 
such cases, the use of another expression host can be beneficial. For example, it was 
demonstrated that the triterpene acid 11-keto-Ⱦ-boswellic acid can efficiently cross 
the membrane of B. megaterium, while no activity was observed with this substrate 
when using recombinant Escherichia coli cells (95). 
 
Microbial steroid hydroxylation 
 
Microbial steroid transformation is a powerful tool for generation of novel steroidal 
drugs, as well as for efficient production of key pharmaceutical intermediates (105, 
106). Biotransformation of steroids can be carried out by microbial P450s with the 
desired regio- and stereoselectivity which is hard to achieve by chemical means. 
Several reactions can be completed in one biotechnological step making the process 
much easier. Bacterial cytochrome P450s play an important role in the steroid 
conversion (107). Different bacterial CYPs are capable of highly selective ring 
oxidation of testosterone as shown in Figure 9. 
 
 
 
 
Figure 9. Hydroxylation of testosterone by bacterial P450s (108). 
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Table 5. Selected commercial and industry relevant CYP processes for steroids. Adapted from (16). 
 
 
 
Steroid pharmaceuticals have a high market demand next to antibiotics. Therefore 
mirobial steroid hydroxylation plays an important role in the industrial scale 
applications. For example, the microbial hydroxylation of progesterone into 11Ƚ-
hydroxyprogesterone catalyzed by Rhizopus arrhizus significantly increased the 
efficiency of the multi-step chemical synthesis of corticosteroid hormones as well as 
led to a reduction in the cortisone manufacturing costs (105, 113). Some of the 
commercialized microbial steroid biotransformations are shown in Table 5. 
 
Drug metabolite production 
 
Drug discovery and development is a costly and time-consuming process involving 
many steps starting from target discovery up to clinical trials. Because drug 
metabolites sometimes have high pharmacological or toxicological properties, they  
            Steroid product Microorganism and/or 
CYPs involved 
Reference/company 
 
 
Cortisiol 
Biotransformtion with 
Curvuaria sp. 
 
 
 
Denovo synthesis in S. 
cerevisiae; 
 
Mammalian CYP11A1, 
CYP17A1, CYP21, 
CYP11A1, 3Ⱦ-HSD 
(109) / Schering 
(1982), now Bayer 
 
 
 
(110) / Sanofi 
 
Cortisone 
 
Biotransformation with 
Rhizopus sp. 
 
 
(111) / Upjohn(1952), 
now Pharmacia and 
Upjohn company, 
Pfizer 
 
 
Pregnenolone 
 
De novo synthesis in 
S.cerevisiae; mammalian 
CYP11A1 
 
(112) / Sanofi 
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sometimes play an important role in drug action and adverse drug reactions. It is 
therefore important to thoroughly study the metabolism of potential drugs as well as 
to characterize the pharmacological and toxicological properties of drug metabolites 
(114). Drug metabolism studies play an important role in the lead optimization stage 
of drug discovery in order to avoid undesirable adverse effects. In accordance with the 
MIST guidelines, identification, quantification and characterization of major 
metabolites are considered to be important for drug safety assessment (115, 116). 
Such studies can require large quantities of the pure metabolites which may be 
difficult to synthesize by conventional chemical methods. Therefore, effective 
strategies are required to obtain sufficient amount of drug metabolites to facilitate 
their structural elucidation as well as for toxicological evaluation (117). Although 
human P450s are involved in Phase I metabolism of many drugs (118), they are often 
inefficient for the production of large quantities of drug metabolites because of their 
membrane bound nature and lower activity (39). Engineered bacterial P450s with 
high activity and selectivity have therefore better perspectives for large scale drug 
metabolite synthesis (119). Figure 10 illustrates the construction of a CYP expression 
library for bacterial P450 monooxygenases for screening and optimization of the most 
efficient biocatalyst (117). Of the bacterial P450s, cytochrome P450 BM3 has been 
engineered for drug metbaolite production harnessing the inherent advantages of 
easily scalability and high selectivity (120, 121). Engineered P450 BM3 variants were 
able to catalyzed the formation of several drug metabolites with high turnover 
numbers, as summarized in Table 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Generalized strategy for the use of bacterial cytochrome P450 for drug metabolite production 
and the use of a bacterial CYP reaction array. Adapted from (117).
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Table 6. Summary of drug metabolite production by engineered P450 BM3 variants. Adapted from (108). 
 
 
 
 
 
Drug Metabolite produced by 
Engineered P450 BM3 variants 
Main human 
P450 involved 
Reference 
Acetaminophen N-acetyl-p-benzoquinone imine  2E1 (122) 
Amitriptyline Nortriptyline  2C19, 3A4, 1A2 (123) 
Amodiaquine N-desethylamodiaquine  2C8 (124) 
 
Astemizole 
6-hydroxyastemizole 
6-hydroxydesmethylastemizole 
Desmethylastemizole  
2D6 
2D6 
2D6 
(125) 
Buspirone (R)-6-hydroxybuspirone  3A4 (126) 
 
Clozapine 
N-demthylclozapine  
Clozapine N-oxide 
1A2 
1A2 
 
(127) 
Dextromethorpha n  3-methoxymorphinan  2D6, 3A4  (124) 
Diclofenac 4’-hydroxy diclofenac 
5-hydroxy diclofenac 
2C9 
3A4 
(128, 129) 
Diltiazem 
 
Demethyldiltiazem  
Di-demethyldiltiazem  
3A4 
3A4 
(123) 
Ibuprofen 2-hydroxy-ibuprofen 2C9 (130) 
Irbesartan 
 
Hydroxyirbesartan  
Di-hydroxyirbesartan  
2C9 
2C9 
(123) 
Lovastatin 6b-hydroxylovastatin  
6'-exomethylenelovastatin  
3A4/5 
3A4/5 
(131) 
Meclofenamic acid 3’-hydroxy-methyl-meclofenamic acid 
4’-hydroxy-meclofenamic acid 
5-hydroxy-meclofenamic acid 
2C19 
2C9 
1A2 
(132) 
Naproxen Desmethylnaproxen  2C9, 1A2 (130) 
Omeprazole 5-hydroxy-omeprazole 2C19 (75) 
Ondansetron Hydroxylondansetron 
Dih d d
3A4, 2D6, 1A2 
3A4 2D6 1A2
(123) 
Phenacetin Acetaminophen  1A2 (133) 
Propafenone 
 
Hydroxylated metabolites  
N-despropylpropafenone  
2D6 
3A4/1A2 
(123) 
Propranolol 4'-hydroxypropranolol  
5'-hydroxypropranolol  
N-despropylpropranolol  
2D6 
2D6 
1A2 
(134) 
Simvastatin 6b-hydroxysimvastatin  
6'-exomethylenesimvastatin  
3A4 
3A4 
(131) 
Tolbutamide 4-hydroxytolbutamide  2C (128) 
Tolfenamic acid 4’-hydroxy-meclofenamic acid 
5-hydroxy-meclofenamic acid 
1A2 
1A2 
(132) 
Verapamil 
 
Norverapamil  3A4 (125) 
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Role of bioactivation in adverse drug reactions 
 
Serious adverse drug reactions (ADRs) are major causes of patient morbidity and 
mortality as well as for drug recalls and black box warnings (135, 136). Four different 
types of ADRs are known of which the Type B idiosyncratic ADRs (IADRs) pose 
significant problem due to their unpredictable nature, non-dependence on dose-
response relationship and lack of animal models (137, 138). Although the exact 
mechanism is as yet unknown, drug metabolism and reactive metabolite formation 
seem to play an important role in ADRs and IADRs (139-141). Under normal 
circumstances, lipophopilic drugs are converted into hydrophilic more soluble 
metabolites that can be easily excreted from body. In some cases, however, 
metabolism can lead to bioactivation of drugs and to the formation of reactive 
metabolites (142, 143). Both phase I and phase II metabolic enzymes can be involved 
in the generation of reactive species of which cytochrome P450 and glucuronyl 
transferases are commonly involved. Figure 11 depicts the generally proposed 
scheme for the role of reactive drug metabolites in drug toxicity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Proposed role of bioactivation in adverse drug reaction (140). 
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Table 7 lists examples of drugs that are known to be bioactivated to reactive 
metabolites and the adverse effects associated with them. Identification of the 
common functional group capable of undergoing bioactivation during the drug design 
stage can help mitigate bioactivation risk (141, 144). The main approaches used to 
minimize bioactivation risk are (a) eliminating the suspect functional group, (b) 
blocking the potential for metabolism and (c) incorporating metabolic soft spots to 
direct metabolism away from the suspect group (144). 
 
 
 
Table 7. Examples of drugs and reactive metabolites possibly involved in ADRs (143, 145). 
 
 
Drugs Reactive intermediate Toxicity 
Acetaminophen Benzoquinoneimine Hepatotoxicity 
Carbamazepine 2-Hydroxy, Benzoquinoneimine Agranulocytosis, Aplastic 
anemia 
Clarithromycin Nitroalkane Hypersensitivity 
Clozapine Nitrenium ion Agranulocytosis 
Dapsone Hydroxulamine, Nitroso Hemolysis, hypersensitivity 
Diclofenac Acylglucuronide, Benzoquinone imine Hepatotoxicity 
Halothane Trifluoroacetyl Hepatitis 
Indomethacin Iminoquinone Hypersensitiv, , 
Hepatotoxicity 
Isonizaid Isonicotinic acid, acetylating species Hypersensitivity 
Mefenamic acid Benzoquinoneimine Hepatoxicity, Nephrotoxicity 
Nefazadone Benzoquinoneimine Hepatotoxicity 
Nevaripine Arene oxide, quinine methide Hepatotoxicity, Skin allergy 
Phenacetin p-Nitrosophenetole Hepatotoxicity 
Tacrine 7-OH-tacrine Hepatotoxicity 
Tamoxifen N-oxide, N-oxide-epoxide Carcinogenesis 
Ticlodipine Keto, S-oxide Agranulocytosis, aplastic 
anemia 
Tielinic acid Thiopene S-oxide Hypersensitivity, hepatitis 
Troglitazone Conjugates, Benzoquinone, Quinone 
epoxide 
Hepatotoxicity 
Valproic acid Acyl glucuronides Hypersensitivity, 
Hepatotoxicity 
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Generation and characterization of reactive intermediates 
 
Three key components are involved in general trapping experiments namely the 
formation of the reactive metabolites, the trapping of electrophiles and the 
subsequent analytical procedures. In vitro generation of electrophilic reactive drug 
metabolites is often done with human or rat liver microsomes in the presence of the 
cytochrome P450 co-factor NADPH (146, 147). Pooled human liver microsomes are 
commonly used as bioactivation system (148). The contribution of the individual 
human CYPs in metabolic activation pathway can be studied using commercially 
available human recombinant CYP supersomes (149, 150).  An alternative for the use 
of human enzyme systems are engineered P450 BM3 mutants. Several P450 BM3 
mutants obtained by a combination of random- and site-directed mutagenesis were 
shown to bioactivate drugs like clozapine, diclofenac, mefenamic acid to the same 
human relevant reactive intermediates (127, 151).  
 
Most of the reactive metabolites with a possible exception of acyl glucuronides are 
highly reactive and short lived, thus making their detection difficult (152). The most 
common way to screen for reactive metabolites is to perform trapping experiments 
(139, 152), with model nucleophiles such as glutathione (GSH) followed by analysis of 
the formed adducts. Although intermediates such as quinones, quinoneimines, 
iminoquinone methides, epoxides, arene oxides and nitrenium ions can be trapped by 
GSH, it is a soft nucleophile and does not always trap all the reactive intermediates. 
For this reason, the hard nucleophile cyanide is also used as a nucleophilic trapping 
agent (153).  
 
Drug candidates are routinely subjected to in vitro evaluation for reactive metabolite 
formation through the GSH trapping experiments. In view of this, rapid, sensitive and 
selective methods for detecting and characterizing reactive metabolites are highly 
desired in the drug discovery process (154, 155). The conjugates thus formed are 
analyzed using LC-MS/MS (156). The most common MS/MS mode for screening of 
GSH conjugates is the neutral loss scan of 129 which is based on the loss from [M + H]+ 
ion of the elements of pyroglutamic acid  in combination with positive ionization 
(157). However, this method is not always successful in detection of some conjugates 
like aliphatic and benzylic thioether conjugates (158). Alternatively, precursor ion 
scanning (m/z 272; loss of H2S) in the negative ionization mode can also be used 
(159). Although mass spectrometry based analyses is the most often used approach 
for detection of GSH conjugates (160), in most cases the unequivocal structures cannot 
be determined by using LC-MS/MS techniques only. In such cases, the additional use 
of NMR is required for structural elucidation which can provide insights into the  
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mechanism of bioactivation (146, 161). However NMR typically requires high quantity 
of the sample for recording a good quality spectrum. 
 
 
 
 
Figure 12. Graphical representation of the generation and characterization of reactive intermediates 
in trapping experiments. Adapted from (162). 
 
 
Large scale production and isolation of GSH conjugates can be facilitated by the use of 
bacterial CYPs as biocatalysts. Unequivocal structural elucidation of GSH conjugates of 
drugs such as clozapine, mefenamic acid has been achieved by this method (163, 164).  
A generalized scheme for generation and characterization of reactive metabolites is 
depicted in Figure 12. 
 
Role of glutathione-S-transferases in detoxification of reactive drug metabolites 
 
The conjugation of GSH to a reactive intermediate can be spontaneous non-enzymatic 
or catalyzed by glutathione-S-transferases (GSTs) which is dependent on the nature of 
the electrophile and the concentration of GSH (165). For example, N-acetyl-p-
benzoquinone imine (NAPQI) may react spontaneously with GSH at physiological 
concentrations but requires GSTs at low concentrations of GSH indicating the 
importance of GSTs in detoxification (166).  
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GSTs are a superfamily of dimeric phase II enzymes, which play an important role in 
the cellular detoxification of electrophiles and oxidants (167, 168). The human GSTs 
exhibit broad catalytic diversity due to the existence of eight cytosolic classes namely 
alpha, mu, pi, sigma, theta, omega, zeta and kappa, classified according to their amino 
acid sequence similarity, substrate specificity and primary and tertiary structures 
(169, 170). The expression pattern of GSTs is distinct in different organs (171, 172). 
For example in the liver, GST A1 and A2 contribute to about 78% of the human hepatic 
cytosolic GSTs (172, 173) (Figure 13). Although the expression of GST P1 is relatively 
low in liver, it has high extrahepatic tissue expression (174, 175). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Distribution of hepatic cytosolic human GSTs. Percentages were calculated based on 
references (172, 173). 
 
 
As previously described, many drugs are bioactivated by cytochrome P450s to short-
lived reactive metabolites that may lead to ADRs. The balance between the rate of 
formation of these highly reactive metabolites and the rate of inactivation by GSH 
conjugation, which may be catalyzed by GSTs, will determine the level of protein 
adduct formation and consequently may determine the risk for ADRs (165, 176). It has 
been shown that GSTs are involved in activation of reactive intermediates of several 
drugs (177). For example, reactive metabolites of valproic acid and acetaminophen 
were efficiently inactivated by addition of rat GSTs (166, 178). Human liver GSTs were 
found to catalyze GSH conjugation of reactive metabolites of clozapine and 
troglitazone (179, 180). Moreover, human GSTs also showed marked differences in the 
catalysis of 2-phenylpropenal and 2-acetylbenzothiophene-S-oxide, the reactive 
intermediates of felbamate and zileuton (181, 182), respectively. An overview of the 
GSH conjugation to reactive intermediates catalyzed by GSTs is presented in Table 8. 
52%
26%
18%
3 % 0.7% 0.3%
GST A1-1
GST A2-2
GST M1-1
GST P1-1
GST T1-1
GST M3-3
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Table 8. Effects of human  glutathione S-transferases on the conjugation of drug reactive intermediates. 
 
Drug Reactive electrophile GST activity ** Ref. 
 
Acetaminophen  * 
 
N-acetyl-p-benzoquinoneimine 
GST P1> 
GST M1> 
GST A1 
(166) 
 
Diclofenac 
 
1’,4’-diclofenac-quinoneimine 
 
 
2,5-diclofenac-quinoneimine 
GST P1~ 
GST M1> 
GST A1 
 
 
 
GST P1>> 
GST M1> 
GST A1 
(183) 
 
 
 
 
Clozapine   
clozapine nitrenium ion 
 
GST P1> 
GST M1> 
GST A1 
(179) 
  
Mefenamic acid 
 
2,5-mefenamic acid-
quinoneimine 
GST P1> 
GST A2> 
GST M1> 
GST M3 
(164) 
 
 
Felbumate 
 
 
2-phenyl-propenal 
GST M1> 
GST P1> 
GST A1 
(181) 
 
 
Zileuton 
 
 
2-acetylbenzothiophene-S-oxide 
GST M1> 
GST P1> 
 
(182) 
 
*   Study was performed using rat liver GSTs; similar results were also observed when human GSTs were      
     used 
** Total GSH conjugation is taken into account for comparing the activity of GSTs 
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Several human GSTs are known to be genetically polymorphic due to point mutations, 
gene deletion and gene duplication (168, 184, 185). In this regard, interindividual 
variations in the detoxification of reactive drug metabolites due to GST genetic 
polymorphism can increase susceptibility to cancers and ADRs (185-187). Individuals 
with GST null genotypes might be at higher risk for toxicity due to the combined effect 
of higher exposure to the reactive metabolites and lower detoxification capacity. Gene 
deletions have been observed for GST M1 and GST T1 with a frequency of the null 
allele at 50% and 18% respectively in Caucasian population (188, 189).  For drugs 
such as diclofenac, tacrine, troglitazone, carbamazepine, GST M1 and T1 null alleles 
have been associated with enhanced risk of hepatotoxicity (190-193). A number of 
single nucleotide polymorphisms (SNPs) have also been identified for GSTP1 (194, 
195).The variants that result from polymorphisms at position 105 and 114, GST P1*A 
(Ile105/Ala114), GST P1*B (Val105/Ala114), GST P1*C (Val105/Val114) and GST 
P1*D (Ile105/Val114) are the most sudied so far. In view of the importance of GST P1 
in detoxfication process, a large number of in vitro studies have been performed to 
investigate the effect of the mutations at position 105 and 114 using various drugs 
and model substrates (196-200). 
 
Aim and scope of this work 
 
The main goal of this thesis was to study the catalytic potential of cytochrome P450 
BM3 enzymes for applications in biotechnology and toxicology. The first section of this 
thesis was performed as a part of a NWO funded, Integrated Biosynthesis and Organic 
Synthesis (IBOS) project titled “Biocatalytic exploitation of monooxygenases” 
(BIOMOX) with a common goal to develop new biocatalytic platforms (isolated 
enzymes and whole cell systems) capable of enantioselective hydroxylation reactions. 
Four academic and three industrial partners were actively involved in this project.  
Chapters 2-4 of this thesis cover the use of P450 BM3 mutants for selective oxidation 
of organic compounds to tackle the challenging task of regio-and stereoselective 
hydroxylation. A collection of novel P450 BM3 mutants were engineered and the 
catalytically active and selective variants were characterized specific for each of the 
applications.  
 
In the last three chapters 5-7, the potential use of P450 BM3 mutants in 
pharmaceutical industry for drug discovery and metabolite safety testing is covered. 
Engineered cytochrome P450 BM3 variants were applied for both stable and reactive 
drug metabolite production. Additionally, they have been used to facilitate the study 
of the role of human GSTs in the inactivation of P450 mediated reactive metabolites.  
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In chapter 2, the regio- and stereoselective hydroxylation of the small isoprenoids Ƚ-
ionone by engineered P450 BM3 variants is discussed. P450 BM3 mutants which 
displayed high selectivity and high total turnover numbers were characterized. The 
origin of the selectivity was rationalized using docking studies. 
 
In Chapter 3 the potential of Rhodococcus erythropolis as a new host for P450 BM3 
mediated whole cell biocatalysis was evaluated. A model steroid substrate 
(norandrostenedione) was used to study the conversion. The combination of mutant 
Rhodococcus strain and a highly active engineered P450 BM3 variant is a promising 
option for whole cell biocatalysis of steroid hydroxylation. 
 
In chapter 4, a semi-rational approach was used to identify the key active site 
residues of P450 BM3 and create a minimal library for the oxidation of a larger 
substrate like testosterone. In-silico modelling studies provided insights into active 
site interactions responsible for this change in selectivity. This study showed that 
small differences in the key substrate interaction residues in P450 BM3 can have a 
profound effect on the stereoselectivity of hydroxylation. 
 
Chapter 5 describes the applicability of P450 BM3 mutants for the generation of 
human relevant drug metabolites of fenamic acid NSAIDs. A library of P450 BM3 
mutants was screened to identify catalytically active and selective mutants which 
were then used for large scale metabolite production to enable structural elucidation 
of metabolites by NMR. These enzymatically synthesized metabolites were used for 
further toxicological studies in chapter 7. 
 
In Chapter 6, P450 BM3 mutants were used as a bioactivation system in addition to 
human liver microsomes to investigate the effect of   four allelic variants of hGSTP1-1 
in their ability to inactivate the reactive drug metabolites of paracetamol, clozapine, 
and diclofenac. 
 
Chapter 7 describes the use of cytochrome P450 BM3 as a tool for bioactivation of 
mefenamic acid and for the structural elucidation of the GSH conjugates. The role of 
human cytchrome P450s involved in the bioactivation pathway as well as the effects 
of a panel of seven major recombinant human GSTs on the formation of GSH 
conjugates of mefenamic acid were also studied.  
 
Finally, Chapter 8 provides an overall summary of the work presented in this thesis 
as well as perspectives for future work. 
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Regio- and stereoselective hydroxylation of Ƚ-ionone 
 
Abstract 
 
Selective hydroxylation of unactivated C-H bond is a crucial step in the synthesis of 
fine chemicals such as hydroxylated terpenoids. In the present study, the ability of 40 
cytochrome P450 BM3 mutants to perform regio- and stereoselective hydroxylation of 
Ƚ-ionone has been investigated. Based on their activity and selectivity to produce 3-
OH-Ƚ-ionone from racemic Ƚ-ionone, 6 BM3 mutants were selected. Out of these, 3 
mutants (M01 A82W, M11 A82W and M11 V87I) showed high selectivity for trans-3-
OH-Ƚ-ionone formation while 3 other mutants (M11 L437N, M11 L437S and M11 
L437T) formed almost equal amounts of both cis-3-OH- and trans-3-OH-Ƚ-ionone. 
Incubation with individual enantiomers showed that M11 L437N, M11 L437S and 
M11 L437T exhibited opposite stereoselectivity producing (3S,6S)-OH-Ƚ-iononewith 
(6S)-enantiomer and (3S,6R)-OH-Ƚ-ionone with (6R)-enantiomer. Thus for the first 
time, BM3 mutants that can selectively produce diastereomers of 3-hydroxy-Ƚ-ionone 
(>90 % de), with high turnover numbers and minimal secondary metabolism, have 
been identified. Docking studies have been performed to rationalize the basis of the 
experimentally observed selectivity. In conclusion, engineered P450 BM3s are 
promising biocatalysts for regio-      Ƚ-
ionones for industrial applications. 
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Introduction 
 
Ionones are a class of norisoprenoids which are widely used in flavor and fragrance 
industry (1) and as building blocks for many chemicals (2). Ƚ-Ionone is one of the 
norisoprenoids which possesses characteristic organoleptic properties. Interestingly, 
the individual enantiomers of Ƚ-ionone possess different odors (3), thereby making 
them important for fragrance industry. The hydroxylated variants of Ƚ-ionone are also 
of commercial interest. For example, derivatives of 3-hydroxy-Ƚ-ionone are used as an 
intermediate for the total synthesis of lutein and its stereoisomers (4), Also, 3-
hydroxy-Ƚ-ionone has been shown to be a potent attractant for B.latifrons during 
pollination (5). 
 
The synthesis of hydroxylated variants of natural products such as terpenes and 
terpenoids still poses a challenge due to the formation of a variety of side products 
and the lack of selectivity of conventional synthetical methods (2, 6). In particular, the 
stereoselective hydroxylation of unactivated sp3 C-H bonds is a challenging aspect in 
modern day chemistry (7, 8). Because enzymes can catalyze reactions with 
remarkable regio- and stereoselectivity under mild conditions, their use as biocatalyst 
for selective production of fine chemicals has gained increased interest over the years 
(9, 10). A variety of mono-oxygenases has been used for selective oxyfunctionalization 
of organic substrates (11). An important class of mono-oxygenases are the 
cytochrome P450s, which are heme-dependent enzymes with the ability to perform 
regio- and stereoselective hydroxylations of a wide range of chemicals (12).  Efforts 
over the last decade have been focussed on engineering P450s to obtain robust and 
useful biocatalysts for industrial applications (13, 14). Protein engineering of P450s 
has proved to be an excellent means to broaden their substrate scope and specificity 
as well as to improve activity (15-18). For example, engineered variants of cytochrome 
P450cam have been shown to exhibit increased regio- and stereoselectivity towards 
terpenes like pinene and limonene (19, 20).  
 
Cytochrome P450 CYP102A1 from Bacillus megaterium, commonly referred to as 
P450 BM3, has good perspectives for the use as biocatalyst for hydroxylation 
reactions of industrial significance because it is the most active P450 so far identified 
(21). The fact that the heme and reductase domain of P450 BM3 are fused into a single 
polypeptide makes the electron transfer very efficient (22). The active site of P450 
BM3 has been re-engineered to accept a broader variety of substrates including 
terpenoids such as ionones (23). Although wild type P450 BM3 exhibits low activity 
Ƚ-ionone hydroxylation, some cytochrome P450 BM3 mutants engineered by 
rational design showed an increased activity. A triple mutant containing A74G F87V  
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ͳͺͺ ǡ      Ƚ-ionone to 3-hydroxy-Ƚ-ionone 
(49%) in addition to a number of other products (24). Also, BM3 mutant F87V 
produced a mixture of 4 oxidized products with Ƚ-ionone without any selectivity (25). 
 Ƚ-ionone at the C-3 position can result in the formation of 
four different diastereomers of 3-hydroxy-Ƚ-ionone. Individual enantiomers (6R)- or 
(6S)-Ƚ-ionone can be hydroxylated to (3R,6R) and (3S,6R) or (3R,6S) and (3S,6S), 
respectively, depending on the selectivity of the reaction. Structures of the 4 possible 
hydroxylated diastereomers are shown in Figure 1.  
 
 
 
Figure 1. Ƚ-ionone enantiomers and their 3´ hydroxylated products. A: (6R)-Ƚ-ionone B: (6S)-
Ƚ-ionone C: (3S,6R)-OH-Ƚ-ionone D: (3R,6S)-OH-Ƚ-ionone  E: (3R,6R)-OH-Ƚ-ionone F: (3S,6S)-OH-Ƚ-ionone. 
C &D are cis isomers and E & F are trans isomers. 
 
 
Ƚ-ionone using different Streptomyces strains 
(26), fungi such as Aspergillus Niger (27), immobilized cells of Nicotium tabacum (28), 
and cultured cells of Caragana chamlagu (29) has been reported. Moreover, different 
bacterial P450s from Bacillus Subtillus, Sorangium cellulosum, Novaspinghobium 
Ƚ-ionone (30-34). 
Ƚ-ionone that have been reported 
so far, trans-3-OH-Ƚ-ionone was found to be the main product (24, 30, 32). Other 
studies reported the formation of 2 diastereomers of 3-hydroxy-Ƚ-ionone from 
 Ƚ-ionone hydroxylation (24, 30, 32). However, from these studies it is not 
clear whether these enzymes are able to catalyze both cis- and trans hydroxylation on 
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each individual enantiomer, or whether they hydroxylate each enantiomer with 
different diastereoselectivity.  
 
In the present study a library of P450 BM3 mutants was evaluated for their ability to 
selectively produce the individual diastereomers of 3-hydroxy-Ƚ-ionone. This library 
was generated by a combination of site-directed mutagenesis of active site residues 
and random mutagenesis by error-prone PCR as described previously (35-37). Thirty 
one mutants of the library were selected based on their proven catalytic diversity 
towards a variety of drugs and steroids (35, 37-39). Nine additional mutants were 
prepared by site-directed mutagenesis of active site residues A82, V87 and L437 using 
M01 or M11 as template, see Table S1. Because some of our P450 BM3 mutants 
showed both cis- and trans-Ƚ-ionone as substrate, 
it was decided to investigate the hydroxylation of each enantiomer individually. In this 
chapter, it is shown for the first time that BM3 mutants can hydroxylate individual 
Ƚ-ionone in a highly regio- and stereoselective manner and with high 
turnover numbers for 3 out of the 4 possible diastereomers. Thus the introduction of a 
hydroxyl group in a single step by engineered BM3 in a highly regio- and 
stereoselective manner gives them good perspectives for industrial applications. 
 
Materials and methods 
 
Materials 
 
Ƚ-ionone, enantiomers (R)-and (S)-Ƚ-ionone and the hydroxy diastereomers 
(3S,6R)-OH-Ƚ-ionone and (3S,6S)-OH-Ƚ-ionone were obtained from DSM Innovative 
synthesis B.V. , Geleen, The Netherlands. All other chemicals were of analytical grade 
and purchased from Sigma unless otherwise mentioned. Restriction endonucleases 
were obtained from Westburg, Pfu polymerase and isopropyl Ⱦ-D-
thiogalactopyranoside (IPTG) were obtained from Fermentas. 
 
Enzymes and plasmids 
 
31 P450 BM3 mutants used in this work were constructed as described previously 
(35, 37, 40). Detailed information about the mutations present is tabulated in Table S2. 
9 other mutants were made by site directed mutagenesis using appropriate 
oligonucleotides). In general, the mutations were introduced in the corresponding 
templates in pBluescript II KS(+) vector by the QuikChange mutagenesis protocol  
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using the forward primers mentioned in. The reverse primers were exactly 
complementary to the forward primers. After mutagenesis, the presence of right 
mutations was verified by DNA sequencing (Service XS, Leiden, The Netherlands). The 
whole gene was subcloned to pET28a+ vector using BamHI and EcoRI sites and later 
transformed to BL21 (DE3) cells for expression.  
 
Expression and purification of P450 BM3 mutants 
 
	Ƚ-ionone hydroxylation, cytosolic fractions of the 
enzymes were used. Wild-type P450 BM3, mutants M01, M11, M01 A82W and M11 
L437N were grown on a large scale and purified as follows: 600 mL terrific broth 
medium with 30 μg/mL kanamycin was inoculated with 15 mL of overnight culture. 
The cells were grown at 37 °C and 175 rpm until the OD600 reached 0.6. The protein 
expression was then induced by the addition of 0.6 mM IPTG. The temperature was 
lowered to 20 °C and 0.5 mM of heme precursor delta aminolevulinic acid was added. 
Expression was allowed to proceed for 18h. Cells were harvested by centrifugation 
(4600 g, 4 °C, 20 min) and the cell pellet was resuspended in 20 mL KPi-glycerol 
buffer (100 mM potassium phosphate [KPi] pH 7.4, 10% glycerol, 0.5 mM EDTA, and 
0.25 mM DTT). Cells were disrupted using a French press (1000 psi, 3 repeats), and 
the cytosolic fraction was separated from the membrane fraction by 
ultracentrifugation of the lysate (120,000 g, 4 °C, 60 min). Then the enzymes were 
purified using Ni-NTA agarose (Sigma). To prevent aspecific binding, 1 mM histidine 
was added to the cytosolic fraction. 3 mL of Ni-NTA slurry was added to 20 mL of 
cytosol and the mixture was equilibrated at 4 °C for 2 hours. The Ni-NTA agarose was 
retained in a polypropylene tube with porous disc (Pierce,Rockford,USA) and was 
washed 4 times with 4 mL Kpi-glycerol buffer containing 2 mM histidine. The P450 
was eluted in 10 mL Kpi-glycerol containing 200 mM histidine. The histidine was 
subsequently removed by repeated washing with Kpi-glycerol buffer in Vivaspin 20 
filtration tube (10,000 MWCO PES, Sartorius) at 4000 g until the histidine 
concentration was below 250 nM. 
 
Incubations of P450 BM3 mutants with Ƚ-ionone and analysis by GC-MS 
 
For the biotransformation reaction, cytosolic fraction containing 200 nM of P450 BM3 
mutants was incubated with 500 μM of racemic Ƚ-ionone in a final volume of 250 μL. 
The reaction was initiated by the addition of 25 μL NADPH regeneration system 
containing 5 mM NADPH, 50 mM glucose-6-phosphate and 20 units of glucose-6-
phosphate dehydrogenase. The reaction was allowed to proceed for 1 hour and then  
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stopped by placing on ice. After addition of 10 μL of 5 mM carbazole as internal 
standard, samples were extracted by vortexing with 2 mL of ethyl acetate for 30 sec.  
Subsequently samples were centrifuged at 4000 g for 5 minutes to separate phases. 
About 1 mL of the organic layer was then transferred to GC vials for analysis. The 
extracts were analyzed using a Hewlett-Packard 6890 series with ATAS 
Programmable Injector 2.1. Samples were separated on a DB-5 GC-column (30 m x 
0.25 mm). Ionization was done by electron impact (EI) at 70 eV with the mass 
  ͷͻ͹͵Ǥ       ʹͷͲǏǤ 
temperature program for the GC was as followǣ ʹǤ   ͸ͲǏǡ  
ʹͲǏ-1 ʹͺͲǏʹͺͲǏͶǤ	
enantiomers, same conditions were used as described above.  
 
Dissociation constant determination by optical spectroscopy 
 
The binding of (R)- or (S)-Ƚ-ionone to wild-type P450 BM3 and mutants M01, M11, 
M01 A82W and M11 L437N was analyzed by optical titrations using a Shimadzu UV-
2501PC spectrophotometer (Shimadzu Duisburg, Germany). The spectra for the 
substrate-ȋͳɊȌe recorded at 24 °C in 1 mL of 100 mM potassium 
  ȋ ͹ǤͶȌ     Ƚ-ionone enantiomers. Increasing 
amounts of (R)- or (SȌȽ-ionone dissolved in methanol were added from appropriate 
stocks up to a final volume of not more than 2% of the total volume of the solution. 
Spectra were recorded after each addition of substrate, and a difference spectrum was 
computed by subtraction of the starting (substrate-free) spectrum from those 
generated at each point in the titration. The maximum apparent absorption change 
ȋȟ390-422) was determined by subtraction of the 
minimum absorption value at the trough in each difference spectrum from the 
maximum value at the peak and these values were plotted versus corresponding 
concentrations of (R)- or (S)-Ƚ-ionone after correction for dilution. Data were 
analyzed by nonlinear regression using GraphPad Prism 4 (GraphPad Sotware, San 
Diego, CA, USA). The spectral dissociation constants (KD) were determined by fitting 
the titration binding curves to the following equation 
 
 
 
 
 ȟ  -to-  ǡ ȟmax is the maximum 
absorbance difference, [S] is the substrate concentration and KD is the dissociation 
constant of the enzyme–substrate complex. For substrate showing tight binding (Kd < 
ͳɊȌǡ(41) 
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 ȟ  -to-  ǡ ȟmax is the maximum 
absorbance difference, [S] is the substrate concentration and [E] is the enzyme 
concentration. 
 
Determination of coupling efficiency  
 
NADPH oxidation rates were measured at 25°C using Libra S12 Biochrom UV-VIS 
spectrophotometer and 1 cm path length cuvettes. To measure the NADPH 
consumption rate, P450 BM3 (final concentration 200 nM) was mixed with 100 mM 
KPi buffer  pH 7.4 containing 2ͲͲɊȽ-ionone enantiomers(R or S) in methanol (2% 
final) in a volume of 1 mL. The reaction was initiated by the addition of NADPH (end 
 ʹͲͲ ɊȌ         ͵Ͳ
seconds. Rates were calculated based on extinction co-ɂα͸ǡʹͲͲ-
1cm-1 (42). To measure the coupling efficiency, the product formation was quantified 
under the same conditions. The percentage of coupling was determined as the ratio of 
the amount of product formed to the amount of NADPH consumed. 
 
Determination of total turnover numbers of M01 A82W and M11 L437N 
 
200 nM of purified enzymes (M01 A82W and M11 L437N) was incubated with 1 mM 
of (R)- or (S)-enantiomers (2% methanol) in a total volume of 500 μL. The reaction 
was initiated by the addition of 50 μL NADPH regenerating system as mentioned in 
section 2.4. The reaction was performed in duplicate in 1.5 mL eppendorf tubes at 
24Ǐ for 12 hours with shaking. The samples were then extracted and analyzed by GC-
MS as described above. Total turnover numbers were calculated as nmol of product 
formed per nmol enzyme by using the calibration curve of (3S,6S)-OH-Ƚ-ionone 
(R2αͲǤͻͻͺʹȌͲǤͳͳǤ 
 
Preparative scale synthesis 
 
Large scale incubation was performed in a 3L baffled flask with 250 nM of purified 
mutant M01 A82W, 48 mg of (S)-Ƚ-ionone (final concentration 1 mM) in a volume of  
250 mL in 100 mM potassium phosphate buffer (pH 7.4) at 24Ǐ. The reaction was 
initiated by addition of 25 mL NADPH regenerating system. The reaction was allowed 
to proceed for 6 hours and then the products were extracted by using ethyl acetate. 
The organic layer was dried over anhydrous Na2SO4 and analyzed by GC-MS to 
determine the substrate conversion and product formation.  
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Computational methods 
 
Mutants M01 A82W and M11 L437N were selected for molecular docking studies as 
they showed distinct stereoselectivity in C-3 hydroxylation. Molecular structures of 
the mutants were modeled based on chain A of the substrate-free crystal structure 
(PDB code 1BU7),(43) using the molecular modeling software MOE (Molecular 
Operating Environment).(44) Side-chains of the mutated amino acids were manually 
replaced using the builder tool, and polar and aromatic hydrogen atoms were added. 
The mutant structures were energy minimized in vacuo using the GROMOS05 
biomolecular simulation package (45, 46) and the GROMOS force field parameter set 
45A4.(47) Subsequently, aliphatic hydrogen atoms were added using MOE. Molecular 
structures of the substrate for use in docking were manually built using the MOE 
program and energetically optimized using the MMFF94x force field, as implemented 
in MOE. Subsequently, (R)- and (S)-Ƚ-ionone were docked into the M01 A82W and 
M11 L437N active sites using GOLD (Genetic Optimization for Ligand Docking),(48) 
version 4.0, and the Chemscore scoring function.(49) The center point of the docking 
sphere was placed in the middle of the protein binding cavity, in between the side 
chain of residue 437 and the heme iron atom, from which the radius was set to 1.5 nm 
to define the active site of the protein. For each enantiomer, four independent docking 
simulations were performed. Per docking simulation, maximally 50 docked poses 
were retained. A maximum of 50000 operations in the GOLD genetic algorithm were 
performed, using a population of 100 genes. Generated binding poses for which all of 
the substrate’s carbon atoms were positioned more than 6 Å away from the heme iron 
center, (which is the hypothetical cut-off for catalytic activity,(50) and which is 
comparable to the distance of 5.6 Å between the heme iron and the C-͵  Ⱦ-
ionone in the crystal structure with PDB code 3OFU(34)) were discarded for further 
analysis. The remaining binding poses were visually inspected using MOE. 
 
Results and Discussion 
 
Screening of the P450 BM3 library with racemic Ƚ-ionone  
 
The goal of the initial screening was to identify P450 BM3 mutants that can produce 3-
OH-Ƚ-ionone with high selectivity. 40 cytochrome P450 BM3 mutants that were tested 
  Ƚ-ionone to trans-3-OH- and cis-3-OH-Ƚ-ionone with different 
selectivities and activities. As shown in Figure 2, three distinct product profiles were 
ǣ Ƚ-ionone predominantly to trans-3-OH-Ƚ-
ionone (Figure 2A), mutants which produced almost equal amounts of both cis- and 
trans-3-hydroxy-Ƚ-ionone (Figure 2B) and mutants with produced significant  
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Figure 2. 
      Ƚ-ionone by (A) M01 A82W (B) 
M11 L437N (C) M11 A74E.  Identification of the peaks: (1) cis-3-OH-Ƚ  R 9.84 (2) trans-3-OH-Ƚ
ionone tR 9.92 (3) 3-oxo-ȽR 10.02 (4) unknown product tR 10.84. 
 
 
amounts of over-oxidation products (Figure 2C). The retention times (tR) of cis-3-OH-
Ƚ-ionone and trans-3-OH-Ƚ-ionone were 9.84 and 9.92 minutes respectively based on 
the tR of the available reference compounds. The product profile of all the mutants 
  Ƚ-ionone is shown in Figure 3. In general, most of the mutants 
were capable of highly regio-selective C-3 hydroxylation of racȽ-ionone. C-3 is 
energetically the most favorable site for hydroxylation because it is an allylic 
methylene group. P450 BM3 mutants exhibiting high selectivity are highlighted in 
	 ͵Ǥ  Ͳͳ ͺʹǡ ͳͳ ͺʹǡ ͳͳ ͺ͹   Ƚ-ionone 
mainly to trans-3-OH-Ƚ-ionone (>85% de), whereas mutants M11 L437N, M11 L437S 
and  M11 L437T produced almost equal amounts of trans-3-OH-Ƚ-ionone and cis-3-
OH-Ƚ-ionone. Consistent with previous study [17], wild-type P450 BM3 showed only 
very low activity, with preference for trans-hydroxylation. 
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Figure 3.       Ƚ-ionone by wild-type P450 BM3 and engineered 
variants. Conversions in % were measured from substrate consumption after 1 hour incubation of 500 μM 
of Ƚ-ione with 200 nM of P450 BM3. Values represent averages of 2 independent experiments with 
less than 10% error. Product selectivity in % was calculated from gas chromatograms by integrating the 
product peaks. Representative P450 BM3 variants showing high selectivity towards formation of trans-3-Ƚ-
ionone (M11 V87I, M11 A82W, M01 A82W), variants that were not selective (M11 L437N, M11 L437S, M11 
L437T, M11 L437N V87F) and a variant showing high over-oxidation product formation (M11 A74E) are 
highlighted. Wild-type P450 BM3 and mutants M01 and M11 are also highlighted for comparison. Of the 40 
mutants tested, only one variant showed <0.5% conversion (M11 V87C) and was therefore not included in 
Figure 3.  
 
 
Conversion to 3-oxo-Ƚ-ionone 
 
ȋͳͳ͹ͶǡͳͳͶ͵͹ȌȽ-ionone to 3-oxo-Ƚ-
ionone and an unidentified over-oxidation product (m/z 206), in addition to trans-3-
OH- and cis-3-OH-Ƚ-ionone. A representative gas chromatogram illustrating this 
product profile is shown in Figure 2C. Incubation of purified P450 BM3 mutants with 
Ƚ-ionone also resulted in the formation of 3-oxo-Ƚ-ionone indicating that the 
secondary oxidation of alcohol to ketone is also mediated by P450 BM3. 3-Oxo-Ƚ-
ionone has been recently shown to be a phagostimulant and also has commercial 
value because of its fragrance (51). The exact mechanism of formation of 3-oxo-Ƚ-
ionone is still to be investigated, but the formation of ketones by engineered P450 has 
been reported before for octane hydroxylation (52, 53). A possible mechanism as  
ͷ͹
Regio- and stereoselective hydroxylation of Ƚ-ionone 
 
mentioned in these studies is theformation of a geminal diol that readily dehydrates to 
form the corresponding ketone group. Also, in the case of 7-hydroxy-delta8-
tetrahydrocannabinol (THC) hydroxylation by hepatic microsomes from Japanese 
monkeys, the formation of 7-oxo-delta8-THC by a similar mechanism has been 
reported (54).  
 
Ƚ-ionone 
 
As seen in Figure 3ǡ         Ƚ-ionone, 
mutants M11 L437N, M11 L437S and M11 L437T initially appeared to be not 
stereoselective by producing almost equal amounts of trans- and cis-3-OH-Ƚ-ionone. 
Ƚ-ionone enantiomer, 
these three mutants were also incubated with the individual enantiomers (6R)- and 
(6S)-Ƚ-ionone. All three mutants turned out to be highly stereoselective with 
individual enantiomers as substrate, producing (3S,6S)-OH-Ƚ-ionone with (6S)-
enantiomer and (3S,6R)-OH-Ƚ-ionone with (6R)-enantiomer. 
 
. 
 
 
Figure 4. Representative gas chromatograms showing opposite stereoselectivity for (A) hydroxylation of 
(6R)-Ƚ-ionone by M11 L437N and (B) hydroxylation of (6S)-Ƚ-ionone by M11 L437N and similar 
stereoselectivity for (C) hydroxylation of (6R)-Ƚ-ionone by M01 A82W and (D) hydroxylation of (6S)-Ƚ-
ionone by M01 A82W. In all cases, the substrate (6R)- or (6S)-Ƚ-ionone was completely oxidized to 
respective products. 
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Figure 4 (A, B) shows the results obtained with mutant M11 L437N. Incubation of 
M11 L437T with (6R)-Ƚ-ionone at a concentration of 500 μM resulted in the formation 
of about 80% of (3S,6R)-OH-Ƚ-ionone, 12% of (3R,6R)-OH-Ƚ-ionone and 8% of 3-oxo-
Ƚ-ionone    ͳ Ǥ  ͳʹ   ǡ Ƚ-ionone was 
completely converted to 3-oxo-Ƚ-ionone In contrast, 12 hour incubations of M11 
Ͷ͵͹Ƚ-ionone enantiomer showed only small amounts of 3-oxo-ionone. This 
shows that BM3 mutant M11 L437N is capable of highly selective hydroxylation with 
minimal formation of secondary oxidation products whereas mutant M11 L437T can 
result in the formation of significant amount of 3-oxo-Ƚ-iononeThe fact that 
incubations with mutant M11 showed also significant amounts (30%) of (3R,6R)-OH-
Ƚ-ionone with the (6R)-enantiomer as substrate, Table 1, shows that substitution 
L437N in mutant M11 has improved stereoselectivity of (6R)-Ƚ-ionone hydroxylation. 
Interestingly, L437 has been recently reported to be a ‘hotspot’ affecting the 
selectivity of terpene hydroxylation (55). 
 
To test whether the L437N substitution also influences stereoselectivity in other M11-
related mutants, the enantiomers of Ƚ-ionone were also incubated with the available 
combinations M11 V87 and M11 V87F L437N, and M11 A82W and M11 A82W L437N.  
As shown in Figure 5A, substitution of L437N also increased relative amount of 
(3S,6R)-OH-Ƚ-ionone when applied to M11 V87F and M11 A82W although to a much 
lower extent when compared to that when applied to M11. When incubated with (6S)-
Ƚ-ionone, the L437N substitution led to a slight increase in formation of (3R,6S)-OH-Ƚ-
ionone when applied to M11 V87F,  whereas the substitution had no effect when 
applied to M11 A82W, Figure 5B. These results confirm that the effect of single amino 
acid substitution is strongly dependent on additional nearby mutations (55, 56). 
 
As shown in Figure 3, M01 A82W metabolized racemic Ƚ-ionone with high activity, 
producing mainly trans-3-OH-Ƚ-ionone, implicating that both enantiomers of Ƚ-ionone 
were stereoselectively hydroxylated.  This was confirmed by incubation of M01 A82W 
with the individual enantiomers.  As shown in Figure 4 (C, D), (6R)-Ƚ-ionone was 
specifically metabolized to (3R,6R)-OH-Ƚ-ionone, whereas (6S)-Ƚ-ionone was 
specifically metabolized to (3S,6S)-OH-Ƚ-ionone. In both cases only minimal amounts 
of secondary oxidation products were observed.  When (6R)-Ƚ-ionone was incubated 
with purified M01, significant amounts of both diastereomers were found, Table 1, 
indicating that mutation A82W has strongly increased stereoselectivity of 
hydroxylation of Ƚ-ionone.  
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Figure 5. Effect of L437N mutation on stereoselectivity of C-3 hydroxylation of Ƚ-ionone enantiomers. Panel 
A and Panel B represent hydroxylation of (6R) and (6S)-Ƚ-ionone respectively.  
 
 
Wild-type P450 BM3, which showed only very low activity when incubated with 
 Ƚ-ionone, showed very low diastereoselectivity, when incubated with the 
  Ƚ-ionone, Table 1. When incubated with (S)-Ƚ-ionone, almost equal 
amounts of (3S,6S)- and (3R,6S)-diastereomers were found, next to significant 
amounts of unidentified oxidation products.  When incubated with (R)-Ƚ-ionone, the 
diastereomeric excess for the (3R,6R)-diastereomer was found to be 51%. 
 
Total turnover numbers for stereoselective hydroxylation 
 
An optimal biocatalyst should ideally be able to catalyze the formation of the desired 
product in highly selective manner (regio-, enantio- or stereo-) in combination with 
high catalytic turnovers and with minimal amount of secondary products (57).  
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Among M11 L437N, M11 L437S and M11 L437T, M11 L437N, which showed the 
highest diastereoselectivity (>90%), see Figure 4, was selected for determination of 
ǤȽ-ionone 
by P450s, mutant M11 L437N is the first engineered P450 BM3 specifically producing 
one of the cis-3-OH products, i.e. (3S,6R), with high stereoselectivity. Additionally, 
among mutants that produced predominantly trans-3-OH-Ƚ-ionone, M01 A82W was 
selected for incubation with individual enantiomers because it exhibited the highest 
diastereoselectivity as well as activity. M01 A82W catalyzed the formation of (3S,6S)-
OH-Ƚ-ionone and (3R,6R)-Ƚ-ionone with (6S)- and (6R)- enantiomers respectively, 
with remarkable selectivity. 
 
The fact that the P450 BM3 mutants M01 A82W and M11 L437N exhibit different 
stereoselectivities towards hydroxylation of (R)-and (S)- enantiomers, makes them 
highly useful for industrial biotechnological applications. M01 A82W catalyzes the 
formation of (3S,6S)-OH-Ƚ-ionone and (3R,6R)-OH-Ƚ-ionone with turnover numbers 
in the range of 3500-4000, Table 1. Similarly M11 L437N can also catalyze the 
formation of (3S,6R)-OH-Ƚ-ionone with high turnover numbers of about 3000 nmol 
product/nmol enzyme. These high turnover numbers indicate that these enzymes 
might be useful for preparative scale biosynthesis (58). For both M01 A82W and M11 
L437N these reactions are carried out with high selectivity to the desired product with 
minimal formation of side products. Purified M01 A82W was used as biocatalyst with 
(S)-Ƚ-ionone (48 mg) as substrate in a volume of 250 mL to illustrate the preparative 
use of this engineered P450 BM3. The reaction resulted in > 90% substrate conversion 
to produce (3S,6S)-OH-Ƚ-ionone (95% de) under the experimental conditions 
mentioned. Therefore, apparently the biotransformation reaction can be scaled up 
without any loss of diastereoselectivity 
 
Ƚ-ionone enantiomers 
 
  Ƚ-ionone enantiomers with the stereoselective mutants M01 
A82W and M11 L437N and their respective templates M01 and M11 were studied by 
spectral binding experiments. Titration of (R)- or (S)-Ƚ-ionone to solutions of purified 
P450 BM3 mutants in all cases resulted in typical type I difference spectra, with a peak 
at 390 nm and a trough at 422 nm, indicative of the conversion of heme iron from low 
spin to high spin. The dissociation constants obtained from these titration studies are 
shown in Table 2. The introduction of the A82W mutation in M01 increased binding 
affinity towards both enantiomers: the dissociation constant (Kd) for M01 A82W was 
decreased approximately 3.5 fold in the case of R-enantiomer and approximately 22 
fold in the case of S-enantiomer when compared to M01.  
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Improved affinity of hydrophobic substrates by A82W mutation in P450 BM3 has 
been reported previously with other substrates like fatty acids and testosterone (38, 
59). Mutation L437N in M11 also apparently increases affinity towards both 
  Ƚ-ionone; dissociation constants were lowered 2.4-3.6 fold in 
comparison to its precursor M11, which exhibited Kd values of 17 μM and 27 μM for R-
enantiomer and S-enantiomer respectively. Wild-type P450 BM3 also showed a typical 
Type I difference spectrum. Dissociation constants obtained were comparable to those 
obtained with the much more active P450 BM3 mutants, being 17.5 and 10.3 μM, 
respectively, for R-Ƚ-ionone and S-Ƚ-ionone.  
 
NADPH consumption and product formation 
 
To study the coupling efficiency of the mutants and wild-type P450 BM3, the rates of 
NADPH oxidation and product formation were determined at 200 μM of substrate, 
Table 2. In case of wild-type BM3, relatively low (4-6%) coupling efficiencies were 
observed for both enantiomers: the NADPH oxidation rates upon addition of R- or S-Ƚ-
ionone were found to be approximately 30 min-1 whereas the product formation was 
only about 1.5 min-1. Wild-type P450 BM3 produced a mixture of 2 diastereomers of 
C-3 hydroxylation and an additional peak with m/z of 208 indicating hydroxylation at 
another carbon with both the enantiomers. Interestingly, no over-oxidation peaks 
were observed with both enantiomers (Table 1). In case of the P450 BM3 mutants 
significantly higher coupling efficiencies, up to 45%, were observed when compared 
to wild-type P450 BM3.  Introduction of mutation A82W in M01 did not significantly 
affect the product formation with R-Ƚ-ionone as substrate, but decreased NADPH-
oxidation 3-fold. The increased affinity towards R-Ƚ-ionone due to the A82W mutation 
in combination with a more productive binding mode therefore may explain the 
increased coupling efficiency 
 
For M11 the introduction of L437N did not increase coupling efficiency of C-3 
hydroxylation of both enantiomers, Table 2. However, the rate of both NAPDH 
oxidation and product formation was increased almost 3 to 4 fold. The higher affinity 
to M11 L437N variant and the higher stereoselectivity when compared to M11 are 
indicative to a different, more productive, binding mode due to the L437N mutation. 
For S-Ƚ-ionone, the A82W mutation in M01 led to approximately 1.7 fold increase in 
rate of NADPH oxidation and 2.7 fold increase in the rate of product formation, 
resulting in an increased coupling efficiency of 44%. For S-enantiomer all four 
variants formed predominantly trans-OH-Ƚ-ionone with M01 A82W exhibiting the 
highest diastereoselectivity (95%). 
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The mutant producing the highest amounts of (3R,6S)-3-OH-Ƚ-ionone was found to be 
M11 L437N V87F, which also showed an aselective product profile with  
racemic-Ƚ-ionone. This mutant produced (3R,6S)-OH-Ƚ-ionone with 40% selectivity 
Interestingly, wild-type P450 BM3 also produced about 36% (3R,6S)-OH-Ƚ-ionone but 
with a much lower activity compared to the BM3 mutant M11 L437N V87F. 
Apparently, the presence of phenylalanine at position 87 seems to increase the 
amount of (3R,6S)-OH-Ƚ-ionone produced. Although this mutant still shows only 
moderate selectivity for the formation of this product, it could be a good starting point 
to improve the stereoselectivity by directed evolution.  
 
Docking studies 
 
Molecular docking studies were performed in order to rationalize the basis for the 
experimentally observed regio- and stereoselectivity of hydroxylation of Ƚ-ionone 
enantiomers. Figure 6 shows representative binding poses as observed in our 
docking studies on the binding of (R)- and (S)-Ƚ-ionone to M01 A82W and M11 
L437N. In case of mutant M01 A82W, the majority of obtained binding poses for both 
(R)- and (S)-Ƚ-ionone was found in a position suitable for C-3 hydroxylation, i.e. C-3 
was found within 6 Å from the heme iron catalytic center, Figure 6A and 6B (50) in 
line with the experimental observation that C-3 is the dominant site-of-metabolism 
The introduction of 82W substantially reduces the size of the binding cavity, which 
results in directing the substrate closer to the heme group and in an increase in 
activity, in line with previous suggestions based on a study on the hydroxylation of 
palmitate by a A82W mutant of BM3 (59). Also among the docking poses obtained for 
M11 L437N in which the substrate was positioned within the catalytic cut-off, C-3 was 
found to be in close proximity of the heme iron atom (Figure 6C and 6D).  
 
Based on the poses in which C-3 was found to be the carbon atom closest to the heme 
iron, the experimentally observed regioselective hydroxylation at C-3 can be 
explained by the formation of a hydrogen bond between the carbonyl oxygen and 
active site residue Ser72, which seems to anchor the ligand such that C-3 points 
toward the heme catalytic center, see Figure 6. Interestingly, substitution of alanine 
by tryptophan has been shown to affect the regioselectivity (38) and along with 
hydrophobic substitutions at position 72 to affect stereoselectivity of hydroxylation of 
larger substrates like steroids (60)ǤȽ-ionone by Ser72 is 
     Ƚ-ionone by His94 upon binding to CYP109D1 as 
observed in a recent docking study of Khatri et al., (32) and by Thr285 as observed in 
a recent docking study by Ly et al. (33) Ƚ-ionone binding to CYP264B1. 
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When docking either (R)- or (S)-Ƚ-ionone into M01 A82W, binding poses were 
predominantly obtained in which the C-3-bound trans-hydrogen is oriented toward 
the heme iron atom (Figure 6A and 6B, respectively). Such binding poses will be 
referred to as “trans-orientated” binding poses. Experimentally, more than 90% of the 
products were found to be hydroxylated at the trans position. These findings suggest 
that the observed binding orientation (Figure 6A and 6B) directs the stereoselectivity 
of the hydroxylation process, in which the substrate is oxidized by the activated iron-
oxo ferryl species (61). When docking (S)-Ƚ-ionone into M11 L437N, predominantly 
trans-orientated binding poses were obtained as well (Figure 6D), but interestingly, 
only for (R)-Ƚ-ionone, a number of docking poses were found in which the cis-
hydrogen was found closest to the heme iron atom (Figure 6C). This offers a possible 
explanation for the experimental finding that hydroxylation at C-3’s cis-position was 
observed for this substrate by M11 L437N. 
 
For M01 A82W, the (R)-enantiomer is oriented with C-3’s trans-hydrogen closest to 
the heme iron atom, due to a steric conflict of the two methyl groups bound to C1 and 
the bulky tryptophan side chain at the 82 position (Figure 6A), whereas M11 L437N 
(lacking this bulky side chain) leaves more space in the active site, making it possible 
for the double methyl groups to point towards the residue-82 side of the cavity as 
seen in Figure 6C. For the (S)-enantiomer, no such direction of the binding orientation 
to prevent sterical hindrance is observed, as seen in Figure 6B and 6D. The role of 
A82W mutation was experimentally further confirmed by incubating P450 BM3 
mutant M11 L437N A82W with R-Ƚ-ionone. In line with the above discussion, the 
addition of A82W to M11 L437N was found to substantially decrease the 
stereoselectivity and cis-hydroxylation at C-3 position of R-Ƚ-ionone, see Figure 5. 
 
In conclusion, these docking studies support the observations that residue 82W plays 
        Ƚ-ionone enantiomers by 
M01 A82W and M11 L437N. The presented docking studies used a wild-type BM3 
crystal structure (PDB code 1BU7) as structural template for the mutants and did not 
explicitly account for the role of possible differences in active-site conformations and 
water molecule orientations, which may affect docking outcomes (62-65). As a first 
exploration of the substrate binding orientation. Currently, the structural analysis of 
the binding of (R)-and (S)-Ƚ-ionone to BM3 mutants such as M01 A82W and M11 
L437N is extended towards a more rigorous study using molecular dynamics 
simulations, thereby allowing inclusion of the effects of protein plasticity (64, 66) and 
water- mediated protein-substrate interactions (67), to make possible a more detailed 
Ƚ-ionone binding process. 
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Figure 6. Binding poses of (R)-Ƚ-ionone (depicted in green in A and C) and of (S)-Ƚ-ionone (depicted in 
magenta in B and D) in mutant M01 A82W (A and B) and M11 L437N (C and D), as obtained from molecular 
docking studies. Selected amino acid residues within the binding cavity of the mutants, and the catalytic 
active heme moiety are depicted as well. The substrate’s main site-of-metabolism (C-3) is marked by a 
sphere. Hydrogen atoms are omitted, except for the C-3 bound hydrogens, which are shown in small 
spheres. Cis-hydrogens are depicted in grey, and trans-hydrogens are depicted in orange. In addition, the 
hydrogen atom at the stereo-center (C-6) are explicitly shown, in small grey spheres, to highlight which 
stereoisomer is depicted. The blue thin line represents the hydrogen bond formed between the side-chain 
   ͹ʹ ǡ      Ƚ-ionone; the dashed line represents 
distances (in Å) of C-3 toward the heme iron atom.  
 
Conclusion 
 
The present sȽ-ionone can be hydroxylated 
by P450 BM3 mutants with high regio- and stereoselectivity along with high turnover 
numbers, which makes them an attractive option for the green production of 
diastereomers of 3-hydroxy-Ƚ-ionone. This is the first time that such stereoselectivity 
Ƚ-ionone hydroxylation by P450 BM3 mutants has been reported. 
Moreover, the formation of (3S,6R)-OH-Ƚ-ionone by M11 L437N (90% de) exhibits the 
ability of engineered P450 BM3 to produce cis-3-OH-Ƚ-ionone. While initial docking 
results yield some insights into the regio- Ƚ-ionone  
͸͹
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hydroxylation and the role played by the A82W mutation in M01 A82W, extensive free 
energy calculations and binding affinities of the individual enantiomers to M01 A82W 
and M11 L437N are needed to further understand the basis of stereoselectivity. 
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Table S1.  Forward primers used for site directed mutagenesis 
 
 
Mutation Oligonucleotide sequences (5´-3´)  Templates 
                  
         
A82Y 
GT CAA GCG CTT AAA TTT GTT CGC GAT ATT TAC GGA GAC GGG 
M11 L437N 
M11 L437S 
GT CAA GCG AAT AAA TTT GTT CGC GAT TTT TAC GGA GAC GGG M01 L75N 
A82W GT CAA GCG CTT AAA TTT GTT CGC GAT ATT TGG GGA GAC GGG M11 L437N 
V87F 
GCA GGA GAC GGG TTA TTC ACT AGT TGG ACG CAT 
M11 L437N 
M11 L437S 
V87I 
GCA GGA GAC GGG TTA ATC ACT AGT TGG ACG CAT 
M11 L437N 
M11 L437S 
                    
L437E 
C TAC GAG CTC GAT ATT AAA GAG ACT GAG ACG TTA AAA CCT GAA GGC 
TTT GTG G M01 
͹ͳ
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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Introduction 
  
          
      (1).    
ǡ 
 (2-4). ͶͷͲ-
- and 
or stereo (5, 6). ͶͷͲ 
ǡǡ
 (7). ǡ
  ͶͷͲ -    
  (8). ͶͷͲ͵     ͶͷͲ 
Bacillus megaterium,         Ǥ   
            
ǡ (9, 10). Protein 
  ǡ -ǡ      
     ͶͷͲ͵  for different regio- and 
stereo         ǡ
alkenesǡ- (10). ͶͷͲ͵
(11-13) Engineered P450 
͵Ǥ 
 
  ͶͷͲ
   (14). 	   ǡ     
   ǡ       -  
    (15).  Escherichia coli     
ͶͷͲ (16-21), also 
-
(22-27). 
 
RhodococcusǤ
 Rhodococcus     ǡ   
         
  (28, 29). Rhodococcus strains are -kn  
   ǡ        
 ǡ  Ȁǡ     
     (30, 31).     
 (32, 33). 
ǡ    Rhodococcus         
ͶͷͲǤe  
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of Rhodococcus       
 (31). 
 
Rhodococcus erythropolis strain SQ1 
        3-ketosteroid ȟ1-
ȋȌ  ͵- ͻȽ- ȋȌ       
degradation  (34-37).   R. erythropolis 
SQ1, 
ͻ Ͷ-androstene-3,17-    
 kstD, kstD2 and kshA1 ǡ      steroid ring 
opening (36).  ǡ  of R. erythropolis,  n 
  ǡ        
Ǥ 
 
   ǡ     ȋȌ  
͵Ͳʹ

ͻ͵ͲʹǤͶͷͲ͵Ͳʹ
      -  (38, 39). 
    Ǥ erythropolis  
ͻ    

ͶͷͲ͵ͲʹǤ 
 
Experimental Section 
 
Materials 
 
All          
mentioned.  
 
Bacterial strains and growth conditions 
 
Rhodococcus erythropolis    ͳ (40)    
ͻ 
ʹͻ ιͳͺͲǤ 
ͻ ȋkstD kstD2 kshA1 Ȍ
 ȋvan der Geize, et al.ǡ ʹͲͲʹȌ. Pre-Rhodococcus 
ͳΨȋȀȌȋȌǡͲǤͷΨȋȀȌ
  ȋȌǡ  ͳΨ ȋȀȌ  (41)Ǥ   
Rhodococcus      ȋȌ   
ȋ͵ͶɊȀȌǤ 
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CHAPTER 3  
 
 
Expression and purification of BM3 mutant M02 
 
 ͶͷͲ ͵  Ͳʹ    E. coli ʹͳ ͵ 
  ʹͺ-Ͳʹ      
 (38). 
 
Determination of dissociation constant and coupling efficiency 
 
ͶͷͲ͵Ͳʹ
    -ʹͷͲͳ  ȋ ǡ

ȌǤ 
              
 (42). 
 
Product isolation and NMR analysis 
 
Large-ͳρͲʹǡͳ
norandrostenedione ʹͷͳͲͲ ȋ
͹ǤͶȌǤ          ͲǤʹ
  ǡ ͳ   ͸-  ͲǤͶ Ȁ  ͸-
        ͵    
ʹͷͲǤ
-Ǥ
 ͳ  semi-
preparative    ͷ Ɋ ͳͺȋʹȌ  ȋʹͷͲ  ͳͲ mm i.d.) from 
Ǥ  ʹȀ ͸ͲΨȀ
ͶͲΨ     norandrostenedione and metabolites. Metabolites 
     ȋʹͷͶ Ȍ   Ǥ 
       H    Ǥ 
ͷͲͲρ
-d4.1H- 
and 1H-1H-Ǥ
    ͷͲͲ ȋ	ǡ Ȍǡ   
operating at 500.13MHz..  
 
S-ͳʹͲͲ
     -of- ȋ	Ȍ  ͸ʹ͵Ͳ  
    ȋȌ      
Ǥ             ͵ͷͲͲ Ǥ
ȋͳͲȀȌȋͷͲȌ 
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    ͵ͷͲ ι.       	
Ǥ     
Ǥ 
 
Cloning and heterologous expression of P450 BM3 mutant M02 in R. 
erythropolis  strain RG9 
 
   ͶͷͲ ͵  Ͳʹ   ͳ-ͶͷͲ͵Ͳʹ 
amplified    ͷǯ--͵ǯ   
Ncoͷǯ -͵ǯ 
  Xho  Ǥ  ͵ͳ͸ͷ      
NcoI/XhoI and liga   NcoI/XhoI sites of pTip-ͳ (43)Ǥ  
ǡ -ͳ̴ͶͷͲ͵ Ͳʹ    R. erythropolis 
ͻ 
 (37). 
 
In vivo biotransformation of norandrostenedione  
 
In vivo     ȋ Ȍ  ʹͷͲ 
  ʹͷ   ȋ͵Ͷ ɊȀȌ  ʹͻι 
 ͳͺͲ Ǥ   ͶͷͲ ͵  Ͳʹ   
ͻ   
   ȋ600 of 16-ʹͲȌ      ȋͳ
ɊȀȌ(43)ǤȋͳȀȌ
   Ͷͺ Ǥ 	  ǡ    
ȀȋͲǤʹɊȌǤ
 ͷ Ɋ ͳͺ  ȋʹͷͲ  ͶǤ͸  ǤǤȌ    
ȋͲǤͷȀȌǣȋ͸ͲǣͶͲǡȀȌǤ
       norandrostenedione. Representative 
-MS Ǥ 
 
Results and discussion 
 
In vitro biotransformation of norandrostenedione by P450 BM3 M02 using 
purified P450 BM3 
 
 ͵Ͳʹ 
Ǥ
ͶͷͲ͵Ͳʹ     ͳ
ȋεͻͷΨȌ m/z   ʹͺͻǡ      -Ǥ
          
Ǥ 
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CHAPTER 3  
 
 
  1H NMR and ȋFigure 
2ȌǤ͵Ǥͻ͹-ͳ͸Ǥ
    ͵Ǥͻ͹      
minal to H-16 (44).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.         in vitro biotransformation of 
  ͶͷͲ ͵  ͲʹǤ B -15 proton     single H-16. 
ǡ͵Ǥͻ͹-16. 
 
 
ǡ   -ͳͷ       -16 (Figure 1ȌǤ 
ͶͷͲ͵
Ͳʹ        –   
(39)Ǥ ǡ      ͵ Ͳʹ   
assigned as 16-Ⱦ-(Figure 2). 
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Synthesis of keto-steroid metabolite in Rhodococcus 
 
 
 
 
 
 
 
 
 
Figure 2. In vitro ͶͷͲ͵Ͳʹ. 
 
 
    ͶͷͲ͵Ͳʹ -VIS 
Ǥ            
͵ͻ͵ͶʹͲǤ
           eme 
ȋFigure 3). 
 
 
 
Figure 3. -ͶͷͲ͵ͲʹǤ
   ȋ ȌǤ         Ͳʹ  
ȋͳͲͲɊȌǤȋͶʹͲȌ
ȋ͵ͻ͵ȌǤ 
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d Ͷρǡ
    ͶͷͲ͵ͲʹǤ  
 ͵͵ΨȋTable 
1ȌǤͶͷͲ͵
ȋȌȋͳͲͲΨȌǡ l-
ȋǤǤȌ(45). 
 
Table 1. Invitro ȋȌ
ͶͷͲ͵Ͳʹ 
 
 
[a] ͸Ͳ  ͵ͶͲȀȀ
Ǥ  ͶͷͲ͵ ȋʹͲͲȌǡ ȋʹͲͲρȌ ȋʹͲͲρȌ 
ȋʹΨȌȋͳͲͲǡ 7.4) 
 
[b] over 6ͲȀȀ
ǤȋΨȌ/ 
 
ȏȐ   ȋρȌ -  ͳ ρ   ͳͲͲ
ǡ͹ǤͶǡǤ
͵ͻͲͶʹͲ-ͶʹʹǤ 
 
 
Invivo biotransformation of NAND in Rhodococcus erythropolis wildtype and RG9 
cells 
 
	ǡ ǤFigure 
4ǡR. erythropolis strain   Ǥ ͷ ǡ  
ͺͲΨdstrain. -MS 
 of a representative sample       a mono-
ȋȀʹͺͻȌ ȋȀʹ͹ͳȌǤe 
R. erythropolis  3-keto-steroid ͻȽ- and 3-keto-steroid 
  (31) adatis are 
be ͻȽ-OH- and 1,4-estradiene-3,17-dione ()  . After ͳʹ ǡ
   ͻȽ-OH-       
Ǥ 
 
͵Ͳʹ
in vitroǡR. erythropolis 
ͻ
P450-mediated steroid biotransformation in vivo  Ǥ ontrol  
  
ͻ      -ͳ    
ȋFigure 5AȌǤ 
Enzyme 
NADPH  
oxidation[a]   
Product 
formation[b] 
Coupling efficiency  
Dissociation  
constant (Kd ) [c] 
Ͳʹ 355.4άʹͳǤʹ ͳʹͲ.4άͺ.1 ͵͵ǤͺάʹǤͺ  ͶǤʹάͲǤͺ 
ͺͳ
Synthesis of keto-steroid metabolite in Rhodococcus 
 
ͶͺȋFigure 6). ǡ
ͶͷͲ͵ͲʹR. erythropolis 
ͻͳ͸Ⱦ-
Ǥ 
 
 
 
Figure 4. norandrostenedione R. erythropolis. 
ȋȌʹͷͲʹͷȋ͵ͶɊȀȌ͵Ͳ͑
ͳͺͲǤǣǡǢdotted lines 
 ͸ͲͲǤ 
 
 
ͶͷͲ͵ͲʹͲǤʹɊ
ͶͷͲ ͵     -  R. 
erythropolis 
ͻ    -ͳ̴ͶͷͲ ͵ ͲʹǤ ͶͷͲ ͵ Ͳʹ
          
 ǡ i.e. ͳͺ ӷʹͷ ӷǡ   
P450 protein expression in E. coli  ȋ  ȌǤ  
 ͳȀǤFigures 5B & 5Cǡ
 in vivo 
ͻsame mono-ȋͳ͸-Ⱦ-
Ȍ    in vitro   ͶͷͲ ͵Ǥ 
 

ͻ-ǡ
16-Ⱦ-ͶͷͲ͵Ǥ 
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Figure 5. Representative H     (A) Profile of 
Rhodococcus 
ͻ  ͶͷͲ ͵  ʹͶ  ȋȌ   
ͻ  
 ͶͷͲ ͵  Ͳʹ  ʹͶ  ȋȌ     Ͳʹ  ʹ  
on.   ȋȌ     16-Ⱦ-
norandrostenedione (16-Ⱦ-OH-Ȍ ͳ͹͹ǤͷǤȗ
P450-͵ȗȗǤ 
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Figure 6. norandrostenedione R. erythropolis 
ͳ͸ͶͷͲ͵ͲʹȋƔ) and 
R. erythropolis 
ͳ͸-ͳȋŸȌǤȋȌ
ʹͷͲʹͷȋ͵ͶɊȀȌ͵Ͳ͑ͳͺͲǤ
ǣǡǢǡǢǡ
͸ͲͲǤ 
 
 
ͲǤ35 g/L of 16-Ⱦ-ʹͲǤ	 not 
observed after ʹͲ (Figure 6). 
 ivated.  formation 16-Ⱦ-OH 
     Ǥ      
 Ȁ  
            
       -s.    
        R. 
ErythropolisǤ      
ͻ     
 ͶͷͲ͵ͳ͸Ⱦ-OH-
degraded (46)   
  ǡ ǤǤ ͵-ketosteroid ȟ1- ͵  ͵- ͻȽ-
ʹ (47, 48). ǡͳ͸Ⱦ-- ͳ͸Ⱦ--
NAN  
ͻ. 
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Figure 7.     orȋȌ   Rhodococcus strain and 
 
ͻͶͷͲ͵Ͳʹ 
 
 
 ͶͷͲRhodococcus 
ͶͷͲ total  of 
s. E. coli is as a     it  
P450s  Ǥǡ   
for  Ǥ E. coliǡ
of  steroids is not   (14). ǡ
for Rhodococcusǡ       
     (30). T,  
  in  Rhodococcus 
organism.  
 
 ǡ     
ͻ  ͶͷͲ ͵  Ͳʹ  
      ͳ͹-keto-steroid, norandrostenedione as 
Ǥ  
O
OCH3 O
OCH3
O
OCH3
OH
4-estrene-3,17-dione (NAND)
1,4-estradiene-3,17-dione (NANDD)
9D-hydroxy-4-estrene-3,17-dione
           (9OH-NAND)
KST
D2
KST
D1
metabolic block
 in strain RG9
O
OCH3
OH
Heterologously expressed P450 BM3 M02 in RG9
16E-hydroxy-4-estrene-3,17-dione
           (16OH-NAND)
Wildtype strain
KSH
m/z 273
m/z 271
m/z 289
m/z 289
ͺͷ
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ͶͷͲ͵
R. erythropolis. ͶͷͲ͵
 ered Rhodococcus        
degradation seems to be a promising       
 formed. 
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Stereoselective C-16 hydroxylation of testosterone 
 
Abstract 
 
Screening of a minimal mutant library revealed a cytochrome P450 BM3 variant M01 
A82W S72I capable of producing ͳ͸Ƚ-OH-testosterone. Remarkably, a single active 
site mutation S72I in M01 A82W reversed the stereoselectivity of hydroxylation from 
ͳ͸Ⱦ ͳ͸ȽǤ ͹ʹ ͳ͸Ⱦ-OH selective variant M11 
V87I also resulted in similar inversion of stereoselectivity. Thus engineered BM3 are 
Ƚ-face of testosterone D-ring with >90 %(e.e). 
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Introduction 
 
CYP102A1, commonly known as cytochrome P450 BM3 is a well known fatty acid 
hydroxylase from Bacillus Megaterium with one of the highest hydroxylation activities 
ever reported for a P450 (1). Although the natural substrates of P450 BM3 are long 
chained fatty acids, its substrate specificity has been broadened by site directed and 
random mutagenesis to a wide variety of other substrates (2-4). Moreover, engineered 
P450 BM3 mutants have gained importance over the years for their potential usage as 
biocatalysts for production of several pharmaceutically relevant human metabolites 
(5-7). Among such metabolites are hydroxylated steroids which are used for various 
therapeutic purposes. Chemical synthesis of specific hydroxylated variants of steroids 
are difficult as it requires multistep synthetic pathways and may yield a lot of side 
products (8). Steroid hydroxylation by microbial biotransformation has gained 
importance through the years. Several microbial strains and isolated P450s have been 
reported to hydroxylate steroids at different positions (9-12).  
 
Engineered P450 BM3 variants have also been described as biocatalysts for steroid 
hydroxylation with different regioselectivities on A or D ring. Since there are multiple 
positions at which steroids can be hydroxylated, they are ideal probes to study the 
effects of active site mutations on regio- and stereoselectivity. The first BM3 variant to 
show testosterone (henceforth abbreviated as TES) metabolism was a triple mutant 
(R47L, L188Q F87V), constructed by rational design and produced 3 mono-
hydroxylated metabolites (13)    ʹȾ-ǡ ͳͷȾ-  ͳ͸Ⱦ-OH TES. 
Recently, it was shown that the residue at position 87 of a drug metabolizing enzyme 
M11 has a strong effect on the regioselectivity of TES hydroxylation (14). BM3 variant 
M11 V87I selectively hyͳ͸Ⱦ(84%) whereas M11 V87A was 
ͳͷȾȋͷ͹ΨȌǤ 
 
More recently, a library of BM3 mutants evolved by iterative saturation mutagenesis 
           ʹȾ  ͳͷȾ
positions (15). Other studies show that BM3 mutants can hydroxylate steroids by 
combinatorial alanine substitutions in the active site (16). We have also shown that 
restriction of active site of BM3 mutant M01 by replacing an alanine at 82 position 
with tryptophan resulted in selective hydroxylation of TES on D-ͳ͸Ⱦ 
(17). However, D-ring hydroxylation of TES by P450 BM3 mutants has been reported 
  Ⱦ-face until now. The regio- or stereoselectivity of the P450 mediated 
oxidation reactions depend upon the orientation of the substrate relative to the 
reactive iron-oxo species which is determined by the active site configuration of the 
P450 enzyme (18). Small variations in the active site of P450s could alter or improve  
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the substrate scope, regio- or stereoselectivity, activity and coupling efficiency (19). It 
is therefore of great interest to modify the active site of cytochrome P450 enzymes in 
order to create novel hydroxy steroids.  
 
Materials and methods 
 
Materials 
Testosterone was purchased from Sigma. Rat liver microsome cytochrome CYP2C11 
was purchased from BD Biosciences, The Netherlands. All other chemicals were of 
analytical grade and purchased from Sigma unless otherwise mentioned. Restriction 
endonucleases were obtained from Westburg. Pfu polymerase and isopropyl Ⱦ-D-
thiogalactopyranoside (IPTG) were obtained from Fermentas. 
 
Sited directed mutagenesis 
 
Mutations at positions 72, 82, 87 and 437 were made by site directed mutagenesis 
using M01 and M11 as template. In general, the mutations were introduced in the 
corresponding templates in pBluescript II KS(+) vector by the QuickChange 
mutagenesis protocol using the  forward primers mentioned in Table 1. The reverse 
primers were exactly complementary to the forward primers. After mutagenesis, the 
presence of right mutations were verified by DNA sequencing (Service XS, Leiden, The 
Netherlands).The whole gene was subcloned to pET28a+ vector using BamHI and 
EcoRI sites and later transformed to BL21 (DE3) cells for expression.  
 
Table 1. Oligonucleotide sequences 
 
    Target sites  Oligonucleotide sequences 
  
72  5’- CGCTTTGATAAAAACTTAXXXCAAGCGCTTAAATTT -3’ a 
82 5’-GTCAAGCGCTTAAATTTGTTCGCGATTTTTGGGGAGACGGG-3’ (W) 
                  87 5’-GCAGGAGACGGGTTAXXXACTAGTTGGACGCAT-3’ b   
 
a XXX represents codon for hydrophobic and charged substitutions ( Ile ATT, Val GTT, 
Asp GAT, Glu GAA) 
 
b XXX represents codon for hydrophobic substitutions (Ala GCC,  Ile ATC, Val GTG, Phe 
TTC).Mutations at position 437 were constructed using primers described in (20) 
 
Expression and purification of BM3 mutants 
 
BM3 mutants were grown on a large scale and purified as follows: 600 mL terrific 
broth medium with 30 μg/mL kanamycin was inoculated with 15 mL of overnight 
culture. The cells were grown at 37 °C and 175 rpm until the OD600 reached 0.6.The  
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protein expression was then induced by the addition of 0.6 mM IPTG. The 
temperature was lowered to 20°C and 0.5 mM of the heme precursor delta 
aminolevulinic acid was added. Expression was allowed to proceed for 18h. Cells were 
harvested by centrifugation (4600 g. 4°C, 20 min) and the pellet was resuspended in 
20 mL KPi-glycerol buffer (100 mM potassium phosphate [KPi] pH 7.4, 10% glycerol, 
0.5 mM EDTA, and 0.25 mM DTT). Cells were disrupted using a French press (1000 
psi, 3 repeats), and the cytosolic fraction was separated from the membrane fraction 
by ultracentrifugation of the lysate (120,000 g, 4°C, 60 min). Then the enzymes were 
purified using Ni-NTA agarose (Sigma). To prevent aspecific binding, 1 mM histidine 
was added to the cytosolic fraction. 3 ml of Ni-NTA slurry was added and the cytosolic 
fraction was equilibrated at 4°C for 2 hours. The Ni-NTA agarose was retained in a 
polypropylene tube with porous disc (Pierce,Rockford,USA) and was washed 4 times 
with 4 ml Kpi-glycerol buffer containing 2 mM histidine. The P450 was eluted in 10 
mL Kpi-glycerol containing 200 mM histidine. The histidine was subsequently 
removed by repeated washing with Kpi-glycerol buffer in Vivaspin 20 filtration tube 
(10,000 MWCO PES, Sartorius) at 4000 g until the histidine concentration was below 
250 nM. 
 
Testosterone metabolism by P450 BM3 mutants and CYP2C11  
 
For the UPLC based library screening, 200nM of cytosolic fraction of BM3 variants was 
incubated with 0.5 mM testosterone in a total volume of 250 μL in 100 mM potassium 
phosphate buffer (pH 7.4). The reaction was initiated by the addition of 25 μL NADPH 
regeneration system containing 2 mM NADPH, 3 mM glucose 6-phosphate and 4 U/mL 
of glucose 6-phosphate dehydrogenase. The reaction was allowed to proceed for 1 
hour at 24°C and then stopped with 250 μL of ice-cold methanol. Based on the library 
screening, for selected mutants (M01 A82W ,M01 A82W S72I, M01 A82W S72V, M11 
87I and M11 87I S72I) incubations were performed with purified enzymes at a 
concentration of 500 nM containing 0.5 mM testosterone in a total volume of 250 μL 
in 100 mM potassium phosphate buffer (pH 7.4). The reaction was initiated by the 
addition of 25 μL NADPH regeneration system as described above. Incubation of 
testosterone with CYP2C11 was performed at an enzyme concentration of 10 pmol 
with 0.5 mM testosterone in a total volume of 250 μL buffer. The reaction was allowed 
to proceed for 30 minutes at 37°C and then stopped with 250 μL of ice-cold methanol. 
Samples were centrifuged for 10 min at 14,000 rpm, after which supernatants were 
transferred to a 96 well plate. Testosterone and metabolites were analyzed by high-
resolution UPLC(21) using an Agilent 1200 system using a Zorbax Eclipse XDB-C18 
column (1.8 μm, 50 mm x 4.6 mm; Agilent, USA). Metabolites and the substrate were 
eluted at a flow rate of 1 mL/ min using an isocratic flow of methanol/water  
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(60:40).The column temperature was maintained at 40°C. UV detection was done at 
254 nm.  
 
LC-MS and GC-MS analysis of new metabolite 
 
Representative samples from incubation of testosterone with M01A82W S72I were 
analyzed using LC-MS/MS. The metabolites of testosterone were seperated by 
reversed-phase liquid chromatography. A Luna 5 Ɋm C18 column (150 mm × 4.6 mm 
i.d.) from Phenomenex was used as the stationary phase, protected by a 4.0 mm × 3.0 
mm i.d. security guard (5 Ɋm) C18 guard column (Phenomenex, Torrance, CA.). An 
isocratic flow of 60:40 MeOH/water (0.1% formic acid) was used as mobile phase. For 
the identification of metabolites, an Agilent 1200 Series Rapid resolution LC system 
was connected to a hybrid quadrupole-timeof- flight (Q-TOF) Agilent 6520 mass 
spectrometer (Agilent Technologies,Waldbronn, Germany), equipped with an 
electrospray ionization (ESI) source and operating in the positive mode. The MS ion 
source parameters were set with a capillary voltage at 3500V; nitrogen was used as 
the desolvation and nebulizing gas at a constant gas temperature of 350°C; drying gas, 
8 L/min; and nebulizer, 40 psig. Nitrogen was used as a collision gas with collision 
energy of 25 V. MS spectra were acquired in full scan analysis over an m/z range of 
50-1000 using a scan rate of 1.003 spectra/s. The MassHunter Workstation Software 
(version B.02.00) was used for system operation and data collection.  
 
For GC-MS analysis, samples from incubation of M01 A82W S72I with testosterone 
were extracted with ethyl acetate and the organic layer was analyzed using a Hewlett-
Packard 6890 series with ATAS Programmable Injector 2.1. Samples were separated 
on a DB-5 GC-column (30 m x 0.25 cm). Ionization was done by electron impact (EI) 
with the mass selective detector 5973. The injector temperature was maintained at 
ʹͷͲǏǤ
ǣͳǤͺͲǏǡ
ramp at 20Ǐ-1 ͵ͲͲǏ͵ͲͲǏͷǤ 
 
Large scale incubation and NMR analysis 
 
Large-scale incubations were performed with 1 μM of mutant M01 A82W S72I, 500 
μM of testosterone in a volume of 25 mL in 100 mM potassium phosphate buffer (pH 
7.4).  The reaction was initiated by addition of 2.5 mL NADPH regenerating system 
containing 2 mM NADPH, 3 mM glucose 6-phosphate and 4 U/mL glucose 6-phosphate 
dehydrogenase. The reaction was allowed to proceed for 6 hours and then the 
products were extracted by using 2 x 50mL dichloromethane. The organic layers were 
collected in a round-bottom flask and evaporated using a rotary evaporator. The dried  
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product was dissolved in 1 mL methanol and the sample was applied by manual 
      ͷ ɊͳͺȋʹȌ  ȋʹͷͲ
mm x 100 mm i.d.) from Phenomenex . An isocratic flow rate of 2 mL/min of eluent 
containing 60% methanol/ 40% water was used to separate testosterone and 
metabolites. Metabolites were detected using UV detection (254 nm) and collected 
manually. Collected fractions were first analyzed for purity by UPLC method as 
described above. The samples were evaporated to dryness under nitrogen stream and 
dissolved in 500 μL of methyl alcohol-d4.Structural identification of the new 
metabolite was performed by a combination of 1D-1H, 1H-1H-COSY and 1H-1H-NOESY 
NMR experiments. NMR spectra were recorded at room temperature using on Bruker 
Avance 500 (Fallanden, Switzerland), equipped with cryoprobe at 500.13MHz. 
 
Computational Methods 
 
MD simulation and docking settings  
 
A combined MD/docking study as previously described for mutants M01 and M01 
A82W in reference 8 was performed on the orientation of testosterone to the heme 
domain of BM3 mutant M01 A82W S72I solvated in water. The starting structure for 
MD simulations of mutant M01 A82W S72I was modeled based on the M01 A82W 
coordinates taken from reference 8, using the molecular modeling software MOE 
(Molecular Operating Environment)(22). The side chain of 72I was manually 
introduced using MOE’s builder tool such that it had minimal overlap with 
surrounding residue atoms. After introduction of the mutation S72I, polar and 
aromatic hydrogen atoms were added and the mutant’s structure was energy 
minimized in vacuo. Energy minimizations were carried out using the GROMOS05 
biomolecular simulation package(23, 24) and the GROMOS force field parameter set 
45A4(25). Subsequently, the protein was solvated in a periodic rectangular box, 
containing 18,176 SPC water molecules(26), with a periodic box volume of 8.6 x 8.6 x 
8.6 nm, using a minimum solute to wall distance of 0.8 nm, and 15 Na+ ions to 
neutralize the system’s charge. The force-field parameters that were used to describe 
the BM3 protein and sodium ions were taken from the GROMOS parameter set 
45A4(25). 
 
In a first set of (equilibration) MD simulations, the system was gradually heated up to 
298 K, in seven separate simulation steps of 20 ps each (at 50, 100, 150, 200, 250 and 
298 K, respectively), in which the volume of the system was kept constant. In the first 
five simulations, position restraints were applied on the protein atoms using a 
gradually decreasing force constant (of 25000, 2500, 250, 25 and 2.5 kJ  
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mol-1 nm-2, respectively) for the harmonic restraints. After the equilibration process, a 
production MD simulation at 298 K with a total length of 3 ns of the systems followed.  
In the production MD simulations, no position restraints were applied, and the 
pressure was kept constant to a target value of 1 atm, using a Berendsen barostat with 
a coupling time of 0.5 ps. The isothermal compressibility was set to 4.575 x 10-4 (kJ 
mol-1 nm-3)-1. In all simulations, a time step of 2 fs was used, and the temperature was 
kept constant at its target value by using a Berendsen thermostat with a coupling time 
of 0.1 ps. Bonds were kept constrained using the SHAKE algorithm(27), with a 
geometric tolerance of 10-4. At every time step, nonbonded interactions were 
calculated up to a distance of 0.8 nm, by means of a pair list, generated every five time 
steps. At every fifth time step, intermediate-range interactions at distances up to 1.4 
nm were calculated and kept constant. A reaction-field contribution was added to the 
energies and forces, to account for the electrostatic interactions outside the cut-off 
radius of 1.4 nm, with a dielectric permittivity of 61. 
 
During the production run, energies were stored every 250 time steps (0.5 ps) for 
analysis. After the 3 ns MD run of the proteins, 1500 coordinate frames were 
generated by writing out protein coordinate files every 1000 time steps (2 ps), which 
were used as protein template structures in further docking studies (after adding 
aliphatic hydrogens using the corresponding tool in MOE). Molecular structures of the 
substrate testosterone were used for individual docking runs as described previously 
(28). Note that two distinct molecular conformations can be distinguished for 
testosterone: a ‘flat’ conformation and a ‘bent’ conformation, characterized by a trans- 
or gauche-orientation of the dihedral angle defined by atoms C2, C1, C10 and C9, 
respectively. In both conformations, the B and C ring are in a chair conformation. 
Combining the 2 x 4 different testosterone orientations and the 1500 protein 
structures obtained from the MD simulation of M01 A82W S72I, testosterone was 
docked into the protein active-sites using the GOLD (Genetic Optimization for Ligand 
Docking)(29) software, version 4.0, and the Chemscore scoring function(30) 
optimized for heme groups (31).  
 
The center point for docking was defined by the mirror image of the sulfur atom of 
Cys400 on the opposite site of the heme iron, from which the docking-active radius 
was set to 1.5 nm to define the active-site of the protein. A maximum of 50000 
operations in the GOLD genetic algorithm were performed, using a population of 100 
genes. After every docking simulation, (maximally) 50 of the highest-ranked obtained 
poses were retained for further analysis. In total, circa 50,000 protein-TES complexes 
were thus obtained and were used as input for post-processing analysis. Obtained 
binding poses were collected for which C16 was the carbon atom in closest proximity  
ͻͺ
CHAPTER 4 
 
to the catalytic heme iron, after discarding the poses for which C16 was positioned 
more than 0.7 nm away from the heme iron center (which is slightly larger than the 
hypothetical cut-off of 0.6 nm for catalytic activity(32)) or closer than 0.3 nm to the 
heme iron (considering that accommodation of a reactive oxygen molecule should be 
possible).  
 
Binding constant determination by optical spectroscopy 
 
The binding of testosterone to P450 BM3 mutants M01 A82W and M01 A82W S72I 
was analyzed by optical titrations using a Shimadzu UV-2501PC spectrophotometer 
(Shimadzu Duisburg, Germany). The spectra for the substrate-  ȋͳ ɊM) 
were recorded at 24 °C in 1 mL of 100 mM potassium phosphate buffer (pH 7.4) prior 
to addition of testosterone. Increasing amounts of testosterone dissolved in methanol 
were added (2 - ʹͷͲɊȌ    
than 2% of the total volume of the solution. Spectra were recorded after each addition 
of substrate, and a difference spectrum was computed by subtraction of the starting 
(substrate-free) spectrum from those generated at each point in the titration. The 
maximum apparent absorption ch       ȋȟ392-
427ȌͲͳͺʹȋȟ412-432) for M01 A82W S72I was determined by subtraction 
of the minimum absorption value at the trough in each difference spectrum from the 
maximum value at the peak and these values were plotted versus corresponding 
testosterone concentrations. Data were analyzed by nonlinear regression using 
GraphPad Prism 4 (GraphPad Sotware, San Diego, CA, USA).  
 
Results and Discussion 
 
Minimal library creation 
 
In our previous work, we provided structural rationalization for the observed 
differences in regioselectivity of TES hydroxylation by BM3 mutants M01 and M01 
A82W (28). During this in silico rationalization study, key active site residues (72, 82, 
87, and 437) were identified which may have an effect on the orientation of TES in the 
active site. In the present study, a minimal library consisting of 25 combinatorial 
single and double mutants was constructed with substitutions at these key active site 
residues based on M01 and M11 (33) as templates. Since BM3 mutants capable of 
hydroxylation at the A or D ring on the beta face with high selectivities have been 
reported before (15, 34), the goal of this screening was to identify mutants with 
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altered regio- and stereoselectivities towards TES hydroxylation. All the BM3 variants 
were successfully expressed and showed a P450 peak as determined from CO 
difference spectrum. UPLC based screening of the mutant library revealed that most of 
ʹȾ-ǡͳͷȾ- and 
ͳ͸Ⱦ-OH testosterone in  different  product ratios. The screening results depicting the 
differences in selectivities are shown in supplementary material Figure 1. 
Interestingly two mutants from the library produced significant amount of a new 
metabolite not reported before for P450 BM3 mediated testosterone hydroxylation 
(35). 
 
Identification of the new metabolite 
 
The new metaboli   ͳͷȾ- and 16Ⱦ-OH testosterone under the 
conditions described in Methods section. LC –MS analysis of the metabolite indicated 
that it was mono-hydroxylated metabolite with an [M+H]+ ion at m/z 305. Moreover, 
the characteristic ions m/z 97, m/z 123 as observed from MS/MS spectrum were 
indicative of D-ring hydroxylation. Rat liver microsomes P450 2C11 is known to 
produc ͳ͸Ƚ-  ʹȽ-OH metabolites with testosterone (36). As an additional 
confirmation, UPLC analysis showed that the newly isolated metabolite and 16-Ƚ-OH-
TES produced by rat liver microsomes co-eluted as shown in Figure 2. The pure 
metabolite collected by preparative HPLC was also analyzed by GC-MS which gave a 
highly reproducible fragmentation pattern comparable to previous report (37).  Based 
on these observations, the new metabolite was tentatively assigned to be 16-Ƚ-OH-
testosterone. 
 
In order to confirm the structure unequivocally, large scale incubations were 
performed to isolate sufficient amount of metabolite for NMR analysis. The identity of 
the metabolite was confirmed by 1    Ɂ0.81 (18-CH3) Ɂ 
1.23 (19-CH3ȌɁ 3.39 (doublet 17-Ƚ with a characteristic J value 5.8) and Ɂ 4.03 (16-
ȾȌ as shown in Figure 3. The 1H NMR chemical shifts were similar to previously 
reported values for 16-Ƚ-OH-testosterone (38, 39). The COSY spectrum also helped to 
understand the site of hydroxylation better. The mutual correlation observed between 
ͳ͹Ɂ͵Ǥ͵ͻͳ͸Ɂ4.03 ppm confirmed that hydroxylation was at C-16 as 
reported previosuly (9). The combination of LC-MS, GC-MS fragmentation pattern 
combined with in depth NMR analysis helped to confirm that the new metabolite 
formed by the P450 BM3 mutant is 16-Ƚ-OH-testosterone. 
 
 
 
ͳͲͳ
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Figure 2. Overlay of UPLC chromatograms depicting co-ͳ͸Ƚ-OH-T (tR 1.30 
min) isolated from incubation of testosterone with BM3 mutant M01 A82W S72I and incubation 
of testosterone with rat liver cytochrome 2C11(36). 
 
 
Effect of the mutation S72I 
 
Analysis of the mutation position revealed that two of the mutants which produced 
ͳ͸Ƚ-OH-TES were based on M01 A82W and had hydrophobic substitutions at position 
72. M01 A82W is a selecti ͳ͸Ⱦ     produce even trace 
ͳ͸Ƚ-OH-TES. The introduction of hydrophobic residues at position 72 in 
M01 A82W had a profound effect on the stereoselectivity. The S72V mutation in M01 
ͺʹͳ͸Ƚ-OH-TES, 15-Ⱦ-OH-TES and 
2-Ⱦ-OH-TES ͳ͸Ⱦ-OH-TES still being the major metabolite (40%). 
 
Interestingly, the introduction of isoleucine at position 72 in M01 A82W resulted in a 
   ͳ͸Ƚ    ȋͺͳΨȌ    ͷΨ  ͳ͸Ⱦ
hydroxy TES was formed (Figure 1ȌǤͳ͸Ƚ
Ǥ ͳ͸Ⱦ   Ͳ  Ͳͳ ͺʹ  ʹͶǤͺ  Ͳͳ ͺʹ ͹ʹǡ 
    ͳ͸Ⱦ   ͳ͸Ƚ ǡ 
(Table 2). The overall specific hydroxylation activity was lowered 2-3 fold upon the 
introduction of hydrophobic residues at position 72 in M01 A82W.  
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Analysis of the dissociation constants revealed that the new mutant M01 A82W S72I 
binds about 2.5 fold less tightly (Kd =102.4 μM) as compared to M01 A82W (Kd =42.5 
μM). Titrations of testosterone with M01 A82W produced a typical type I spectrum 
with a peak at 392 nm and trough at 427 nm indicative of the conversion of the heme 
iron from low spin to high spin. On the other hand, M01 A82W S72I produced an 
altered type I spectra with a red shift in the peak maxima from 392 nm to 412 nm as 
observed in the difference spectrum (Figure 4). Previously, the binding of lanosterol 
to Mycobacterium tuberculosis 14-Ƚ-demethylase containing an active site mutation 
F89H exhibited a similar shift in peak maxima from 390 to 412 nm (40). Binding of 
piperonylic acid to a plant P450 CYP73A1 also resulted in Soret peak maxima shift to 
412 nm. Although the mechanism for such a shift is not completely elucidated yet, it 
may possibly indicate a ligand induced alteration in the heme protein structure (41).  
 
 
 
[a]Testosterone hydroxylation activities were measured with 500 nM of purified P450 BM3 mutants and 0.5 
mM testosterone. The values represent average calculated from 2 independent experiments with ± 5% 
error. Hydroxylation activity is reported as nmol product/nmol enzyme/hour. 
 
 
It was interesting to observe that the complete reversal in stereoselectivity was seen 
only in the combination of A82W and S72I mutations. Single mutants with 
hydrophobic substitutions at position 72 in M01 did not have a big effect on the 
product distribution compared to M01 itself. Such synergistic effects of P450 BM3 
double mutants have been shown to affect regio- and stereoselectivity. For example, 
hydrophobic substitutions at positions 87 and 328 improved selectivity of terpene 
hydroxylation (42) and combined substitutions at 82 and 438 residues have been 
shown to control stereoselectivity of styrene epoxidation (43). 
 
 
 
 
Table 2. Testosterone C-16 hydroxylation activity by M01 A82W and the constructed 72 position 
mutants. 
Mutant                                       C-16 hydroxylation activity [a] 
 ͳ͸Ƚ-
OH  
           ͳ͸Ⱦ-OH       ͳ͸Ƚ-ǣͳ͸Ⱦ-OH 
M01 A82W - 397 0 
M01 A82W S72V 63 127 0.49 
M01 A82W S72I 174 7 24.8 
ͳͲͶ
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Figure 4. Spectral shifts induced by the binding of testosterone to A. M01 A82W and B. M01 A82W S72I by 
addition of increasing concentrations of testosterone (2 - 250 μM) dissolved in methanol. The inset shows 
the absorption changes plotted against the concentrations of testosterone used in titrations. For calculating 
Kd values, data points were fitted using Graphpad Prism software as explained in Materials and methods. 
Binding constants were found to be A. 42.5 μM and B. 102.4 μM 
 
 
 
ͳͲͷ
CHAPTER 4 
  
͹ʹͳ͸Ⱦ-OH-TES selective mutant could also 
produce similar change in stereoselectivity, we introduced the S72I mutation in BM3 
variant M11 87I which has been shown previously to hydroxylate testosterone 
  ͳ͸Ⱦ  (17). Interestingly, the combinatorial V87I S72I double 
mutation also inverted      ͳ͸Ƚ-OH-TES 
with >90% e.e. As also observed for M01A82W S72I, the overall hydroxylation activity 
was reduced approximately 3 fold in comparison with M11 87I itself. In future work, 
the activity of the selectivͳ͸Ƚ be improved by random 
mutagenesis. 
 
Computational studies  
 
Position 72 is the first residue in the B’-helix (44) and it can play an important role in 
substrate interactions. To our knowledge, only a few studies involving the effect of 
mutations at position 72 on BM3 hydroxylation activity and selectivity have been 
reported (45, 46). From our results, the substitution of hydrophobic amino acids in 
place of serine at position 72 had a significant effect on the selectivity and activity of 
TES hydroxylation. Prior computational studies in our laboratory suggested that 
active site residue serine 72 may have a potential anchoring effect on ligand binding 
orientation in the BM3 binding pocket by facilitating a hydrogen bond possibility with 
the carbonyl group of TES A-ring in BM3 mutant M01 A82W. By removing this 
hydrogen bonding possibility (by replacing serine by a hydrophobic residue), the 
preferred binding orientation of TES in BM3 mutant M01 A82W might be affected.  
 
To rationalize the observed enantioselectivity for TES hydroxylation by BM3 mutant 
M01 A82W S72I, in silico site-of-metabolism (SOM) prediction was performed using a 
combined Molecular Dynamics (MD) and ligand docking approach (as described 
previously) to account for the flexibility and plasticity of the protein and to identify 
possible orientations of TES binding in the M01 A82W S72I active site. Detailed 
computational studies investigating the favorable binding orientation of substrates in 
the P450 active site to rationalize and predict the substrate’s preferred SOM have 
been reported before (47). In accordance with those studies we found that in the 
         ͳ͸Ƚ 
was observed, C16 and H16Ƚ were within a distance of 2-6 Å from the heme iron atom 
ͳ͸ǡͳ͸Ƚ
and the heme iron atom (Fe-H-C angle) was in the range of 120-180°. For the obtained 
poses in which C16 was found to be the carbon atom closest to the heme iron atom 
ȋ	ȌǡȽȾ	Ǥ 
 
ͳͲ͸
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ͳ͸Ƚͳ͸ȾǤIt 
was observed that for the poses with H16Ƚ closer to Fe, a higher density for which the 
hydrogen is within close proximity (2-4 Å) is observed than for H16Ⱦ, in line with the 
   ͳ͸Ƚ Ǥ  Figure 5 depicts typically 
observed poses co  ͳ͸Ƚ  ͳ͸Ⱦ   
conformations showing the two predominant rotamers of the I72 side chain. Poses for 
ͳ͸Ƚ-OH (in green) are found to form a steady hydrogen bond to the backbone moiety 
of Ala330, which is not observed for binding poses   ͳ͸Ⱦ-OH (in 
black). Moreover, different rotamers of I72 show sterical hindrance of its side chain 
ͳ͸ȾǤ͵͵Ͳ
and sterical hindrance with I72 offer a structural explanation of the observed 
ͳ͸ȽͲͳͺʹ͹ʹǤ 
 
The present study shows that small differences in key substrate interaction residues 
in P450 BM3 can have profound effect on the stereoselectivity of TES hydroxylation. 
To our knowledge, M01 A82W S72I and M11 V87I S72I are the first BM3 variants 
   ͳ͸Ƚ Ǥ      
the stereoselectivity also makes it an ideal candidate for further mechanistic studies. 
In conclusion, these results lead to a better understanding of substrate orientation in 
the BM3 active site, opening up possibilities to design mutants with novel selectivities 
as well as scope to improve existing variants towards steroid hydroxylation. 
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Generation of fenamic acid NSAIDs metabolites 
 
Abstract 
 
Cytochrome P450 BM3 mutants are promising biocatalysts for the production of drug 
metabolites. In the present study, the ability of cytochrome P450 BM3 mutants to 
produce oxidative metabolites of structurally related NSAIDs meclofenamic acid, 
mefenamic acid and tolfenamic acid was investigated. A library of engineered P450 
BM3 mutants was screened with meclofenamic acid (1) to identify catalytically active 
and selective mutants. Three mono-hydroxylated metabolites were identified for 1. 
The hydroxylated products were confirmed by NMR analysis to be 3’-hydroxy-methyl- 
(1a), 5-hydroxy-meclofenamic acid (1b) and 4'-hydroxy- (1c) which are human 
relevant metabolites. P450 BM3 variants containing V87I and V87F mutation showed 
high selectivity for benzylic and aromatic hydroxylation of MCFA respectively. The 
applicability of these mutants to selectively hydroxylate structurally similar drugs 
such as mefenamic acid (2) and tolfenamic acid (3) was also investigated. The tested 
variants showed high total turnover numbers in the order of 4000- 6000 and can be 
used as biocatalysts for preparative scale synthesis. Both 1 and 2 could undergo 
benzylic and aromatic hydroxylation by the P450 BM3 mutants, whereas 3 was 
hydroxylated only on aromatic rings.  The P450 BM3 variant M11 V87F hydroxylated 
the aromatic ring at 4’ position of all three drugs tested with high regioselectivity. In 
conclusion, engineered P450 BM3 mutants that are capable of benzylic or aromatic 
hydroxylation of fenamic acid containing NSAIDs, with high selectivity and turnover 
numbers have been identified. This shows their potential use as a greener alternative 
for the generation of drug metabolites.  
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Introduction 
 
Meclofenamic acid (1), mefenamic acid (2) and tolfenamic acid (3) belong to the 
group of fenamic acid containing NSAIDs (fenamates) which are used for the 
treatment of pain and inflammation (1). They inhibit the production of prostaglandins 
formed by cyclo-oxygenase and thereby exhibit anti-inflammatory effect (2). This 
group of drugs is structurally similar to diclofenac, a widely studied NSAID for its 
idiosyncratic hepatotoxic effect. Unlike diclofenac which can undergo only aromatic 
hydroxylation, these compounds can undergo both P450 mediated benzylic and 
aromatic hydroxylation (3, 4). For example, hydroxylation on the benzylic group (3’-
hydroxy-methyl) is reported to be the major P450 mediated metabolite for 2 in 
addition to aromatic ring hydroxylated metabolites (5). 
 
Benzylic alcohols can be bioactivated to toxic reactive intermediate catalyzed by 
human sulfotransferases which can react with DNA leading to genotoxicity (6). 
Additionally, the aromatic hydroxylated metabolites of these compounds can lead to 
the formation of quinone imines which are reactive towards sulfhydryl groups of 
proteins, and therefore can be responsible for the adverse reactions caused by these 
drugs (7, 8). In the case of structurally similar drug diclofenac, quinone imines have 
been reported to be more cytotoxic compared to the quantitatively more abundant 
acyl glucuronides (9). The recent regulatory guidance of Food and Drug 
Administration (FDA) has made it increasingly important to perform toxicological 
evaluation of drugs metabolites which are formed more than 10% of the parent drug 
systemic exposure (10, 11). Therefore, the generation of both benzylic and aromatic 
hydroxylated metabolites of these drugs to facilitate pharmacological and 
toxicological evaluation is of significant importance. 
 
Selective oxyfunctionalization of many compounds including drugs by chemical means 
still poses a challenge (12). Enzymes which are capable of introducing an oxygen atom 
in a highly regioselective manner are of high demand in organic synthesis (13). The 
use of engineered bacterial cytochrome P450s for the production of drug metabolites 
has gained importance over the years (14, 15). Among the bacterial P450s, 
cytochrome CYP102A1 (Cytochrome P450 BM3) from Bacillus megaterium is a well 
known fatty acid hydroxylase. In the last two decades, P450 BM3 was widely studied 
in order to expand its substrate specificity for biotechnological purposes (16). 
Directed evolution combined with rational and semi-rational techniques have resulted 
in a wide array of catalytically active and selective mutants that can be employed for 
hydroxylation of various compounds (17). Of particular interest is the exploitation of 
these monooxgenases for the production of drug metabolites (18). 
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Recent studies have reported the ability of cytochrome P450 BM3 mutants to produce 
human relevant drug metabolites of several drugs including NSAIDs (19-21). 
Engineered P450 BM3 mediated hydroxylation of NSAIDs like diclofenac, ibuprofen 
and naproxen have been reported (22-24). 
 
In the present study, fenamic acid NSAIDs (Figure 1) have been used as examples to 
demonstrate the ability of P450 BM3 mutants to produce human relevant metabolites. 
The aim of this study is to identify P450 BM3 variants capable of selective benzylic 
and aromatic hydroxylation with minimal secondary oxidation of fenamic acid NSAIDs 
that can be used as biocatalysts for large-scale drug metabolite production. A library 
of catalytically diverse P450 BM3 mutants were screened with 1. Large scale 
incubations were performed with the selective BM3 variants and the structures of the 
metabolites were elucidated by NMR analysis. Application of these selective mutants 
towards structurally related 2 and 3 has also been studied. Docking studies were 
performed to get preliminary insights into the experimentally observed ring 
selectivity and to identify the key interactions in the active site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.Structure of fenamic acid NSAIDS used in this study.  
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Materials and Methods 
 
Materials 
 
Mefenamic acid, meclofenamic acid sodium salt and tolfenamic acid were purchased 
from Sigma (Schnelldorf, Germany). Human liver microsomes (HLM) pooled from 
different individual donors were obtained from BD Gentest TM (San Jose, USA) and 
contained 20 mg/mL protein (Cat. No. 452161). All other chemicals were of analytical 
grade and purchased from standard suppliers unless otherwise mentioned.  
 
Expression and purification of P450 BM3 mutants 
 
Expression of the CYP102A1 mutants was performed by transforming competent 
E.Coli BL21 cells with the corresponding pET28+vectors. P450 BM3 mutant M11, M11 
V87I , M11 L437N V87I and M11 V87F were grown on a large scale and purified using 
nickel affinity column as described previously (25). CYP concentrations were 
determined using carbon monoxide (CO) difference spectrum assay as described by 
Omura et al., (26). 
 
Metabolism of fenamic acid containing NSAIDS by engineered P450 BM3 
mutants 
 
For the biotransformation reaction, cytosolic fraction containing 150 nM of 63 
different P450 BM3 mutants and wildtype BM3 was incubated with 500 μM of 1 (from 
DMSO stock solution), in a final volume of 250 μL in 100 mM potassium phosphate 
buffer. The reactions were initiated by addition of an NADPH regenerating system 
(final concentrations of 0.5 mM NADPH, 10 mM glucose 6-phosphate, and 0.4 unit/mL 
glucose-6-phosphate dehydrogenase). The reaction was allowed to proceed for 1 hour 
at 24 ӷ       ʹͷͲ Ɋ -cold methanol. The protein was 
removed by centrifugation for 15 min at 13000 rpm. The supernatant was analysed by 
HPLC method as described below. Selected mutants were incubated with 2 and 3 to 
evaluate the applicability of these mutants towards these fenamic acid NSAIDS using 
150 nM enzyme and 500 μM drug. Human liver microsomes (HLM) incubations were 
also performed for ϐ2 mg/mL HLM. The 
reactions were initiated as above and allowed to proceed for 1 hour at 37 ӷC. 
 
Analytical methods 
 
The analyses of metabolites were performed by reversed-phase liquid 
chromatography on a Shimadzu HPLC equipped with two LC-20AD pumps, a SIL20AC 
ʹͲͷɊͳͺȋͶǤ͸ͳͷͲ 
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mm) as stationary phase. For separation of parent compound and metabolites, a 
gradient method was used with two mobile phases: solvent A (0.8 % acetonitrile, 99% 
water, 0.2% formic acid) and solvent B (0.8% water, 99% acetonitrile, 0.2% formic 
acid). For 2, the first 5 min was isocratic at 40% solvent B. From 5 till 30 min, the 
concentration of solvent B linearly increased to 100%, followed by linear decrease 
back to 40% until 30.5 min. Isocratic re-equilibration at 40% solvent B was 
maintained until 45 min. For separation of metabolites of 1 and 3, a similar gradient 
was used starting with 5% solvent B instead of 40%. The flow rate was 0.5 mL/min 
and the detection was at 254 nm. A standard curve of respective metabolites of 2 was 
used to determine the concentrations of the formed metabolites of 2. For 1 and 3, the 
concentration of the products formed was calculated based on a calibration curve of 
the parent drug by taking into account a correction factor for the extinction 
coefficients.Representative samples were analyzed by using an Agilent 1200 Series 
Rapid resolution LC system connected to a time-of-flight (TOF) Agilent 6230 mass 
spectrometer equipped with electrospray ionization (ESI) source and operating in the 
positive mode. The MS ion source parameters were set with a capillary voltage at 
3500 V. Nitrogen was used as drying gas (10 L/min) and nebulizing gas (pressure 50 
psig) at a constant gas temperature of 350 °C. Data analysis was performed using 
Agilent MassHunter Qualitative analysis software. 
 
Dissociation constant determination by optical spectroscopy 
 
The binding of fenamic acid NSAIDs to BM3 mutants was studied by optical titration 
using a Shimadzu UV-2501PC spectrophotometer (Shimadzu Duisburg, Germany) as 
described previously (27). 
 
Isolation of metabolites for NMR analysis 
 
To obtain the oxidative metabolites of 1, 2 and 3, incubations were performed in a 5 
mL reaction volume containing 250 nM purified P450 BM3 mutant, 500 μM respective 
fenamic acids and a NADPH regenerating system in 100 mM potassium phosphate 
buffer pH 7.4. The reactions were allowed to continue for 4 h at 25°C. The reactions 
were terminated by adding an equal volume of ice cold methanol containing 2 % (v/v)  
of aqueous 50 mM ascorbic acid and centrifuged for 15 min at 14000 rpm. After 
precipitation of the proteins, a series of 1 mL injections of the sample was applied on a  
semi-preparative HPLC column Luna 5 μm C18(2) (250 mm x 10 mm i.d.) from 
Phenomenex (Torrance, CA, USA) which was previously equilibrated with 100% 
eluent A. A flow rate of 1.5 mL/min and a gradient using the eluent A (0.8% 
acetonitrile, 99% water, and 0.2% formic acid) and B (99% acetonitrile, 0.8% water, 
and 0.2% formic acid) was applied for separation of formed metabolites. The first 10  
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min was isocratic at 20% eluent B: from 10 to 40 min, the percentage of eluent B 
increased linearly to 100% followed by linear decrease back to 20% until 45.5 min. 
Isocratic re-equilibration at 20% solvent B was maintained until 60 min. Metabolites 
were detected using UV detection (254 nm) and collected by automated fraction 
collector. Collected fractions were first analyzed for purity and identity by the 
analytical HPLC and LC-MS methods as described above. The samples were 
evaporated to dryness under a nitrogen stream and redissolved in 500 μL of methyl 
alcohol-d4. 1H-NMR-analysis was performed on Bruker Avance 500 (Fallanden, 
Switzerland), equipped with cryoprobe. 1H-NMR measurements were carried out at 
500.23 MHz. 
 
Determination of kinetic parameters  
 
For the determination of kinetic parameters, the enzyme concentration and 
incubation time of the reaction were chosen in such a way that product formation was  
linear with time (data not shown). Incubations were performed in 100 mM potassium 
phosphate buffer (pH 7.4), with 150 nM purified P450 BM3 mutants. The final volume 
ʹͷͲɊǡͻte concentrations ranging from 
3.125-ͺͲͲɊǤ
(final concentrations of 0.5 mM NADPH, 10 mM glucose 6-phosphate, and 0.4 unit/mL 
glucose-6-phosphate dehydrogenase). All incubations were performed in duplicates. 
The reaction was allowed to proceed for 5 min at 24 °C and then stopped by addition 
ʹͷͲɊ-cold methanol. The protein was removed by centrifugation for 15 min 
at 13000 rpm. The supernatant was analyzed by HPLC method as described above. 
The data were fitted with the Hill’s equation, using the Graphpad Prism5 software. 
 
Determination of total turnover numbers (TTN)  
 
To determine total turnover numbers, 150 nM of purified enzymes was incubated 
with 1 mM of fenamic acid NSAIDs (2% DMSO) in a total volume of 250 μL. The 
reaction was initiated by the addition of 50 μL NADPH regenerating system as 
mentioned above. The reaction was performed in duplicate in 1.5 mL eppendorf tubes 
ʹͷǏͶǏͳʹǤ 
were analyzed by HPLC as described in section 4.4. Total turnover numbers were 
calculated as nmol of product formed per nmol enzyme. 
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Preparative scale synthesis 
 
Large scale incubation was performed in a baffled flask with 150 nM of purified 
mutant M11 V87F, 12 mg of 2 (final concentration 1 mM) in a volume of 50 mL in 100 
mM potassium phosphate buffer (pH 7.4Ȍ  ʹͶǏǤ     
addition of 5 mL NADPH regenerating system. The reaction was allowed to proceed 
for 6 hours and then the stopped with ice-cold methanol. The metabolites were 
separated by semi-preparative HPLC method as described in section 4.6. The pure 
fractions containing 2b were evaporated to dryness using a vacuum centrifuge to 
result in an isolated yield of 6.8 mg 2b. 
 
Results and Discussion 
 
Selection of P450 BM3 variants 
 
In the present study, 78 mutants of P450 BM3 were selected for screening with 1. 
These variants were pre-selected based on their catalytic diversity towards a variety 
of drugs and steroids. Mutants M01, M02, M05, and M11 were previously constructed 
from a triple mutant by subsequent random-mutagenesis. Mutants M01 and M11 were 
used as templates for additional site-directed mutagenesis of active site residues, 
guided by computational modelling of the active site of P450 BM3. Positions which 
were selected for mutagenesis were residues 72, 74, 82, 87 and 437 which appear to 
be key active site residues and have profound influence on regio- and stereoselectivity 
of P450 BM3 mutants (20, 22, 28, 29). 
 
Oxidation of meclofenamic acid by engineered P450 BM3 mutants and 
structural identification of products 
 
Wildtype P450 BM3 was tested for its ability to convert 1. Consistent with previous 
studies reporting about conversion of NSAIDs like diclofenac and naproxen, only very 
low substrate conversion (<0.5% of the parent drug concentration) was observed 
with wildtype BM3 and 1. On the other hand, engineered P450 BM3 mutants showed 
much higher substrate conversions, with distinct product profiles. For example, BM3 
variant M11 was able to convert 1 to three mono-hydroxylated products 1a, 1b and 1c 
(m/z 312) with no particular selectivity. (Figure 2A) In order to identify the 
metabolites, large scale incubations of 1 with BM3 mutant M11 were carried out to 
generate enough material for NMR analysis. Figure 2B-D shows the aromatic region 
of 1H NMR of the 3 metabolites. As a characteristic feature, dichloro-ring hydroxylated 
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Figure 2. Metabolism of meclofenamic acid (1) by P450 BM3 mutant M11 and structural 
elucidation of metabolites A. Representative HPLC chromatogram obtained after incubation of 1 
ȋͷͲͲ ɊȌ  ͵  ͳͳ (150 nM). Aromatic region of 1H NMR spectrum of the 
metabolites B. 1a C. 1c and D. 1b 
 
 
metabolites of 1 show a signal coming from H-͸ɁͺǤͲͳ  
doublet pattern with an ortho and meta coupling (Figure 2B,C). In the case of C-5 
hydroxylation on the carboxy phenyl ring, the signal corresponding to H-6 shifted 
Ɂ͹ǤͶʹǤAdditionally, in the case of benzylic hydroxylation at the 3’ 
position, a characteristic singlet corresponding to –CH2 appears arɁͶǤ͹Ͳ Ǥ
The structure of metabolite 1awas assigned based on NMR analysis to be the benzylic  
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hydroxylated product of 1 at its 3’ position. Metabolite 1a was found to co-elute with 
the major metabolite 3-hydroxy-methyl-meclofenamic acid (30), formed after 
incubation of 1 with human liver microsomes (HLM). Metabolites 1c and 1b were 
identified as products of aromatic hydroxylation at position C-4’of the dichloro phenyl 
ring and at position C-5 of carboxy phenyl ring, respectively (see Supplementary 
Information). These aromatic hydroxylated metabolites were also formed in HLM 
incubations and therefore engineered P450 BM3 can produce human relevant 
metabolites of 1. 
 
Selective benzylic vs aromatic hydroxylation of 1 by engineered P450 BM3 
mutants 
 
Figure 3 shows the diversity of P450 BM3 mutants towards either benzylic or 
aromatic hydroxylation of 1. Most of the mutants were able to convert 1 with different 
activities and hydroxylation selectivities.  
 
 
 
Figure 3. Product profile and relative activity of P450 BM3 engineered variants towards meclofenamic acid 
(1) hydroxylation. Activity in % were measured from substrate consumption after 1 hour incubation of 500 
μM of 1 with 150 nM of P450 BM3 relative to the most active mutant M11 L437N V87F. Values represent 
averages of 2 independent experiments with less than 10% error. Product selectivity in % was calculated 
from HPLC chromatograms by integrating the product peaks and represented by different shades in each 
bar. Representative P450 BM3 variants showing high selectivity towards benzylic hydroxylation (M11 V87I, 
M11 L437N V87I and variants showing high selectivity towards aromatic hydroxylation (M11 V87F, M11 
L437N V87F) are highlighted.  
 
122
CHAPTER 5 
 
Wild-type P450 BM3 showed less than 0.5 % conversion of 1. Of all the tested 
variants, mutant M11 L437N V87F showed the highest activity with 72% selectivity 
for hydroxylation at the 4’position. Interestingly, mutants of M11 with mutations 
(either isoleucine or phenylalanine) at position 87 showed a remarkable increase in 
selectivity of product formation. Representative chromatograms obtained after 
incubation of 1 with P450 BM3 mutants M11 L437N V87I and M11 V87F are shown in 
Figure 4. M11 L437N V87I showed a high selectivity (83%) towards formation of 1a, 
whereas M11 V87F showed a high selectivity (89%) for formation of 1c. Because of 
the higher aromatic selectivity, mutant M11 V87F was selected for further studies. 
 
Residue 87 is located in close proximity to the propionate group of the haem and 
therefore affects the accessibility of the substrate to the reactive centre. Previously, it 
was shown that the residue at position 87 can play a critical role in substrate binding 
and in the change of the spin state of the haem iron, thereby possibly affecting trends 
in regioselectivity by P450 BM3 mutants (31).  
 
 
 
 
Figure 4. Representative HPLC chromatograms showing high selectivity of meclofenamic acid 
hydroxylation on 3’-methyl group by BM3 mutant M11 L437N V87I (solid line) and high selectivity of 
hydroxylation at 4’position on aromatic ring by P450 BM3 variant M11 V87F (dotted line) 
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In terms of aromatic or benzylic hydroxylation of compounds by engineered P450 
BM3, hydroxylation of xylenes have been studied and it has been previously shown 
that the active site architecture and the residue at position 87 can play a role in 
determining the preference for hydroxylation in line with our experimental 
observations (31, 32). Moreover, kinetic isotope effects have also been used to 
delineate the importance of residue at position 87 for aromatic or benzylic 
hydroxylation (33). 
 
Application to other structurally related NSAIDS mefenamic acid and tolfenamic 
acid 
 
In order to evaluate the applicability of selective P450 BM3 mutants M11, M11 V87I, 
M11 L437N V87I, M11 V87F towards the metabolism of structurally similar drugs, 
conversion of 2 and 3 were also studied. The product selectivities are shown in Table 
1. Mutant M11 converted 2 to three mono-hydroxylated metabolites (m/z 258). These 
three metabolites were identified by NMR to be 3’- hydroxymethyl-mefenamic acid 
(2a), 4’-hydroxy-mefenamic acid (2b) and 5-hydroxy-mefenamic acid (2c) which are 
corresponding to the regioselectivity of the metabolites formed with 1. Introduction of 
phenyl alanine at 87 position was found to increase the regioselectivtity towards the 
formation of 2b to 76%.  In case of V87I mutation, the selectivity shifted towards the 
hydroxylation of benzylic methyl group which was observed as the major site of 
metabolism.  
 
For 3, the P450 BM3 variants M11, M11 V87I and M11 V87F formed two mono-
hydroxylated metabolites (m/z 278) which were identified as aromatic ring 
hydroxylation products: 4’-hydroxy-tolfenamic acid (3a) and 5-hydroxy-tolfenamic 
acid (3b) (Supplementary information). As observed for 1 and 2 as well, the 
introduction of the V87F mutation promoted aromatic hydroxylation specifically at 4’ 
position. This observation is consistent with previous studies reporting aromatic 
hydroxylation of substrates like mono-substituted benzenes and o-xylene by P450 
BM3 variants containing phenylalanine at position 87 (32, 34). Interestingly, no 
benzylic hydroxylation was observed for 3. 
 
Aromatic ring preference for hydroxylation by P450 BM3 mutants 
 
In general, among the aromatic hydroxylation products of fenamic acid NSAIDs, the 
P450 BM3 variants showed a preference towards hydroxylation at the dichloro phenyl 
ring (1) or dimethyl phenyl ring (2) compared to the carboxy phenyl ring (Table 1). 
Previously, it has been shown that for the arylacetic acid containing NSAID diclofenac, 
hydroxylation at the 4’ position was the major product produced by engineered P450  
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BM3 mutants (22, 24). In order to rationalize the observed ring preference for 
hydroxylation, in silico docking studies were performed with BM3 mutant M11 and 2 
as a model, using the GOLD (version 5.2) software (35) and the docking settings as 
previously described (27). Docking of 2 into M11 predominantly shows the 
occurrence of binding poses in which 2 is docked with its dimethyl phenyl ring toward 
the heme group, with either 3’-methyl or C-4’ in closest proximity of the heme iron 
center (see Figure 5, panels A and B, respectively). These binding orientations are 
stabilized by formation of a hydrogen bond between the 2 carboxyl group and the 
side-chain hydroxyl group of Ser72. In only a single binding pose obtained from 
docking, the carboxy phenyl ring was found in close proximityof the porphyrin ring 
(Figure 5, panel C). In this pose, the carbon atoms of the phenyl ring are situated 
further than 6 Å from the heme iron, which is typically taken as a cut-off distance for 
possible catalytic activity. Importantly, no stabilizing hydrogen bonding interactions 
(or salt-bridge formation) of 2’s carboxyl group with the protein was observed with 
the C-5 ring in the closest proximity of Fe (Figure 5, panel C), which can explain the 
observed preference for hydroxylation of the other phenyl ring of the fenamic acids.  
 
 
 
 
 
Figure 5. Binding poses of mefenamic acid (depicted in ball-and-stick and with green carbon atoms) in M11 
(A,B,C) as observed in docking studies. Selected amino acid residues within the binding cavity of the 
mutants and the heme group are explicitly depicted in stick representation while aromatic and aliphatic 
hydrogens are omitted. Atoms prone to 3’-methyl aliphatic hydrogen abstraction (A) or to aromatic 
oxidative addition at C-4’position (B) are marked with a red circle, and the dashed red lines represent their 
distances (in Å) from the heme iron atom. In (C), the C-5 position is marked with a red circle. Dashed blue 
lines represent hydrogen bonds. 
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This docking study showed that upon hydrogen bonding to Ser72,  2 can adopt 
binding conformations that are consistent with either benzylic oxidation at 3’-methyl 
or aromatic hydroxylation at C-4’ (Figure 5, panels A and B). In addition, 3’-methyl 
and/or C-4’ were consistently found to be in closer proximity of Fe than 2’-methyl, 
which offers a structural rationalization of the fact that no hydroxylation of the 2’-
methyl group has been experimentally observed, although a similar reactivity can be 
expected for the two methyl groups of 2. It also explains why no benzylic 
hydroxylation is found for 3, in which the methyl group in position 3’ is substituted by 
a chlorine atom. The observed benzylic and aromatic hydroxylation selectivity in 
different mutants will be further rationalized in near future in extensive molecular 
dynamics (MD) simulation based studies. 
 
Characterization of fenamic acid metabolism by P450 BM3 variants  
 
Enzyme kinetic parameters were determined for the three fenamic acid NSAIDs and 
BM3 variants which showed high selectivity for benzylic and aromatic hydroxylation. 
For 1 and 2, introduction of V87F mutation in M11 led to a 1.6 and 3 fold decrease 
respectively in the catalytic efficiency (Vmax/Km) towards formation of benzylic 
hydroxylation at 3’position, while the catalytic efficiency towards aromatic 
hydroxylation (4’-OH) was not affected (Table 1). This resulted in the higher 
selectivity for aromatic hydroxylation. For 3, V87F mutation led to a 1.4 fold increase 
in Vmax/Km resulting in a higher catalytic efficiency for 4’ hydroxylation of all the three 
drugs tested. On the other hand, the introduction of V87I mutation in M11 led to a 5 
fold decrease in the catalytic efficiency (Vmax/Km) towards formation of 2b, while the 
catalytic efficiency towards benzylic hydroxylation was increased by approximately 
1.2 fold. The marked decrease in aromatic hydroxylation efficiency by V87I mutation 
can be attributed to increased selectivity towards benzylic hydroxylation. Similar 
results were also observed for 1. For 3, the introduction of V87I mutation increased 
the C-5 hydroxylation catalytic efficiency by 1.5 fold. In comparison to 2 and 1, BM3 
variants showed higher C-5 hydroxylation efficiency for 3 which can be attributed to 
the lack of benzylic hydroxylation. In all cases, the Hill coefficients were not 
significantly different from one which indicates that co-operativity does not take 
place.  
 
In order to evaluate the effect of mutations on the binding of the fenamic acid drugs in 
the active site of P450 BM3, spectroscopic titrations with the respective drug were 
carried out. Binding of fenamic acid NSAIDs to the tested BM3 variants resulted in a 
typical type I spectra (Figure 6) with a peak around 390 nm and trough at 420 nm  
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Figure 6. UV-VIS difference spectra of (A) meclofenamic acid binding to M11 L437N V87I and (B) 
mefenamic acid binding to M11 V87I. 
 
 
which is indicative of the conversion of the haem spin state from low to high. For 
mutant M11 with 1 and 3, a reverse type I spectra was observed. Further studies are 
currently being done to elucidate the binding mode of these two drugs in mutant M11. 
Table 1 shows the dissociation constants (KD) as obtained for the binding of 
fenamates to the BM3 mutants. The mutations showed varied effect with respect to 
dissociation constant values depending on the substrate. For example, in the case of 2, 
the introduction of V87I mutation in M11 led to a 3 fold increase in KD value while the  
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V87F mutation led to a 12.6 fold increase. The binding parameters could not be 
determined for wildtype P450 BM3 owing to lack of spin state shift. Previously, it was 
reported that the structurally similar compound diclofenac did not show any spin 
state shift with wild type P450 BM3 (24). 
 
Total turnover numbers and scalability of the reaction 
 
To determine the preparative scale use of the BM3 variants for the synthesis of 
metabolites of fenamic acid NSAIDs, total turnover numbers (TTNs) for selective 
mutants were calculated. As shown in Table 1, the TTNs ranged from 2000- 6000 
depending on the mutant and drug combination. Higher TTNs were observed for 2 
hydroxylation. These values are in the order of magnitude required for preparative 
scale synthesis (Table 2). Additionally, TTNs were also calculated at 4 °C. No 
remarkable difference in TTNs was observed in comparison to those at 25 °C. 
Interestingly, at lower temperatures, an increase (upto 10 %) in aromatic 
hydroxylation at C-5 position was observed. Previously, it has been reported that the 
P450 BM3 mediated regioselectivity of butane hydroxylation can be altered by 
changing the reaction temperatures (36). 
 
 
Table 2.Total turnover numbers towards metabolism of drugs by engineered P450 BM3 
variants. 
 
 
 
 
 
 
Drug Therapeutic Type TTNs Reference 
Artemisinin Antimalarial agent   434 Zhang et al., 2010 (37) 
Buspirone Antianxiety drug 3800 Landwehr et al., 2006 (38) 
Cyclopentanecarboxylic acid Precursor to carbovir 9200 Munzer et al., 2005 (39) 
Ibuprofen NSAID   650 Rentmeister et al., 2011(23) 
Mefenamic acid NSAID 6000 This study 
Naproxen NSAID 1010 Rentmeister et al.,2011 (23) 
Parthenolide Antileukemic agent 4980 Kolev et al.,2013 (40) 
Phenacetin Analgesic   930 Kim et al., 2010 (41) 
Verapamil Antiarrhythmic agent 1500 Sawayama et al.,2009 (21) 
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To illustrate the scalabitity of the reaction, 2 was chosen as an example. Incubations in 
a volume of 50 mL containing 12 mg of 2 (1 mM) and 150 nM of mutant M11 V87F in 
the presence of a glucose-6-phosphate dehydrogenase catalyzed NADPH regenerating 
system resulted in 90 % substrate conversion with 75 % regioselectivity for formation 
of 2b. This illustrates that the reaction can be scaled up without any loss of 
regioselectivity. Additionally, very minimal secondary oxidation to quinoneimines was 
observed indicating that this P450 BM3 mutant catalyzes the first step very efficiently. 
After isolation of the metabolite, 6.8 mg 2b was obtained. 2b is an important ring 
hydroxylated metabolite that can be bioactivated to reactive quinoneimines. 
Therefore, this enzymatically synthesized metabolite can be used as a standard in 
cellular studies as well as a substrate for further toxicological evaluation. 
 
Conclusions 
 
Tailoring cytochrome P450 BM3 mutants for selective drug metabolite production has 
gained considerable importance over the past years. In the current work, we studied 
the ability of P450 BM3 variants to produce metabolites of three drugs belonging to 
the fenamate class of NSAIDs and associated with adverse reactions. Our study has 
identified engineered P450 BM3 variants that are capable of synthesis of benzylic or 
aromatic ring hydroxylated metabolites of the fenamic acid NSAIDs as an alternative 
to their human P450 counterparts. As a result, these mutants with high total turnover 
numbers can be employed as biocatalytic tools for large-scale production of the 
respective drug metabolite to facilitate toxicological evaluation. In general, amino-acid 
substitution at the active site residue 87 of P450 BM3 from valine to isoleucine or 
phenylalanine led to more selective hydroxylation at either a benzylic or aromatic 
position respectively. Future studies will focus to understand the structural 
determinants of the selective hydroxylation which in turn will help to design mutants 
with novel regioselectivites. 
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Characterization of the hydroxylated metabolites of 1, 2 and 3 by 1H NMR spectroscopy 
 
3’ -OH-methyl-meclofenamic acid (1a) 
 
1H NMR (500 MHz, METHANOL-d4ȌɁͶǤ͹ͳȋǡʹȌ͸ǤʹʹȋǡJ=8.5 Hz, 1 H) 6.69 - 6.76 (m, 1 
H) 7.14 - 7.22 (m, 1 H) 7.47 (d, J=8.5 Hz, 1 H) 7.51 (d, J=8.5 Hz, 1 H) 8.02 (dd, 1 H) 
 
4’ -OH-meclofenamic acid (1c) 
1H NMR (500 MHz, METHANOL-d4ȌɁʹǤʹ͹ȋǡ͵Ȍ͸ǤͳͶȋǡJ=8.2 Hz, 1 H) 6.63 - 6.67 (m, 1 
H) 6.92 (s, 1 H) 7.14 (td, J=7.8, 1.7 Hz, 1 H) 7.99 (dd, J=7.4, 1.7 Hz, 1 H) 
 
5 -OH-meclofenamic acid (1c) 
 
1H NMR (500 MHz, METHANOL-d4) Ɂppm 2.41( s, 3 H) 6.15 (d, J=8.2 Hz, 1 H) 6.75 (dd, J=8.4, 1.1 
Hz, 1 H) 7.16 (d, J=8.5 Hz, 1 H) 7.35 (d, J=7.6 Hz, 1 H) 7.43 (d, 1H) 
 
3’ -OH-methyl-mefenamic acid (2a) 
 
1H NMR (500 MHz, METHANOL-d4ȌɁʹǤʹͷȋǡ͵ȌͶǤ͸ͻȋǡʹȌ͸Ǥ͸͸- 6.70 (m, 1 H) 6.72 - 
6.76 (m, 1 H) 7.20 - 7.28 (m, 4 H) 7.97 (dd, J=8.2, 1.6 Hz, 1 H) 
 
4’ -OH-mefenamic acid (2b) 
 
1H NMR (500 MHz, METHANOL-d4ȌɁʹǤͳʹȋǡ͵ȌʹǤͳͺȋǡ͵Ȍ͸ǤͶͳȋǡJ=8.2 Hz, 1 H) 6.55 
(t, J=7.6 Hz, 1 H) 6.66 (d, J=8.5 Hz, 1 H) 6.89 (d, J=8.5 Hz, 1 H) 7.11 (ddd, J=8.5, 7.6, 1.6 Hz, 1 H) 
7.91 (dd, J=7.9, 1.6 Hz, 1 H) 
 
5 -OH-mefenamic acid (2c) 
 
1H NMR (500 MHz, METHANOL-d4) ɁʹǤͳ͹ȋǡ͵ȌʹǤ͵ʹȋǡ͵Ȍ͸Ǥ͹ͶȋǡJ=8.8 Hz, 1 H) 6.83 
(dd, J=8.8, 2.8 Hz, 1 H) 6.91 (d, J=7.3 Hz, 1 H) 7.03 (t, J=7.6 Hz, 1 H) 7.09 (d, J=7.9 Hz, 1 H) 7.42 
(d, J=2.8 Hz, 1 H) 
 
4’ -OH-tolfenamic acid (3a) 
 
1H NMR (500 MHz, METHANOL-d4) Ɂ ppm 2.25 (s, 3 H) 6.46 (d, J=8.5 Hz, 1 H) 6.61 - 6.66 (m, 1 
H) 6.83 (d, J=8.5 Hz, 1 H) 7.04 (d, J=8.5 Hz, 1 H) 7.21 (td, J=6.9, 1.7 Hz, 1 H) 7.95 (dd, J=8.0, 1.7 
Hz, 1 H) 
 
5 -OH-tolfenamic acid (3b) 
 
1H NMR (500 MHz, METHANOL-d4ȌɁʹǤ͵Ͷȋǡ͵Ȍ͸ǤͺͶ(m, J=6.6 Hz, 1 H) 6.93-6.96 (m, 1 
H) 7.00 (d, J=7.3, 1 H) 7.06  (t, J=7.9,1 H) 7.20 (d, J=7.6, 1 H) 7.45 (d, 1 H) 
133
134
                                      
 
Chapter 6 
 
 
 
APPLICATION OF ENGINEERED CYTOCHROME 
P450 BM3 MUTANTS TO STUDY THE EFFECT OF 
HUMAN GLUTATHIONE S-TRANSFERASE GSTP1-1 
POLYMORPHISMS ON THE DETOXIFICATION OF 
REACTIVE DRUG METABOLITES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Harini Venkataraman*, Sanja Dragovic*, Selina Begheijn,  
  Nico P.E. Vermeulen and Jan N.M. Commandeur, Toxicology  
  Letters (2014) 224, 272-281 
    
                * Equal contribution 
  
 
 
  Role of hGSTP1-1 polymorphisms 
 
Abstract 
 
Recent association studies suggest that genetically determined deficiencies in GSTs 
might be a risk factor for idiosyncratic adverse drug reactions resulting from the 
formation of reactive drug metabolites. hGSTP1-1 is polymorphic in the human 
population with a number of single nucleotide polymorphisms that yield an amino 
acid change in the encoded protein. Three allelic variants of hGSTP1-1 containing an 
Ile105Val or Ala114Val substitution, or a combination of both, have been the most 
widely studied and showed different activity when compared to wild-type hGSTP1-
1*A (Ile105/Ala114). In the present study, we studied the ability of these allelic 
variants to catalyze the GSH conjugation of reactive metabolites of acetaminophen, 
clozapine, and diclofenac formed by bioactivation in in vitro incubations by human 
liver microsomes and drug metabolizing P450 BM3 mutants. The results show that 
effects of change of amino acid at residue 105 and 114 on conjugation reactions was 
substrate dependent. A single substitution at residue 105 affects the ability to catalyze 
GSH conjugation, while when both residue 105 and 114 were substituted the effect 
was additionally enhanced. Single mutation at position 114 did not show a significant 
effect. The different hGSTP1-1 mutants showed slightly altered regioselectivities in 
formation of individual GSH conjugates of clozapine which suggests that the binding 
orientation of the reactive nitrenium ion of clozapine is affected by the mutations. For 
diclofenac, a significant decrease in activity in GSH-conjugation of diclofenac 1',4'-
quinone imine was observed for variants hGSTP1-1*B (Val105/Ala114) and hGSTP1-
1*C (Val105/Val114). However, since the differences in total GSH conjugation activity 
catalysed by these allelic variants were not higher than 30%, interindividual 
differences in inactivation of reactive intermediates by hGSTP1-1 are not likely to be a 
major factor in determining interindividual difference in susceptibility to adverse 
drug reactions induced by the drugs studied. 
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Introduction 
 
Glutathione S-transferases (GSTs) are a superfamily of dimeric phase II enzymes, 
which play an important role in the cellular defense system (1, 2). The human GSTs 
exhibi           ǣ Ƚ
(alphaȌǡ Ɋ ȋmuȌǡ Ɏ ȋpiȌǡ ɐ ȋsigmaȌǡ Ʌ ȋthetaȌǡ Ɉ ȋkappaȌǡ ɍ ȋomega) ӗ (zeta)  and 
microsomal GSTs (3).  The major role of these GSTs is to catalyze the conjugation of 
reduced glutathione (GSH) to electrophilic compounds and the reduction of organic 
hydroperoxides, thereby preventing cytotoxicity or mutagenicity. Furthermore, 
upregulation of GSTs in tumor tissues can contribute to resistence against alkylating 
antitumor agents (2). It is well established that many drugs are bioactivated by 
cytochrome P450s to short-lived reactive metabolites that may be responsible for 
adverse drug reactions (ADRs) (4). The balance between the rate of formation of these 
highly reactive metabolites and their inactivation by GSH conjugation, which may be 
catalyzed by GSTs, will determine the level of protein adduct formation and may 
determine the risk for ADRs (4, 5).  
 
In humans, several GSTs are known to be genetically polymorphic due to point 
mutations, gene deletion and gene duplication (1, 6). Therefore, interindividual 
variations in the GSTs due to genetic polymorphism have been proposed as potentially 
important factors determining susceptibility to cancer and ADRs (7-10). One of the 
polymorphic GSTs, human GSTP1-1 (hGSTP1-1). is highly expressed in most 
extrahepetic tissues (11,12) and overexpressed in many tumor forms (1,2,9).  Because 
hGSTP1-1 has high activity in the inactivation of many environmental carcinogens and 
antitumor agents, its genetic polymorphisms have been subject of many studies to test 
whether they might affect susceptibility of individuals to different types of cancer and 
the efficacy of chemotherapy (6, 9). For hGSTP1-1, a number of single nucleotide 
polymorphisms (SNPs) have been identified that yield an amino acid change in the 
encoded protein, i.e. Ile105Val (13), Ala114Val (14), Asp147Tyr (15), Phe151Leu (16), 
and Gly169Asp (17). Four allelic forms of hGSTP1-1, resulting from combinations of 
the first two SNPs, have been subject to most studies so far. The variants that result 
from polymorphisms at position 105 and 114 are hGSTP1*A (Ile105/Ala114), 
hGSTP1*B (Val105/Ala114), hGSTP1*C (Val105/Val114) and hGSTP1*D 
(Ile105/Val114). The allele frequencies of the genotypes in Caucasian poulations are: 
hGSTP1*A, 0.685; hGSTP1*B, 0.262, and hGSTP1*C, 0.0687 (18). Although frequently 
tested in in vitro studies the occurrence of allele hGSTP1*D remains to be established. 
The effect of the mutations at position 105 and 114 of hGSTP1 has been studied in 
vitro using approximately thirty different electrophilic drugs and model substrates,  
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including 1-chloro-2,4-dinitrobenzene (CDNB), ethacrynic acid, chlorambucil, 
thiopeta, acrolein and diol epoxides of several polycyclic aromatic hydrocarbons 
(PAHs), see supplementary Table S1. However, the activity of hGSTP1-1 variants in 
inactivation of very short-lived reactive drug metabolites, which can only be tested in 
presence of a bioactivating system, has not yet been evaluated. In the present study, 
the effect of GSTP1-1 allelic variants on the GSH-dependent inactivation of the highly 
reactive metabolites of acetaminophen (APAP), clozapine (CLZ) and diclofenac (DF) 
was studied because in vitro studies have shown that hGSTP1 showed high activity in 
inactivation of the reactive metabolites of these drugs formed by cytochrome P450s 
(19-21). 
 
APAP is bioactivated by cytochrome P450 to N-acetyl-p-benzoquinone imine (NAPQI), 
a highly reactive intermediate which covalently binds to proteins, thereby causing 
hepatotoxicity (4, 22). Among the GSTs investigated, GSTP1-1 was the most active 
catalyst in GSH-conjugation of synthetical NAPQI in both rats and humans (19). 
Although GSTP1-1 is expressed in only low amounts in human liver (12), a recent 
clinical study by Buchard et al. suggests that homozygous carriers of the hGSTP1*C 
variant have a decreased risk for APAP hepatotoxicity (23). However, it has not been 
tested whether GSTP1-variants differ in the activity in inactivation of NAPQI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Reactive intermediates of acetaminophen (a), clozapine (b) and diclofenac (c,d) and identified 
structures of GSH-conjugates formed by wild-type hGSTP1-1. NAPQI, N-acetyl-p-benzoquinoneimine; DF-
1',4'-QI, diclofenac 1',4'-quinoneimine; DF-2,5-QI, diclofenac 2,5-quinoneimine. 
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The use of the antipsychotic drug CLZ is restricted because of the risk of life-
threatening agranulocytosis and hepatotoxicity, both of which are considered to the 
result of bioactivation to a reactive nitrenium ion by myeloperoxidase and 
cytochrome P450s, respectively (24-26). The nitrenium ion of CLZ is efficiently 
inactivated by GSH, forming multiple regioisomeric GSH conjugates as summarized in 
Table 1. Dragovic et al. showed that hGSTP1-1 has high activity in the inactivation of 
reactive nitrenium ion by catalyzing both chlorine-substitution and GSH-addition 
reactions, Figure 1 (20). GSTP1-1 is highly expressed in white blood cells (27) and 
hence polymorphism of GSTP1-1 might be a risk factor for occurrence of 
agranulocytosis in case mutations strongly affect the inactivation of the nitrenium ion. 
 
Treatment with the nonsteroidal anti-inflammatory drug DF is associated with serious 
gastrointestinal injury and rare cases of idiosyncratic hepatotoxicity (28,29). Although 
the exact mechanisms of these ADRs remain to be established, formation of reactive 
metabolites by cytochrome P450s is considered to play an important role in the onset 
of these toxic events (29,30). Based on the structure of GSH-conjugates identified in 
microsomal incubations at least four different reactive intermediates have been 
proposed for DF. Quantitatively the major ones are quinoneimines resulting from 
dehydrogenation of 4’-hydroxy diclofenac and 5-hydroxy diclofenac, Figure 1 (31). 
Minor GSH-conjugates result from a quinonemethide formed via oxidative 
decarboxylation (32), and an as yet unidentied reactive intermediate resulting in 
chlorine substitution of DF (33). We recently showed that hGSTP1-1 has high activity 
in catalysing GSH-conjugation of all reactive intermediates. Because hGSTP1-1 is 
abundantly expressed in the gastrointestinal tract, polymorphisms of hGSTP1-1 might 
be risk factor for the occurrence of gastrointestinal injury in case the amino acid 
substitutions influence GSH-conjugation of the different reactive intermediates 
formed by P450s.  
 
The aim of the present study was to investigate whether the allelic variants of 
hGSTP1-1 have different activity in the GSH conjugation of reactive metabolites 
generated by P450s in incubations of APAP, CLZ, and DF. Because the reactive 
intermediates of CLZ and DF can be conjugated to GSH at different positions, Figure 1, 
also the effect of the mutations on regioselectivity of GSH-conjugation will be studied, 
which might be indicative for different binding orientations. Reactive intermediates 
were generated using human liver microsomes (HLM), and purified drug metabolizing 
mutants of bacterial CYP102A1 as bioactivation systems. The CYP102A1 mutants 
were selected because of their ability to produce human relevant GSH conjugates at 
high activity and to circumvent interference of microsomal GSTs (5, 20). 
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Materials and methods 
 
Enzymes, plasmids and chemicals  
 
The bacterial CYP102A1 mutants CYP102A1 M11H, CYP102A1 M11H Phe87, and 
CYP102A1 M11 L437N were prepared and purified as described previously (20, 35, 
36). Human liver microsomes (HLM), pooled from 50 donors, were obtained from 
Xenotech (Lenexa, United States) and contained 20 mg/mL protein. Escherichia coli 
XL-1 Blue cells containing the expression plasmid for human GSTP1-1, was kind gift 
from Prof. Mannervik (Department of Biochemistry and Organic chemistry, Uppsala 
University, Sweden). All other chemicals and reagents were of analytical grade and 
obtained from standard suppliers. 
 
Site directed mutagenesis of hGSTP1-1 isoforms 
 
Three variants of wild type hGSTP1-1 (hGSTP1*A), namely hGSTP1*B (Val105, 
Ala114), hGSTP1*C (Val105, Val114) and hGSTP1*D (Ile105, Val114), were 
constructed by site directed mutagenesis. The single mutants hGSTP1*B and 
hGSTP1*D were constructed using the expression vector pKKD-hGST P1-1 as the 
template. The double mutant hGSTP1*C was constructed by introducing Ile104Val 
mutation in pKKD-hGSTP1*D (Ile105, Val114). The mutations were introduced by the 
Quikchange mutagenesis protocol using the following forward primers:   
 
Ile104Val :   CGC TGC AAA TAC GTC TCC CTC ATC TAC                
Ala113Val : C ACC AAC TAT GAG GTG GGC AAG GAT GAC 
The mutated amino acid position is indicated in bold. The reverse primers were 
exactly complementary to the forward primers. After mutagenesis, the presence of 
right mutations was verified by DNA sequencing (Service XS, Leiden, The 
Netherlands).  
 
Expression and purification of hGSTP1-1 enzymes  
 
Human GSTP1*A and its variants hGSTP1*B, hGSTP1*C and hGSTP1*D were 
expressed in E. coli XL-1 Blue cells. pKKD expression plasmids containing the different 
hGSTP1-1 genes, were transformed into E.coli XL-1 Blue cells. Expression and 
purification were essentially conducted as previously described (20). Purity of the 
enzymes was checked by SDS-polyacrylamide gel electrophoresis on a 12% gel with 
Coomassie staining as well as by reversed-phase liquid chromatography using a 
method adapted from Jenkins et al. (37). 
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Protein concentrations were determined according to the method of Bradford (38) 
with reagent obtained from Bio-Rad. The specific activity of the purified GSTs was 
assayed according to Habig et al. (39). The specific activities of the purified 
recombinant human GSTP1*A and its polymorphic variants using CDNB as a substrate 
  ǣ ʹͲǤͳ ɊȀȀ   
ͳȗǡ ͳͲǤ͸ ɊȀȀ
  
ͳȗǡ  ͻǤʹ ɊȀȀ   
ͳȗ  17.3 
ɊȀȀ
ͳȗǤ 
 
Bioactivation of the drugs and GSH conjugates formation in the presence of 
hGSTP1-1 variants 
 
Incubations were performed using purified CYP102A1 M11H as bioactivation system 
for APAP (34). Mutant CYP102A1 M11H Phe87 was used for CLZ (35) and CYP102A1 
M11 L437N for DF (21) as we have shown that these enzymes have high activity and 
selectivity for bioactivation to reactive intermediates. CLZ and APAP incubations were 
performed at a final enzyme concentration of 250 nM while for DF incubations were 
performed at a final BM3 concentration of 500 nM. All incubations were performed in 
ͳͲͲ     ȋ ͹ǤͶȌ      ʹͷͲ ɊǤ 
 ͷͲͲɊǤ  from the stock 
solutions was not more than 2% in the incubations. The allelic variants of hGSTP1-1 
ͲǤʹͷǡͲǤͷǡͳǡʹǡͶǡͺɊ
the linearity of product formation with protein concentration and to compare their 
ǤͺɊ
ͳ-1 was used in 
the incubations to investigate enzymatic GSH conjugation of the other substrates. 
Incubations with hGSTP1-ͳͳͲͲɊ GSH. Reactions 
with CLZ were started by adding 0.5 mM NADPH (final concentration) and performed 
for 30 min at 24°C, as described previously (20). For the other substrates, an NAPDH 
regenerating system (final concentrations: 0.5 mM NADPH, 20 mM glucose-6-
phosphate and 2 units/mL of glucose-6-phosphate dehydrogenase) was used to start 
the reaction and incubations were performed for 60 min at 24 °C. Reactions 
ʹͷɊͳͲΨ-cold 
HClO4. In case of D	ʹͷͲɊ-cold methanol with 2% 50 mM ascorbic acid in water 
was added to stop incubations. All samples were centrifuged for 15 min at 14000 rpm. 
The supernatants were analyzed by HPLC and LC-MS, as described below. 
 
Incubations were also performed usinǤͷͲͲɊ
incubated in 100 mM Kpi buffer, pH 7.4, for 30 minutes at 37°C with 1 mg/mL 
ǡͳͲͲɊ
ͺɊ
ͳ-1. 
Reactions were started with 0.5 mM NADPH (final concentration). For DF and APAP,  
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ͳͲͲǡ͹ǤͶǡʹͷͲɊ
ͷͲͲɊǡʹȀǡͳͲͲɊ

ͺɊ
ͳ-1. Reactions were initiated by 
the addition of NADPH regenerating system (final concentrations: 0.5 mM NADPH, 20 
mM glucose-6-phosphate and 2 units/mL of glucose-6-phosphate dehydrogenase) and 
were incubated for 60 min at 37°C. Reactions were terminated depending on the 
substrate as described above and centrifuged at 14000 rpm for 15 min to remove 
precipitated proteins. 
 
Analytical methods 
 
The analyses of the GSH-conjugates were performed by reversed-phase liquid 
ͷɊͳͺȋͶǤ͸x 150 mm) as stationary phase, 
 	̻ͳͺ͵ǤͷɊȋͶǤ͸ͳͲͲȌ
used. For incubations of CLZ and DF, a gradient method was used where two mobile 
phases were mixed: eluent A (1% acetonitrile, 99% water, 0.2% formic acid) and 
eluent B (1% water, 99% acetonitrile, 0.2% formic acid). The gradient used was: 0 to 5 
min isocratic at 0% eluent B; 5 to 30 min a linear increase to 100%  eluent B; 30 to 
30.5 min linear decrease to 0% eluent B;  30.5 to 40 min isocratic re-equilibration at 
0% solvent B. The flow rate was 0.5 mL/min. For analysis of metabolites of APAP, an 
isocratic method was used with a mobile phase consisting of 18% methanol, 82% 
water, and 0.1 % trifluoroacetic acid (TFA) and a flow rate of 1 mL/min. Samples were 
      ͷͲ Ɋ     Ȁ   
wavelength of 243 nm (APAP) or 254 nm (CLZ, DF). Quantification is based on the 
substrate standard curves, assuming that the extinction coefficients of the GSH 
adducts are equal to that of the substrate.  
 
All metabolites were identified using an Agilent 1200 Series Rapid resolution LC 
system was connected to a hybrid quadrupole-time-of-flight (Q-TOF) Agilent 6520 
mass spectrometer, equipped with electrospray ionization (ESI) source and operating 
in the positive mode as described in Dragovic et al. (20). The characteristics of the 
GSH-conjugates analyzed in the incubations are tabulated in Table 1. 
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Table 1. Characteristics of the GSH conjugates formed by bioactivation of the drugs used in this study. 
           
Abbreviation GSH conjugates                            tret (min)       m/z       
                                                                                                                                                                                          ([M+H]+) 
           
Clozapine      
CG-1  6-(glutathione-S-yl)-clozapine                             14.3                       632.23  
CG-3  9-(glutathione-S-yl)-clozapine                            14.0                       632.23  
CG-4  7-(glutathione-S-yl)-clozapine NI                           13.5                       632.23  
CG-5  (1-4)-(glutathione-S-yl)-clozapine                            14.6                       632.23  
CG-6  8-(glutathione-S-yl)-deschloroclozapine                            11.8                       598.27 
Diclofenac     
M1  5-hydroxy-4/6-(glutathione-S-yl)-diclofenac         19.7                       617.09  
M2  4’-hydroxy-3’-(glutathione-S-yl)-diclofenac        20.0                       617.09  
M3  5-hydroxy-4/6-(glutathione-S-yl)-diclofenac        20.4                       617.09  
M5  4’-hydroxy-2’-(glutathione-S-yl)-diclofenac       19.7                       583.13  
DPAB-SG                    2-(2,6-dichlorophenylamino)-benzyl-                                 21.7                       557.13  
                                       S-thioether glutathione              
DF-SG  2’-(glutathione-S-yl)-deschlorodiclofenac                           19.5                       567.14  
Acetaminophen 
APAP-SG 3-(glutathion-S-yl)-acetaminophen         10.3                       457.11 
           
 
 
Results 
 
Activity of hGSTP1-1 variants in inactivation of clozapine nitrenium ion 
 
Consistent with previous results, addition of hGSTP1-1 to incubations of CLZ with 
CYP102A1 M11H Phe87 resulted in major changes of the profile and concentrations of 
GSH conjugates (20). For each of the allelic variants of hGSTP1-1, the increase in 
formation of GSH conjugates CG-4, CG-5 and CG-6 was proportional with the hGSTP1-1 
concentrations when varied from 0.5 to 8 μM (data not shown). Table 2 shows the 
effects observed at 8 μM of hGSTP1-1 variants. The amount of the total GSH conjugates 
of CLZ was increased 2.4 to 2.7-fold, when compared to the non-enzymatic 
conjugation. However, none of the three variants showed a statistically significant 
difference compared to wild-type hGSTP1*A. As shown in Figure 2A, the variants only 
showed slightly different profiles of GST-dependent GSH conjugates. For hGSTP1-1*B 
and hGSTP1-1*C CG-6 was produced at 2-fold higher amount than CG-5. For mutants 
hGSTP1-1*A and hGSTP1-1*D conjugate CG-6 was produced at 2.7- and 2.5-fold higher 
amounts, respectively, than CG-5. The minor GSH conjugate, CG-4, was increased with 
the highest activity by hGSTP1*B and hGSTP1*C being 2 times higher comparing to 
hGSTP1*A, after subtraction of non-enzymatic conjugation. 
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As can be seen from Table 2, the variants of hGSTP1-1 enzyme also did not show 
significant differences in total GSH conjugate formation when bioactivation reactions 
were performed with HLM which might be due to the almost 4-fold lower amounts of 
GSH-conjugates formed. However, similar differences in the ratio of GST-dependent 
conjugates CG-6 and CG-5 were observed. Again, hGSTP1-1*A and hGSTP1-1*D 
produced conjugate CG-6 at relatively higher amounts than CG-5. The effect on 
relative amount of CG-4 could not be confirmed because this conjugate is mainly 
produced by the microsomal GST present in HLM (19). 
 
Activity of hGSTP1-1 variants in inactivation of reactive metabolites of 
diclofenac 
 
As shown in Table 2, all hGSTP1-1 variants showed very high activity in catalysing 
GSH-conjugation of reactive DF metabolites when using CYP102A1 as bioactivating 
system. The total amount of GSH-conjugates was increased 7- to almost 9-fold.  
hGSTP1*A and hGSTP1*D showed the highest activity for the formation of total GSH 
conjugates. When corrected for the non-enzymatic conjugation hGSTP1*B and 
hGSTP1*C appeared to have 20% and 30% lower activity, respectively, compared to 
the other variants.  
 
DF is bioactivated by CYP102A1 to different reactive intermediates, of which 
diclofenac 1',4'-quinoneimine (DF-1'4'-QI), formed via 4'-hydroxylation, and 
diclofenac 2,5-quinoneimine (DF-2,5-QI), formed via 5-hydroxylation, are 
quantitatively the major ones. As shown in Table 2, the GSH-conjugation of DF-1'4'-QI 
was more affected by the polymorphic mutations with hGSTP1*C exhibiting the lowest 
activity in formation of the corresponding GSH-conjugates M2 and M5. When 
correcting for the non-enzymatic reaction, hGSTP1*C showed almost 40% lower 
activity when compared to the wild type hGSTP1*A. Activities of hGSTP1*B and 
hGSTP1*D were 22% and 17% lower, respectively. No differences in the ratio of M2 
and M5 were observed, Figure 3A.  
ͳͶͶ
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A)   
 
 
 
 
 
 
 
B)  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effect of 8 μM of hGSTP1*A, hGSTP1*B, hGSTP1*C, and hGSTP1*D on the regioselectivity of GSH-
conjugation of the nitrenium ion of CLZ.  CLZ was bioactivated to reactive metabolites using CYP102A1 
M11H Phe87 mutant (A) or HLM (B).  
 
What concerns the GSH-conjugation of DF-2,5-QI,  only hGSTP1*D appeared to have 
25% higher activity than wild-type hGSTP1*A, whereas hGSTP1*C and hGSTP1*B 
showed similar activity. As shown in Figure 3B, small changes were observed in the 
regioselectivity of GSH-conjugation of DF-2,5-QI since the relative amount of GSH-
conjugate M1 was slightly higher in variants hGSTP1*A and hGSTP1*D. No significant 
differences were observed between the hGSTP1-1 polymorphic variants for the 
formation of the minor GSH conjugates DF-SG (m/z 567) and DPAB-SG (m/z 557) 
which are formed by the two minor bioactivation pathways (data not shown) (32,33). 
In case of HLM as bioactivation system, addition of 8 μM of hGST-variants increased 
the total GSH-conjugation of reactive metabolites of DF about 4-fold, Table 1.  No 
significant differences were observed between the activities and regioselectivities of 
the hGSTP1-1 variants, which may be explained by the lower levels of reactive  
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intermediates produced and the analytical error, Figure 4.  The fact that GSH-
conjugation of DF-1'4'-QI is increased to a smaller extent by hGSTP1-1, whereas a 
significantly different ratio of conjugates M2 and M5 was found, point to contribution 
of microsomal GST in the HLM incubations, Figure 4B. Again no significant differences 
were observed between the polymorphic variants of hGSTP1-1 for the formation of 
DF-SG and DPAB-SG (data not shown). 
 
A)  
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of 8 μM hGSTP1*A, hGSTP1*B, hGSTP1*C, and hGSTP1*D on the regioselectivity of GSH 
conjugation of DF-1',4'-QI (A) and DF-2,5-QI (B), using CYP102A1 M11 L437N mutant as bioactivation 
system. 
 
Activity of hGSTP1-1 variants in inactivation of acetaminophen reactive 
metabolites  
 
ͺɊ
ͳ-1 mutants to the incubation of APAP with CYP102A1 
M11H, in the presence of 100 μM GSH, increased the concentrations of NAPQI-SG 
about 10-fold, Table 2. Variants hGSTP1*A, hGSTP1*B and hGSTP1*D did not show 
statistically significant differences in conjugation of NAPQI. Only hGSTP1*C showed a 
15% decreased activity compared to hGSTP1*A. When using HLM as bioactivation  
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system, however, no significant differences were found in the activity of the hGSTP1-1 
variants. 
 
 
A)   
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
Figure 4. Effect of 8 μM hGSTP1*A, hGSTP1*B, hGSTP1*C, and hGSTP1*D on the regioselectivity 
of GSH conjugation of DF-1',4'-QI (A) and DF-2,5-QI (B), using human liver microsomes as 
bioactivation system. 
 
Discussion 
 
Because hGSTP1-1 is highly expressed in normal extrahepatic tissues and 
overexpressed in many tumors types, in some cases in response to antitumor drugs. 
Therefore, a large number of studies have been performed to investigate whether 
genetic polymorphism of hGSTP1-1 has consequences for the inactivation of 
carcinogenic diolepoxides of PAHs or alkylating antitumor drugs, such as thiotepa and 
chlorambucil, since these might be revelant for susceptibility to carcinogenesis and 
efficacy of antitumor treatment. Table 3 summarizes the relative activities observed 
for the hGSTP1-1-variants with amino acid substitutions Ile105Val and/or Ala114Val  
ͳͶͺ
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when compared to wild-type hGSTP1-1*A, which is set at 100% for all compounds. 
The data shown in Table 3 are based on the kcat/Km-values reported because this 
enzyme kinetical parameter will most likely the most relevant parameter to describe 
differences in enzyme activity at the low, physiologically relevant, concentrations of 
reactive carcinogens and toxicants. Only data is shown of studies in which at least 
three of the hGSTP1-1 variants were compared; for a more complete list see Table S1. 
The results of the present study show that the amino acid substitutions Ile105Val and 
Ala114Val have differential effects on the activity of hGSTP1-1, dependent on the 
reactive intermediate involved, consistent with the previous studies which have been 
performed with chemically stable electrophilic compounds, see Table 3. For CLZ no 
significant differences were observed in the total rate by which the CLZ nitrenium ion 
is conjugated to GSH by hGSTP1-1. The only significant effect which was observed in 
both CYP102A1 and HLM incubations was a slight change in regioselectivity in GSH-
conjugation to the CLZ nitrenium ion. In both hGSTP1*B and hGSTP1*C, which share 
the Ile105Val substitution, an increase in the relative amount of GSH-conjugates CG-4 
and CG-5 was found while substitution of chlorine by GSH and formation of CG-6 was 
decreased, Figure 2. Although no association studies have been carried out yet to 
study the role of hGSTP1-1-polymorphism as risk factor for CLZ-induced 
agranulocytosis, the present data see to rule out that genetically determined 
differences in hGSTP1-1 activity in white blood cells might determine susceptibility. 
 
As shown in Tables 2 and 3, variant hGSTP1-1*B and hGSTP1-1*C both showed a 
significant decreased total activity in GSH-conjugation of reactive metabolites of DF, 
which could be mainly attribited to a decreased GSH-conjugation of DF-1',4'-QI, which 
is quantitatively the major reactive intermediate formed.  Both hGSTP1-1*B and 
hGSTP1-1*C contain amino acid substitution Ile105Val which was also shown to be 
detrimental for the GSH-conjugation of the antitumor agents chlorambucil and 
thiotepa, and for the general GST-substrate CDNB but benificial for the catalysis of 
GSH-conjugation of ethacrynic acid and several carcinogenic diolepoxides of PAHs, 
Table 3. According to the available crystal structures of hGSTP1*A, hGSTP1*B and 
hGSTP1*C (42, 43), amino acid residue 105 is localized in the H-site of hGSTP1-1 and 
can affect enzyme activity in several ways, dependent on the substrate.  First, the 
Ile105Val substitution can affect the shape of the active-site, because the Val105 has 
more conformational freedom than Ile105. For large substrates, Val105 can point 
away from the active site, which allows the accommodating of larger substrates, such 
as BPDE, for catalysis (42).  Also, amino acid residue 105 is close to residue Tyr109, 
which for some substrates plays an important role in the catalytic mechanism of 
hGSTP1-1 by stabilizing the intermediate complex (44). Furthermore, substitution 
Ile105Val has shown to affect the hydrophobicity/hydrophilicity of the H-site of 
ͳͶͻ
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CHAPTER 6 
 
hGSTP1-1 by influencing the number of active-site water molecules which can affect 
substrate binding and/or product release (45). Which of these mechanisms contribute 
to the decreased GSH-conjugation of DF-'1,'4-QI and the slight change in 
regioselectivity of GSH-conjugation of CLZ-nitrenium ion is not known. 
 
A recent association study has shown that the frequency of hGSTP1*C-allele was 
significantly lower in APAP-poisoned patients than in insensitive patients, which 
suggests that this genotype may reduce the risk of APAP-hepatotoxicity (23). The 
results of the present study shows that the hGSTP1*C variant had the lowest activity 
in catalysing the GSH-conjugation of NAPQI, Table 1. However, this activity was only 
15% lower than that of hGSTP1-1*A, which is not likely to be of toxicological 
relevance, also considering the fact that the current study was performed at reduced 
GSH-concentration, to minimize non-enzymatic GSH-conjugation, and that hGSTP1-1 
is expressed in the human liver only to a significant extent in the biliary tree (11).   
In conclusion, the results of the present study show that the amino acid substitutions 
Ile105Val and Ala115Val in hGSTP1-1 have only relatively minor effect on the activity 
of GSH-conjugation of the reactive metabolites of APAP, CLZ and DF. Differences in the 
rate of inactivation of their reactive intermediates are, therefore, unlikely to play a 
role in the susceptibility to their toxic side-effects.  However, in recent years it has 
been shown that GSTP1-1 also can directly influence signalling pathways underlying 
stress response, apoptosis, inflammation, and cell proliferation by protein-protein 
interaction and protein glutathionylation (46). Interestingly, it was recently shown 
that only variants hGSTP1-1*A and hGSTP1-1*C were able to reactivate the 
antooxidant enzyme peroxiredoxin VI, whereas variants hGSTP1-1*B and hGSTP1-1*D 
were without effect, suggesting that these polymorphisms may influence human 
population susceptibility to oxidant stress (47). Therefore, these factors rather than 
interindividual differences in the rate of GSH-conjugation of reactive drug metabolites 
by hGSTP1-1 can play a role in susceptibility to adverse drug reactions induced by the 
drugs studied. 
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Bioactivation Of Mefenamic Acid By Cytochrome P450s 
 
 
Abstract 
 
Mefenamic acid (MFA) has been associated with rare but severe cases of 
hepatotoxicity, nephrotoxicity and hypersensitivity reactions which are believed to 
result from the formation of reactive metabolites. Although formation of protein-
reactive acylating metabolites by phase 2 metabolism has been well-studied and 
proposed as cause of these toxic side effects, the oxidative bioactivation of MFA has 
not yet been competely characterized. In the present study, the oxidative bioactivation 
of MFA was studied using human liver microsomes (HLM) and recombinant human 
P450 enzymes. In addition to the major metabolite 3’-OH-methyl-MFA, resulting from 
the benzylic hydroxylation by CYP2C9, 4'-hydroxy-MFA and 5-hydroxy-MFA were 
identified as metabolites resulting from oxidative metabolism of both aromatic rings 
of MFA. In presence of GSH, three GSH conjugates were formed which appeared to 
result from GSH-conjugation of the two quinoneimines formed by further oxidation of 
4'-hydroxy-MFA and 5-hydroxy-MFA. The major GSH-conjugate was identified as 4’-
OH-5’glutathionyl-MFA and was formed at the highest activity by CYP1A2 and to a 
lesser extent by CYP2C9 and CYP3A4. Two minor GSH-conjugates resulted from 
secondary oxidation of 5-hydroxy-MFA and were formed at the highest activity by 
CYP1A2 and to a lesser extent by CYP3A4. Additionally, the ability of seven human 
glutathione S-transferases (hGSTs) to catalyze the GSH conjugation of the 
quinoneimines formed by P450s was also investigated.  The highest increase of total 
GSH-conjugation was observed by adding hGSTP1-1, followed by hepatic hGSTs 
hGSTA2-2 and hGSTM1-1. The results of this study show that next to phase 2 
metabolites, also reactive quinoneimines formed by oxidative bioactivation might 
contribute to the idiosyncratic toxicity of MFA.   
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Introduction 
 
Mefenamic acid (MFA) belongs to the class of N-aryl-anthranilic acid containing non-
steroidal anti-inflammatory drugs (NSAIDs) and is widely used in the treatment of 
pain, arthritis and dysmenorrhea (1, 2). The anti-inflammatory effect of MFA is due to 
the inhibition of the production of prostaglandins formed by cyclooxygenase (COX) 
enzymes (3). Use of MFA has been associated with gastrointestinal toxicity which is a 
common adverse effect of carboxyl-group containing NSAIDs (4, 5). Additionally, MFA 
has also been shown to produce rare cases of nephrotoxicity and hepatotoxicity in 
patients (6-8). 
 
A proposed mechanism for the NSAID-mediated toxicity is the bioactivation of the 
drug to chemically reactive metabolites which can then covalently bind to proteins 
(9). Both formation of acyl glucuronides and reactive oxidative metabolites, such as 
arene oxides and quinoneimines, have been shown to contribute to irreversible 
protein binding of NSAIDs. In case of MFA, glucuronidation of the parent drug and its 
oxidative metabolites appear to be the major pathways of metabolism. Analysis of the 
urine samples of patients undergoing MFA therapy showed that glucuronides of 3’-
hydroxy-methyl-MFA, 3’-carboxy-MFA and MFA itself were excreted as metabolites 
(10). MFA is mainly glucuronidated to form 1-O-acyl-MFA glucuronide (MFA-1-O-G) 
which can bind irreversibly to proteins in vitro and ex vivo. The covalent binding of 
MFA to cellular protein was increased in Chinese hamster V79 cells expressing UGT 
1A9 (2). Also the involvement of UGT1A9 and UGT2A7 in the glucuronidation of MFA 
by human kidney cortical microsomes has been reported (11). More recently, MFA-
acyl-adenylate (MFA-AMP), MFA-S-acyl-coenzyme A (MFA-CoA) and MFA-S-acyl-
glutathione (MFA-GSH) were shown to be additional reactive acylating metabolites of 
MFA which appeared to be even more reactive than MFA-1-O-G (1, 12).  
 
Although the bioactivation of MFA by phase II-enzymes to acylating metabolites has 
been well characterized, the possible role of oxidative bioactivation is much less 
defined. In the case of diclofenac, protein modification by oxidative metabolites were 
suggested to be more critical for acute cytotoxicity than modification by its acyl 
glucuronide (13).  It has been shown previously that MFA is mainly metabolized via 
benzylic hydroxylation to 3’-hydroxymethyl-MFA in human liver microsomes (HLM) 
(14, 15) (Figure 1). Inhibition studies showed that cytochrome P450 2C9 (CYP2C9) is 
the major enzyme involved. 3’-Hydroxymethyl-MFA is further metabolized to form the 
3’-carboxy-MFA.  Zheng et al. showed that incubation of MFA with HLM in the 
presence of NAPDH and GSH resulted in the formation of GSH conjugates with m/z  
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563 and m/z 547 which were proposed to originate from quinoneimine and epoxide 
metabolites, respectively (16). A corresponding GSH conjugate, with m/z 561 when 
detected using negative electrospray ionization, was recently found in incubations of 
MFA with rat liver microsomes in the presence of GSH (17).  The specific enzymes 
involved in these oxidative bioactivation reactions and the structures of the GSH-
conjugates, however, have not yet been investigated. The conjugation of reactive 
quinoneimines to GSH can be spontaneous and/or mediated by glutathione S-
transferases (GSTs) (18). Because several human GSTs are known to be genetically 
polymorphic, interindividual variations in GSTs have been proposed as one of the 
factors determining susceptibility to adverse drug reactions (19, 20). For the 
structurally similar drug diclofenac,it has been shown that hGSTs play an important 
role in the inactivation of diclofenac quinoneimines (21). In a recent study, hGSTP1-1 
was shown to catalyze GSH conjugation which indicated the importance of hGST in the 
inactivation of quinoneimines (22). However, for MFA, the effect of other human 
hGSTs has not yet been reported. 
 
The aim of this study is to characterize the P450 dependent pathways that are 
involved in the oxidative bioactivation of MFA. To identify the specific P450s involved 
in bioactivation, incubations were performed with HLM, with and without isoenzyme-
specific inhibitors, and recombinant human P450 enzymes. To enable structural 
elucidation of the metabolites by NMR, the drug metabolizing cytochrome P450 BM3 
mutant CYP102A1 M11H was used to produce human relevant metabolites of MFA in 
large amounts (23-25). The role of a panel of seven human GSTs in the GSH 
conjugation of reactive quinoneimine metabolites was studied in incubations of MFA 
using drug-metabolizing bacterial P450 BM3 mutant (CYP102A1M11H) as 
bioactivation system.  
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Materials and methods 
 
Materials 
 
Human liver microsomes (HLM; Lot No. 0710619), pooled from 50 donors, were 
obtained from Xenotech (Lenexa, USA) and contained 20 mg protein/mL. Supersomes 
containing cDNA-expressed human cytochrome P450 enzymes were purchased from 
BD Biosciences (Breda, Netherlands). The enzymes used were CYP1A1(Lot No. 
35400), CYP1A2 (Lot No. 21667), CYP2A6 (Lot No. 33769), CYP3A4 (Lot No.38275), 
CYP3A5 (Lot No. 44743), CYP1B1 (Lot No. 26314), CYP2B6 (Lot No. 62543),CYP2C8 
(Lot No. 62556), CYP2C9*1(Arg144) (Lot No. 41274), CYP2C18 (Lot No. 
11301),CYP2C19 (Lot No. 62542), CYP2D6*1 (Lot No. 38273), CYP2E1 (Lot No. 
44748) and CYP2J2 (Lot.No. 456264). Cytochrome P450 BM3 mutant CYP102A1M11H 
was expressed and purified as described previously (24). MFA was purchased from 
Sigma Aldrich. Escherichia coli XL-1 Blue cells containing the expression plasmid for 
human GSTP1-1, M1-1, A1-1 was a kind gift from Prof. Mannervik (Department of 
Biochemistry and Organic chemistry, Uppsala University, Sweden). Expression 
plasmid for GST T1-1 was a kind gift from Prof. Hayes (Biomedical Research Centre, 
University of Dundee, Scotland, United Kingdom). All other chemicals and reagents 
were of analytical grade and obtained from standard suppliers. 
 
Construction of expression plasmids for hGST A2-2, hGST M2-2 and hGST 
 M3-3 
 
The coding region of GSTA2-2, GSTM2-2 and GSTM3-3 was amplified by polymerase 
chain reaction from human GST cDNA clones obtained from Origene, Rockville, USA 
(SC119650 for A2-2, SC119651 for M2-2, SC319401 for M3-3) using the following 
gene specific primers flanked by upstream restriction site NdeI and downstream site 
BamH1. 
GSTA2-2 (F) : 5’- GGA ATT CCA T ATG GCA GAG AAG CCC AAG CTC C - 3’  
GSTA2-2 (R) : 5’- CG GGA TCC  TTA AAA CCT GAA AAT CTT CCT TGA TTC -3’ 
GSTM2-2 (F) : 5’- GGA ATTC CAT ATGCCCATGACACTGGGGTAC-3’ 
GSTM2-2 (R) : 5’-CG GGA TCC  CTA CTT GTT GCC CCA GAC AGC CAT C -3’ 
GSTM3-3 (F) : 5’ -GGA ATTC CAT ATGTCG TGC GAG TCG TCT ATG G-3’ 
GSTM3-3 (R) : 5’-CG GGA TCC  TCA GCA TAC AGG CTT GTT GCC CC-3’ 
 
The amplified gene was subcloned into the NdeI and BamHI sites of the pET-20b(+) 
vector (Novagen, Madison, WI), and introduced into E. coli BL21(DE3). The subcloned 
cDNAs were confirmed by sequencing (Macrogen, Amsterdam, The Netherlands).  
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Expression and purification of hGST enzymes  
 
Human GST enzymes were expressed and purified as described previously (25). 
Protein concentrations were determined according to the method of Bradford (26) 
with reagent obtained from Bio-Rad. Purity of the enzymes was checked by SDS 
polyacrylamide gel electrophoresis on a 12% gel with Coomassie staining. The specific 
activity of the purified hGSTs was assayed according to Habig et al., (27) . The specific 
activities of the purified recombinant hGSTs using 1 mM CDNB as a substrate were: 
27.6 μmol/min/mg protein for GSTA1-1, 11.5 μmol/min/mg protein for GSTA2-2, 
58.9 μmol/min/mg protein for GSTM1-1, 35.7 μmol/min/mg protein for GSTM2-2, 4.2 
μmol/min/mg protein for GSTM3-3 and 47.7 μmol/min/mg protein for GSTP1-1. The 
specific activity of hGSTT1-1 was determined using 1,2-epoxy-3 
(pnnitrophenoxy)propane as a substrate as described (28) and was 1.83 
ɊȀȀotein. 
 
Incubation of MFA with HLM and recombinant human cytochrome P450s 
 
Incubations containing 100 ɊM MFA with and without 5 mM GSH were performed in 
100 mM potassium phosphate buffer (pH 7.4) at a final volume of 250 ɊL containing 2 
mg/ml HLM. Reactions were initiated by the addition of a NADPH regenerating system 
(0.5 mM NADPH, 20 mM glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate 
dehydrogenase, final concentrations) and performed for 60 min at 37 ºC.For 
bioactivation of MFA by recombinant human P450s, incubations were performed at a 
ͳʹͷɊͳͲͲȋ͹ǤͶȌǡ
ͳͲͲɊ	ȋȌǡͷ
ͶͷͲ
of 100 nM. Final DMSO concentrations in the incubations were always below 1%. For 
3 of the most active human CYPs (CYP1A2, CYP2C9, CYP3A4) and HLM, incubations 
were also performed as described above at low MFA concentration of 5 μM. Reactions 
were initiated by the addition of NADPH regenerating system and continued for 60 
min at 37 ºC.  All reactions were terminated by addition of an equal volume of ice-cold 
methanol containing 2% (v/v) of aqueous 50 mM ascorbic acid and centrifuged for 15 
min at 14000 rpm. The supernatants were analyzed by reversed-phase liquid 
chromatography and LC-MS/MS as described below.  
 
Inhibition of metabolite formation in incubations of MFA with pooled human 
liver microsomes by isoenzyme-specific inhibitors of P450s 
 
The contribution of individual human P450s to metabolite formation in incubation of 
MFA with pooled HLM was determined by performing incubations in the presence or 
absence of specific inhibitors of individual P450 enzymes. The final concentration of 
HLM was 2 mg/mL. Incubations were performed in 100 mM potassium phosphate  
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buffer (pH 7.4) and at a final volume of 100 μL. The concentration of MFA was 100 μM 
and the final concentration of DMSO in incubations was less than 1%. P450 selective 
inhibitors, furafylline (FURA,10 μM), ketoconazole (KTZ, 2 μM), sulfaphenazole (SPZ, 
10 μM) and quinidine (QND, 2 μM)  were used to investigate the involvement of 
CYP1A2, CYP3A4, CYP2C9 and CYP2D6 respectively (29-31). All inhibitors were 
dissolved in methanol and the final concentration of methanol in the incubations did 
not exceed 1%. Reactions were initiated by the addition of NADPH regenerating 
system and incubated for 60 min at 37 ºC. Incubations containing the mechanism-
based inhibitor FURA were first pre-incubated for 15 min in the presence of NADPH 
before addition of MFA. The reactions were terminated by the addition of 100 μL of 
ice-cold methanol containing 2% (v/v) of 50 mM aqueous ascorbic acid and 
centrifuged for 15 min at 14000 rpm. The supernatants were analyzed by HPLC and 
LC-MS/MS, as described in section 2.7. Control incubations without MFA were 
performed under the same conditions to ensure that the presence of inhibitors did not 
interfere with the quantification of formed metabolites.  
 
Bioactivation of 4’-OH and 5-OH mefenamic acid in the presence of GSH and 
human recombinant hGSTs 
 
Incubations in 100 mM potassium phosphate buffer (KPi buffer, pH 7.4) containing 4’-
OH-MFA or 5-OH-MFA (final concentration 50 μM) were performed using purified 
CYP102A1 M11H (20 nM) as bioactivation system in the presence of 0.1 mM GSH for 
60 minutes at 24 °C. The concentration of CYP102A1 M11H was chosen such that 
bioactivation rates similar to that of HLM (2 mg/ml) were obtained. Enzymatic GSH 

ͺɊ
(final concentration) of hGSTs A1-1, A2-2, M1-1, M2-2, M3-3, P1-1 or T1-1 to the 
incubations in the presence of 0.5 mM GSH. The reactions were initiated and stopped 
as described above. Samples were analyzed by an LC-MS method described below. 
 
Analytical methods 
 
The analyses of metabolites were performed by reversed-phase liquid 
chromatography on a Shimadzu HPLC equipped with two LC-20AD pumps, a SIL20AC 
ʹͲͷɊͳͺȋͶǤ͸ͳͷͲȌ
as stationary phase. For separation of parent compound and metabolites, a gradient 
method was used with two mobile phases: solvent A (1% acetonitrile, 99% water, 
0.2% formic acid) and solvent B (1% water, 99% acetonitrile, 0.2% formic acid). The 
first 5 min was isocratic at 20% solvent B. From 5 till 30 min the concentration of 
solvent B linearly increased to 100%, followed by linear decrease back to 20% until  
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30.5 min. Isocratic re-equilibration at 20% solvent B was maintained until 45 min. The 
flow rate was 0.5 mL/min and the detection was at 254 nm. For MS analysis, samples 
were analyzed by using an Agilent 1200 Series Rapid resolution LC system connected 
to a time-of-flight (TOF) Agilent 6230 mass spectrometer equipped with electrospray 
ionization (ESI) source and operating in the positive mode. The MS ion source 
parameters were set with a capillary voltage at 3500 V. Nitrogen was used as drying 
gas (10 L/min) and nebulizing gas (pressure 50 psig) at a constant gas temperature of 
350 °C. MS spectra were acquired using Agilent TOF system. Data analysis was 
performed using Agilent MassHunter Qualitative analysis software. For the product 
ion spectrum, samples were analyzed by automated MS/MS analysis using an Agilent 
1200 Series Rapid resolution LC system connected to a hybrid quadrupole-time-of-
flight (Q-TOF) Agilent 6520 mass spectrometer (Agilent Technologies, Waldbronn, 
Germany).  
 
Large scale incubation of MFA with cytochrome P450 BM3 mutant CYP102A1 
M11H 
 
To obtain the oxidative metabolites and major GSH conjugate MG1 of MFA on a 
preparative scale, large scale incubations were performed with CYP102A1 M11H as 
biocatalyst. A 20 mL reaction volume containing 250 nM purified CYP102A1 M11H, 
500 μM MFA, 5 mM GSH and an NADPH regenerating system (0.5 mM NADPH, 20 mM 
glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase) was prepared in 
100 mM potassium phosphate buffer pH 7.4. The reactions were allowed to continue 
for 4 h at 25°C. The reactions were terminated by adding an equal volume of ice cold 
methanol containing 2 % (v/v) of aqueous 50 mM ascorbic acid and centrifuged for 15 
min at 14000 rpm. After precipitation of the proteins, the sample was evaporated and 
reconstituted in 20% B. A series of 1 mL injections of the sample were loaded on a 
preparative HPLC column Luna 5 μm C18(2) column (250 mm x 10 mm i.d.) from 
Phenomenex (Torrance, CA, USA) which was initially equilibrated with 20% eluent B. 
A flow rate of 1.5 mL/min and a gradient using the eluent A (0.8% acetonitrile, 99% 
water, and 0.2% formic acid) and B (99% acetonitrile, 0.8% water, and 0.2% formic 
acid) was applied for separation of formed MFA metabolites. The first 10 min was 
isocratic at 20% eluent B: from 10 to 45 min, the percentage of eluent B increased 
linearly to 100% followed by linear decrease back to 20% until 45.5 min. Isocratic re-
equilibration at 20% solvent B was maintained until 60 min. Metabolites were 
detected using UV detection (254 nm) and collected by automated fraction collector. 
Collected fractions were first analyzed for purity and identity by the analytical HPLC 
and LC-MS/MS methods as described above. The samples were evaporated to dryness 
under a nitrogen stream and redissolved in 500 μL of methyl alcohol-d4. 1H-NMR- 
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analysis was performed on Bruker Avance 500 (Fallanden, Switzerland), equipped 
with cryoprobe. 1H-NMR measurements were carried out at 500 MHz. The structural 
assignment of the metabolites was done by using COSY spectrum. 
 
Quantification of isolated metabolites of mefenamic acid by 1H NMR 
 
To enable absolute quantification of the major metabolites of mefenamic acid by NMR, 
dimethyl formamide (DMF) was used as an internal standard. A final concentration of 
3.2 mM DMF was added to dmso-d6 solutions of M1, M2 and MG1 and analyzed by 1H 
NMR. All NMR data were acquired on Bruker 500 MHz spectrometer equipped with 5 
mm cryoprobe. DMF was selected as internal standard because its signals (singlets at 
2.73 ppm and 2.89 ppm corresponding to 2 methyl groups) do not interfere with the 
aliphatic proton signals of MFA metabolites. By integrating the signals of aliphatic 
methyl group protons of M1 [5H], M2 [6H] and MG1 [6H] and comparing to that of 
DMF ([6H]), the concentration of the metabolites were determined. Standard curves of 
3’-OH-MFA, 4’-OH-MFA and the major GSH conjugate were prepared using these 
solutions quantified by 1H NMR spectroscopy. The samples were analyzed by HPLC-
UV and LC-MS methods as described above. Linear standard curves were obtained for 
each of the metabolites by HPLC UV-ȋͲǤͷɊ-ͳͲͲɊȌ-ȋͲǤͲʹͲɊ-
ͳͲͲɊȌǤM2 and MG1 were used to estimate the amount of M3 
and minor GSH conjugates (MG2 and MG3) respectively as high amount of material 
could not be generated to enable NMR quantification. 
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Results 
 
Oxidative metabolism of MFA by HLM 
 
MFA was first incubated with HLM in the presence of NAPDH and GSH to identify all 
the oxidative metabolites and GSH conjugates. As shown in Figure 2A, incubation of 
MFA with HLM produced 3 metabolites (M1, M2, M3) with an m/z value of 258.11 
(Figure 2B) corresponding to mono-oxygenated products. The major product M1 
contributed to about 84 % of the total mono-hydroxylated product formed while M2 
and M3 accounted for about 13% and 3% respectively.  The major product of MFA 
formed by human P450s was previously identified as 3’-hydroxy-methyl-MFA (15, 32). 
 
As shown in Figure 2C, in the presence of 5 mM GSH, three GSH conjugates were 
observed with m/z values of 563, indicating the incorporation of both an oxygen atom 
and GSH into the MFA moiety. These products implicate the involvement of 
quinoneimine intermediates. The product ion spectrum of the major conjugate MG1 
showed the characteristic fragments arising from the cleavage of the GSH moiety such 
as the loss of glycine, loss of pyroglutamate, loss of GSH, cleavage between the 
cysteinyl C-S bond with charge retention on the aromatic moiety and further loss of a 
water molecule from the fragment ion (Supplementary Figure S1). 
 
Table 1 Oxidative metabolites and GSH conjugates formed in incubation of MFA with HLM and 
CYP102A1 M11H 
 
 
a Retention time tr  in minutes is based on HPLC-UV chromatogram  b Retention time tr  in minutes is based 
on MS analysis  c m/z values correspond to the singly protonated  molecule [(M+H)]+ 
 
 
Metabolites tr(min) Exact mass 
m/zc 
Elemental composition Proposed structure 
Oxidative 
metabolites a 
     
M1 21.58 258.117 C15H15NO3  MFA+O 
M2 
M3 
23.35 
23.68 
258.117 
258.117 
C15H15NO3 
C15H15NO3 
 MFA+O 
MFA+O 
 
GSH-conjugates b 
     
MG1 16.41 563.189 C25H31N4O9S  MFA+O+SG 
MG2 15.97 563.189 C25H31N4O9S  MFA+O+SG 
MG3 15.27 563.189 C25H31N4O9S  MFA+O+SG 
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Figure 2.A. Representative HPLC chromatogram obtained after incubation of mefenamic acid (100 μM) 
with human liver microsomes (2 mg/ml) in presence of NADPH and reduced glutathione (GSH). B.  
Extracted ion chromatogram (EIC) at m/z 258.11 of mono-hydroxylated metabolites C. Extracted ion 
chromatogram (EIC) at m/z 563.18 of GSH conjugates  
 
 
The product ion spectrum of MG1 was identical to the GSH conjugate observed by 
Zheng et al.,(2007) which was attributed to GSH conjugation to a quinoneimine 
metabolite.  However, it was not yet elucidated which ring of MFA was bioactivated to 
the quinoneimine. The product ion spectrum of the two minor GSH conjugates is 
shown in Supplementary Figure S2. The product ions with m/z 244, m/z 444 and 
m/z 519 show that the GSH conjugates MG2 and MG3 are most likely to be derived 
from 5-OH-MFA pathway, corresponding to aromatic hydroxylation on carboxy 
phenyl ring. These two minor conjugates were not reported previously in the study of 
Zheng et al. (2007). 
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Figure 3. A. Representative HPLC chromatogram obtained after incubation of mefenamic acid (500 μM) 
with CYP102A1 in presence of NADPH and reduced glutathione (GSH). S1, S2 and S3 denote secondary 
oxidation products with m/z 274 , m/z 272 and m/z 256 respectively. B. Extracted ion chromatogram (EIC) 
at m/z 258.11 of mono-hydroxylated metabolites C. Extracted ion chromatogram (EIC) at m/z 563.18 of 
GSH conjugates 
 
Large scale production of MFA metabolites by CYP102A1 M11H and structural 
elucidation by NMR 
 
Incubation of CYP102A1 M11H with MFA resulted in the formation of all relevant 
metabolites as observed in HLM incubation (Figure 3). The retention times and the 
fragmentation patterns of the products formed by CYP102A1 M11H and HLM were 
identical (Table 1). In addition, three metabolites with m/z values of 274 (S1), 272 
(S2) and 256 (S3) were observed in the CYP102A1 M11H incubation, possibly due to 
secondary oxygenation and dehydrogenation. In the case of CYP102A1 M11H 
incubation, M1 contributed to about 20% of the total mono-hydroxylated product 
formed whereas M2 and M3 contributed to about 70% and 10% respectively. 
Although the product ratio of the hydroxylated metabolites was different between 
CYP102A1 M11 and HLM, cytochrome P450 BM3 mutant was highly active and 
converted more than 70% of MFA to the oxidative metabolites. 
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As shown in Figure 3C, CYP102A1 M11H was also able to produce all 3 human 
relevant GSH conjugates, with the highest production of the major GSH conjugate 
MG1. The retention time and fragmentation pattern of the GSH conjugates were 
identical to those observed in HLM incubations. Large scale incubations were 
performed using CYP102A1 M11H as biotransformation system to generate the 
metabolites on large scale for the structural information of the metabolites by NMR.  
The 1H NMR spectrum of M1 was identical to that of 3’-OH-methyl MFA, as previously 
described (33). The 1H NMR spectra of M2 and M3, showed that the two benzylic 
methyl groups were unchanged implicating that the hydroxylation has taken place on 
any one of the aromatic rings.  
 
Table 2. 1H NMR  shifts of aromatic region for the mefenamic acid metabolites M2, M3 and 
major glutathione conjugate MG1 formed by CYP102A1 M11H. 
 
Proton 4’-OH-MFA (M2) 5-OH-MFA (M3) 
(MG1) 
 
2’-CH3 2.12(1H,s) 2.17(1H,s) 2.13(1H,s) 
 
3’-CH3 2.18(1H,s) 2.32(1H,s) 2.26(1H,s) 
 
4’-H - 7.09(1H,d) 
J=7.9Hz 
- 
 
 
5’-H 6.88 (1H,d) 
J=8.5 Hz 
7.03(1H,t) 
J= 7.7 Hz 
- 
 
 
6’-H 6.67 (1H,d) 
J=8.5 Hz 
 
6.92(1H,d) 
J=7.3 Hz 
7.22 (1H,s) 
3-H 6.41 (1H,d) 
J=8.2 Hz 
 
6.74(1H,d) 
J=8.8 Hz 
6.48(1H,d) 
J=8.5 Hz 
 
4-H 7.11(1H,ddd) 
J=8.5, 7.6, 1.6 Hz 
6.83(1H,dd) 
J=8.9, 3.0 Hz 
7.25(1H,ddd) 
J=8.8, 6.9, 1.6 Hz 
 
5-H 6.57(1H,t) 
J=7.6 Hz 
- 6.63(1H,t) 
J=7.6 Hz 
 
6-H 7.91(1H,dd) 
J=7.9, 1.6 Hz 
7.42(1H,d) 
J=2.8 Hz 
 
7.94(1H,dd) 
J=7.9, 1.6 Hz 
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Figure 4. Comparison of aromatic regions of  1H HMR spectrum of  A. 4’-OH-MFA B. Major GSH 
conjugate  4’-OH-5’-(glutathion-S-yl)-MFA (MG1)  formed via 4’-OH pathway. 
 
The aromatic region of 1H NMR spectrum of M2 showed 6 signals with an integral of 6 
protons. The presence of a doublet of doublet signal with ortho coupling of 7.9 Hz and 
meta coupling of 1.6 Hz corresponding to proton H-6 in the carboxy phenyl ring, 
indicated that protons H-5 and H-4 were still present (Table 2). Also the presence of 
doublet of doublet of doublet multiplicity pattern (ddd) with 2 ortho couplings and 
one meta coupling corresponding to H-4 was found. This indicates that the hydroxyl 
group is localized on the dimethyl phenyl ring. The aromatic protons of this ring were 
assigned with help of COSY spectra (Supplementary Figure S3). The presence of 
doublets at 6.88 and 6.67 ppm with strong ortho couplings corresponding to H-5’ and 
H-6’, respectively and the absence of a signal corresponding to H-4’ indicated that the 
metabolite M2 results from hydroxylation at 4’ position on the dimethyl phenyl ring. 
Metabolite M3, which is also hydroxylated on an aromatic ring, did not show the 
characteristic meta and ortho coupling arising from H-6, clearly showing that the 
hydroxylation took place on the carboxy phenyl ring. The H-6 proton of metabolite M3 
is strongly shifted 0.5 ppm up-ȋɁ͹ǤͶʹȌ
pattern  from a double doublet (dd) to a doublet (d) with a coupling constant of 2.8 Hz  
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corresponding to a meta coupling. Also, H-4 proton showed only one ortho coupling 
and one meta coupling indicating that proton H-5 was not present anymore 
confirming that the position of hydroxylation was C-5 thus assigning M3 to be 5-OH-
MFA. 
 
Figure 4B shows the aromatic region of 1H NMR spectra of the major GSH conjugate 
MG1 isolated by preparative HPLC from the large scale incubation. The signal at 7.94 
ppm corresponding to H-6 proton gives rise to doublet of doublet with both ortho and 
meta coupling with the neighbouring protons. This confirms that the major GSH 
conjugate formed is via the hydroxylation on dimethyl phenyl ring. Comparison of the 
1H NMR spectrum of 4´-OH-MFA and the GSH conjugate MG1 clearly shows all signals 
from carboxy phenyl ring protons were identical (Figure 4). Additionally, the 
dimethyl phenyl ring showed only a singlet from one proton. Based on COSY spectra, 
this proton was assigned to be H-6’ (Supplementary Figure S4). This further 
confirms that the addition of GSH has taken place at C-5’ position in the dimethyl 
phenyl ring. Therefore the major GSH conjugate was assigned as 4´-hydroxy-5´-
glutathionyl-MFA (4´-OH-5´-GS-MFA) which can be rationalized by GSH-conjugation of 
MFA-1',4'-quinoneimine (MFA-1',4'-QI). NMR characterization of the minor GSH 
conjugates was not possible because of the low amount of products formed. However, 
incubation of purified 5-OH-MFA with HLM and GSH resulted in the formation of both 
MG2 and MG3 (Supplementary Figure S5). This indicates that these two GSH 
conjugates are derived from MFA-2,5-quinoneimine (MFA-2,5-QI) which is formed by 
secondary oxidation of 5-OH-MFA. 
 
Metabolism and bioactivation of MFA by recombinant P450s 
 
To investigate the contribution of individual human cytochrome P450 enzymes to the 
identified metabolites of MFA, incubations were performed with Supersomes 
containing human recombinant P450s at MFA concentration of 100 μM. Figure 5 
shows the activities relative to the most active CYP. The major metabolite of MFA, M1, 
was produced mainly by CYP2C9 and to a lesser extent by CYP2C19 (Figure 5A). The 
relative rates of the formation of 4’-OH-MFA and the major GSH adduct MG1 from 4’-
OH pathway with respect to the most active P450 is shown in Figure 5B. CYP1A2 and 
CYP2C9 showed the highest activity, forming almost equal amounts of 4’-OH-MFA 
followed by CYP1A1 and CYP3A4 to a lesser extent. CYP1A2 showed the highest 
activity for MG1 which results from the addition of GSH to MFA-1',4'-QI. CYP2C9 also 
produced MG1, however the amount of MG1 formed by CYP1A2 was higher than that 
of CYP2C9, suggesting that CYP1A2 may catalyze the second oxidation step more 
efficiently.  
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Figure 5C shows the relative rates of the formation of 5-OH-MFA and the minor GSH 
adducts resulting from MFA-2,5-QI. CYP1A2 catalyzed the formation of 5-OH MFA 
followed by CYP3A4, CYP2C19 and CYP1A1. The formation of minor GSH conjugates 
derived from the 5-OH pathway was also predominantly catalyzed by CYP1A2 
(Supplementary Figure S6) and to a relatively lower extent by CYP 3A4 and CYP 1A1 
(Figure 5B). Similar results were also obtained when incubations were performed at 
	ȋͷɊȌͶͷͲ
CYP1A2, 2C9 and 3A4 (Figure 5D,E,F). As shown in Figure 5D, the formation of M1 
was primarily catalyzed by CYP 2C9. CYP1A2 was the major P450 isoform involved in 
the bioactivation pathway forming the highest amount of MG1 (Figure 5E) as well as 
in the formation of M3 (Figure 5F). 
 
3.4.Inhibition of oxidative metabolism of MFA by HLM by P450-specific 
inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Effect of CYP450 inhibitors on the metabolism of mefenamic acid (MFA) by HLM to A. 4’-OH 
mefenamic acid (4’-OH-MFA) and major GSH conjugate MG1 formed via the 4’-OH quinone imine pathway 
B. A. 5-OH mefenamic acid (5-OH-MFA) and minor GSH conjugates MG2 and MG3 formed via the 5-OH-
quinone imine pathway. Data are expressed as % of control activity and represent mean of duplicate 
determinations. 
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Incubations of MFA with HLM were performed with P450 isoenzyme-specific 
inhibitors to test the effect of the inhibitors on the formation of M2, M3 and the GSH 
conjugates (MG1, MG2 and MG3) formed by the respective quinoneimine pathways. 
Figure 6 shows the effect of P450 isoenzyme selective inhibitors on the formation of 
4’-OH and 5-OH-MFA and their corresponding GSH conjugates.The results obtained 
are expressed as percentage of activity of the control HLM incubation in which no 
inhibitor was added. As shown in Figure 6A, addition of the CYP2C9-inhibitor SPZ 
resulted in the highest amount of inhibition (75%) for the formation of 4’-OH-MFA, 
followed by the CYP1A2-inhibitor FUR. FUR and SPZ inhibited the formation of the 
major GSH conjugate MG1 to almost similar extent which is consistent with the results 
obtained with recombinant P450s.  
 
For the formation of 5-OH-MFA (M3) and the corresponding GSH conjugates derived 
from this pathway, addition of FUR inhibited formation of M3, MG2 and MG3 about 
70% (Figure 6B). The results from the inhibition studies was consistent with the 
results obtained with the recombinant P450 incubations indicating that CYP1A2 and 
CYP2C9 play an important role for the 4’-OH pathway while CYP1A2 is the main 
isoform for the 5-OH pathway. 
 
Human glutathione S-transferases mediated inactivation of mefenamic acid 
quinoneimines 
 
In order to study the effect of human glutathione S-transferases in the inactivation of 
the quinoneimine intermediates of MFA, incubations were performed with 4’- and 5-
OH-MFA in the presence of one of the 7 hGSTs and cytochrome P450 M11 as 
bioactivation system. As shown in Figure 7A, using 4’-OH-MFA as a substrate, 
ͺɊ
ͳǤ͵– 1.5 
fold increase compared to the non-enzymatic formation of MG1. This increase in GSH 
conjugation is moderate in comparison to structurally comparable 4’-OH-diclofenac  
which showed much higher GSH conjugation in the presence of hGSTs (21). This may 
be attributed to the fact that the non-enzymatic glutathione conjugation is higher for 
MFA than diclofenac. 
 
For 5-OH-MFA, GSH conjugate formation from MFA-2,5-QI was significantly increased 
by the addition of the different hGSTs. Consistent with previous study, hGSTP1-1 
showed the highest increase (about 8.5 fold) towards the formation of GSH conjugates 
in comparison to the non-enzymatic conjugation (22). The addition of hepatic hGSTs 
A2-2 and M1-1 also resulted in 3.5-4 fold increase towards the formation of GSH 
conjugates from 5-OH pathway (Figure 7B). 
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Figure 7. ͺɊ-S-transferases in the inactivation of A. MFA-1’4’-quinoneimine 
B. MFA-2,5-quinoneimine 
 
Discussion 
 
Several recent studies have demonstrated that the carboxylic acid-containing NSAID 
MFA can be bioactivated by phase 2-enzymes to a variety of protein-reactive acylating 
metabolites, such as MFA-1-O-G, MFA-AMP, MFA-CoA and MFA-GSH (1, 12). The 
formation of protein adducts from these acylating agents have been suggested to play 
a role in the onset of the idiosyncratic toxicities of MFA, which include hepatic and 
renal toxicity and hypersensitivity reactions (8, 34, 35). Although GSH-conjugates 
derived from oxidative bioactivation of MFA have been detected previously (16, 17), 
the structures of the reactive intermediates and the P450s involved have not yet been 
characterized. Therefore, the aim of the present study was to characterize the P450-
dependent bioactivation of MFA to quinoneimines and their inactivation by human 
glutathione S-transferases in more detail. 
 
Consistent with previous studies, the major P450 mediated oxidative metabolite 
formed by HLM was found to be 3’-OH-methyl-MFA (15, 32). In addition to 3’-OH-
methyl-MFA, 4'-OH-MFA (M2) and 5-OH-MFA (M3) were identified as metabolites 
resulting from aromatic hydroxylation, Figure 2. These two hydroxylated MFA-
metabolites can be bioactivated by dehydrogenation to reactive quinoneimines, as has  
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been previously reported for drugs like diclofenac, meclofenamic acid, glafenine, 
lumiracoxib (36-39). For the structurally related NSAIDs diclofenac and meclofenamic 
acid, several GSH conjugates have been identified that result from GSH-conjugation to 
the quinoneimines formed via the 4’-OH- and 5-OH-hydroxylation pathways (38, 40). 
Zheng et al., previously reported the formation of one GSH adduct of MFA with m/z 
563 which was tentatively assigned to a reactive quinoneimine metabolite (16).  In the 
present incubations with HLM and recombinant P450s, three GSH conjugates with 
m/z value of 563 could be detected that can be explained by GSH-conjugation to 
reactive quinoneimine metabolites. The major conjugate MG1 with m/z 563 was 
unequivocally identified by 1H NMR as a GSH-conjugate formed from MFA-1',4'-QI 
(Figure 4). The two minor GSH conjugates MG2 and MG3 with m/z 563, which were 
not identified previously, were identified as regioisomeric GSH-conjugates derived 
from MFA-2,5-QI. Formation of GSH conjugates with m/z 547 which were reported by 
Zheng et al., was not observed in our incubations of MFA with HLM and recombinant 
P450s. This may be explained by the higher sensitivity of the multiple reaction 
monitoring method used. The extremely low levels of these products may question the 
toxicological relevance of the short-lived epoxide intermediates of MFA. 
 
A proposed mechanism for the formation of the major GSH conjugate as well as the 2 
minor GSH conjugates is depicted in Figure 8.  The first step involves the oxidation on 
either one of the aromatic rings to yield 4’-OH-MFA or 5-OH-MFA. This is followed by 
a P450 mediated dehydrogenation of 4’-OH-MFA or 5-OH-MFA that results in the 
corresponding reactive quinoneimines. As shown in Figure 5, the incubations of MFA 
with recombinant human P450s showed that both CYP1A2 and CYP2C9 catalyze the 
formation of 4’-OH-MFA while the GSH conjugate MG1 was formed at higher amounts 
by CYP1A2 compared to CYP2C9. Pooled HLM inhibition studies with P450 selective 
inhibitor showed that both CYP2C9 and CYP1A2 inhibited the formation of MG1 to 
almost equal amounts (Figure 6). This may be due to the relatively higher abundance 
of CYP2C9 compared to CYP1A2 in human liver (41, 42). Aromatic oxidation to 5-OH 
and the formation of GSH conjugates MG2 and MG3 was mainly catalyzed by CYP1A2. 
Previously, it was shown that MFA inhibited phenacetin O- deethylation catalyzed by 
CYP1A2 with IC50 value < 10 μM, indicating that it has a high affinity for CYP1A2 (43). 
However, prior to this study, there is no information available about the involvement 
of CYP1A2 or other human P450s in the bioactivation pathway of MFA. CYP2C9 is 
polymorphic in human population (44) and polymorphic variants of CYP2C9 have 
been shown to exhibit differences in metabolic clearance for NSAIDs (45). 
Additionally, CYP1A2 is an inducible P450 enzyme (46) and therefore variations in 
CYP1A2 and CYP2C9 enzyme activities between individuals can be a risk factor for 
adverse drug reactions caused by MFA. 
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Figure 8. Proposed bioactivation pathway of mefenamic acid in HLM mediated via quinone imine pathway. 
Dashed arrows indicate the shifting of metabolic pathway towards bioactivation due to CYP2C9 
polymorphism or CYP1A2 enzyme induction. 
 
 
Quinoneimines formed from the diphenyl amine moiety of NSAIDs have been shown 
to play an important role in hepatotoxicity (47).  In the present study, the capacity of 
human hGSTs to inactivate MFA quinoneimines was also studied. Based on our study, 
the major GSH pathway towards the formation of 4’-OH-5’-SG-MFA was not 
significantly increased by the addition of hGSTs consistent with previous report (22). 
However, the minor GSH pathway towards the formation of 5-OH-4/6-SG-MFA was 
significantly increased by the addition of hepatic hGSTs A1-1, A2-2 and M1-1 and P1-
1. For the total GSH conjugation, hGST P1-1 was found to be the most active GST 
catalyzing the formation of GSH conjugates. A recent study reported that among the 
human hepatic drug metabolizing enzymes, hGST A1 and A2 enzymes were shown to 
exhibit one of the highest differences in expression among individuals (48). Therefore, 
polymorphism of cytochrome P450s at the bioactivation level combined with 
interindividual variations in the hGST expression at the detoxification level may be a 
potential risk factor in susceptibility to adverse drug reactions. Although hGSTP1 is 
expressed in low quantities in liver, it has high extrahepatic tissue expression. For 
example, hGSTP1-1 is highly expressed throughout the gastrointestinal (GI) tract with 
a slight decrease of expression from stomach to colon (49). Apart from hepatotoxicity, 
MFA has also been associated with GI tract toxicity (4, 5, 50). Therefore, reduced 
protective effect of hGSTP1 due to genetic polymorphism may be an aggravating 
factor for the adverse effects. The contribution of MFA quinoneimines to MFA induced  
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toxicity still remains to be established in cellular context. Cellular toxicity studies 
using transgenic knock out models lacking a specific hGST or P450 can provide more 
insights into the mechanism of bioactivation/bio-inactivation. 
 
 In conclusion, MFA undergoes P450-mediated aromatic ring hydroxylation as a minor 
pathway which is subsequently involved in bioactivation to two different reactive 
quinoneimines and formation of MFA-GSH conjugates in human liver microsomes. The 
major GSH conjugate was found to be arising from the 4’-OH quinoneimine pathway 
and subsequent GSH conjugation on C-5’ position. Our study shows that in addition to 
other Phase II metabolites, reactive quinoneimines formed from aromatic 
hydroxylation of MFA and reduced hGST activity may also contribute to the adverse 
effects of MFA. 
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Supplemental Data 
 
 
 
Figure S1. Product ion spectra of the major GSH conjugate MG1 (m/z 563) formed via quinoneimine 
pathway obtained after incubation of HLM with 5 mM glutathione.   
 
 
 
 
Figure S2: Product ion spectra of the minor GSH conjugates A. MG3 and B. MG2 (m/z 563) formed via 
quinoneimine pathway obtained after incubation of HLM with 5 mM glutathione.   
184
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Figure S3: COSY spectrum of 4’-OH-MFA (M2) 
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Figure S4: COSY spectrum of 4’-OH-5’-SG-MFA (MG1) 
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Figure S5: Extracted ion chromatogram (EIC) of m/z 563.18 obtained from incubations of human liver 
microsomes (2 mg/mL) with A. 4’-OH-MFA and  B. 5-OH-MFA. The GSH conjugates MG1 and MG2, MG3 are 
labelled. 
 
 
 
 
Figure S6: HPLC chromatograms showing mefenamic acid metabolites formed in vitro by CYP1A2 (lower 
trace) and CYP1A2 in the presence of GSH (upper trace).100 ɊM MFA was incubated for 60 minutes with 
100 nM of CYP1A2. M1 (3’-OH-methyl-MFA) M2 (4’-OH-MFA) M3 (5-OH-MFA). MG1 is the major GSH 
conjugate derived from 4’-OH pathway. MG2 and MG3 are GSH conjugates derived from 5-OH pathway. 
Background peak ‘X’ was also present in the control incubations.  
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Summary, Conclusions And Perspectives 
 
Summary 
 
The application of enzymes as biocatalysts in chemical and pharmaceutical industry 
has gained considerable importance over the years. Enzymes are capable of catalyzing 
a wide range of reactions with high selectivity under mild conditions. Oxidative 
biocatalysts are especially of great significance because of the ease with which they 
are capable of catalyzing many reactions including the selective oxidation of 
unactivated C-H bond (1, 2). Regio- and stereoselective oxidation of compounds 
ranging from fine chemicals to drug like compounds is of high value in the chemical 
industry. This thesis covers the potential of cytochrome P450 BM3 mutants for 
metabolite production for different applications. 
 
The main goal of this thesis was to engineer bacterial cytochrome P450 BM3 enzyme 
for regio- and stereoselective hydroxylation of fine chemicals, steroids and drugs. 
Novel site-directed mutants specific for different applications have been developed. 
Mutants M01 and M11 which were generated prior to this study (3), were used as 
templates for additional site-directed mutagenesis of active site residues guided by 
computational modelling of the active site of P450 BM3. The engineered P450 BM3 
mutants mimicking human liver mcirosomes were used for the synthesis of drug 
metabolites for toxicological studies. Additionally, engineered P450 BM3 mutants 
were used for the large scale production of GSH conjugates to enable structural 
elucidation by NMR and for bioactivation of drugs to study the effect of human 
glutathione-S-transferases.  
 
The work described in chapters 2, 3 and 4 of this thesis was performed as a part of an 
IBOS project titled “Biocatalytic exploitation of monooxygenases” (BIOMOX). The aim 
of this part was to engineer and characterize P450 BM3 enzymes for selective 
oxidation of fine chemicals and steroids. The last 3 chapters (5, 6 and 7) describe the 
use of engineered cytochrome P450 BM3 variants for drug metabolite production and 
their potential use in toxicological studies. 
 
Chapter 1 gives a general introduction to the various scientific aspects covered in this 
thesis. In this chapter, the potential of oxidative biocatalysts and in particular 
monooxygenases is discussed. Cytochrome P450s are a class of heme-dependent 
mono-oxygenases which metabolize more than 75 % of the drugs in the market. 
Although human P450s are widely known for their biotransformation of xenobiotic 
compounds, their use at preparative scale is limited because of their low stability and 
membrane bound nature. Microbial P450s are soluble and easier to express and 
therefore are an attractive alternative for metabolite synthesis compared to their  
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human counterparts (4). Protein engineering of bacterial P450s and specifically P450 
BM3 has proved to be an excellent means to broaden their substrate scope, specificity 
and to improve their activity. Recent examples of protein engineering from literature 
to illustrate the tuning of bacterial P450s for selective oxidations are discussed in this 
chapter (5, 6).  
 
 The preparative scale synthesis and isolation of drug metabolites is of utmost 
importance in light of the recent regulatory guidelines of FDA (7). There is a growing 
need to find green alternatives for synthesis of drug metabolites (8). The optimization 
of P450 BM3 for improved production of drug metabolites is also discussed in this 
chapter. Apart from the metabolism of drugs, P450s are also involved in 
bioactivation reactions leading to the formation of toxic reactive intermediates. 
These reactive metabolites can lead to covalent modifications of proteins thus 
resulting in adverse drug reactions. Development of effective methods for detection 
and structural elucidation of reactive metabolites early in drug development is 
important for the development of safer drugs (9). Different strategies employed for 
reactive metabolite and glutathione (GSH) conjugates generation are discussed in this 
chapter. The conjugation of a reactive metabolite to GSH can be spontaneous or 
catalyzed by human glutathione-S-transferases (hGSTs) (10). The role of hGSTs in the 
detoxification of the reactive metabolites by catalyzing GSH conjugation reactions is 
also covered in this chapter. 
  
 
Figure 1. Examples of compounds used in this thesis as substrates for engineered P450 BM3 
variants 
 
Enzymes capable of selective oxidation of fine chemicals are of high value in the 
chemical industry (11). Ƚ-ionone and its hydroxylated variants have organoleptic 
properties and are of commercial interest in the flavour and fragrance industry. In 
chapter 2, a library of P450 BM3 mutants was screened for their potential to 
selectively hydroxylate Ƚ-ionone. Initial screening with racemic Ƚ-ionone revealed 
that mutants M01 A82W, M11 A82W and M11 V87I selectively hydroxylated Ƚ-ionone  
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at C-3 with trans stereoselectivity while mutants of M11 with mutation at 437 position 
formed almost equal amounts of both cis and trans diastereomers of 3-OH-Ƚ-ionone. 
Interestingly, incubation with individual enantiomers (6R)- and (6S)-Ƚ-ionone showed 
that the mutant M11 L437N showed opposite stereoselectivity resulting in the 
formation of (3S,6R)-OH and (3S,6S)-OH-Ƚ-ionone respectively with >90% d.e. One of 
the mutants tested M11 V87F L437N showed moderate selectivity (40%) for the 
formation of (3R, 6S)-OH diastereomer which could be used as a starting template for 
further optimization.Docking studies identified the importance of residue at position 
82 in the stereoselective hydroxylation of Ƚ-ionone enantiomers. These engineered 
P450 BM3 mutants with high total turnover numbers can be used for preparative 
scale oxidation of small molecules like Ƚ-ionone. 
 
In chapter 3, the potential of Rhodococcus erythropolis as a host for P450 BM3 
mediated whole cell biocatalysis was explored using norandrostenedione (nordione) 
as a model substrate. The wildtype Rhodococcus strain breaks down steroids because 
ͻȽ-hydroxylase and 3-ketosteroid dehydrogenase activities, thus hampering its 
use as a host for steroid bioconversion. By distrupting the genes encoding these 
catabolic enzymes, several mutants of Rhodococcus erythropolis do not degrade 
steroids. One such mutant RG9 was used in this chapter to heterologously express 
P450 BM3 mutant M02 and study the biotransformation of nordione. P450 BM3 
variant M02 has been shown to convert steroids with high selectivity and therefore 
was chosen for this study. Using in vitro biotransformation, the structure of the 
product was first determined by NMR to be 16-Ⱦ-OH-nordione. The BM3 variant M02 
was then heterologously expressed in RG9 and the biotransformation was studied. 
About 0.35 g/L of the product was formed which corresponded to the product 16-Ⱦ-
OH-nordione formed in vitro. Therefore, the product conversion in RG9 is P450 BM3 
mediated. This study shows that the combination of mutant Rhodococcus strain and a 
highly active engineered P450 BM3 variant is a promising option for whole cell 
biocatalysis. 
 
In chapter 4, a semi-rational approach was used to identify the key active site 
residues involved in the binding of testosterone in P450 BM3. Residues 72, 82, 87 and 
437 were identified to have an effect on the binding orientation of testosterone. A 
minimal library consisting of combinatorial single and double mutations at these 
residues was constructed. At the time of this study, P450 BM3 mutants capable of 
hydroxylation of only A or D ring on the Ⱦ-face of testosterone were reported. 
Screening of the minimal library revealed that two mutants were able to produce a 
new metabolite which was not reported before. One of these BM3 mutants, M01 
A82W S72I was to used to scale up the reaction and the new metabolite was identified  
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by a combination of HPLC co-elution, GC-MS and NMR analysis to be 16-Ƚ-hydroxy-
testosterone. The introduction of S72I mutation led to about four fold decrease in the 
catalytic activity in comparison to its parent M01 A82W. Nevertheless, this mutant 
could invert the stereoselectivity of testosterone C-16 hydroxylation by only one 
mutation. The parent mutant M01 A82W was known to catalyze C-16 hydroxylation 
with 100% Ⱦ-enantioselectivity. Introduction of this mutation in another 16-Ⱦ-
hydroxylase variant M11 V87I also resulted in a similar change in enantioselectivity. 
In-silico modelling studies provided insights into active site interactions responsible 
for this change in selectivity. By replacing the polar serine with a hydrophobic 
isoleucine at position 72, the hydrogen bond formation with the A-ring carbonyl group 
of testosterone which was necessary for 16-Ⱦwas removed. In addition, 
different rotamers of isoleucine showed steric hindrance of its side chain with 
testosterone bound in a conformation suitable for 16-Ⱦ hydroxylation. This study 
showed that small differences in the key substrate interaction residues in P450 BM3 
can have a profound effect on the stereoselectivity of hydroxylation. 
 
In chapter 5, the applicability of P450 BM3 mutants for the generation of human 
relevant metabolites of fenamic acid NSAIDs was studied. A library of mutants was 
screened with meclofenamic acid to identify catalytically active and selective mutants. 
Mutants of M11 with isoleucine and phenylalanine at position 87 were found to 
selectively hydroxylate at benzylic and aromatic positions of meclofenamic acid. 
Engineered P450 BM3 variants were used as biocatalysts to enable structural 
elucidation of metabolites by NMR. The isolated metabolites were found to be 3’-
hydroxy-methyl, 4’-hydroxy and 5-hydroxy-meclofenamic acid. These mutants were 
also found to hydroxylate structurally similar compounds mefenamic acid and 
tolfenamic acid with high selectivity and total turnover numbers ranging from 4000-
6000. It was found that while both mefenamic acid and meclofenamic could undergo 
benzylic as well as aromatic hydroxylation by engineered P450 BM3 variants, 
tolfenamic acid was hydroxylated only on aromatic rings. Computational studies 
helped to rationalize the observed aromatic ring selectivity of P450 BM3 mediated 
hydroxylation. The enzymatically synthesized metabolites can be used as references 
for cellular studies as well as for further toxicological evaluation. 
 
In chapter 6, engineered P450 BM3 mutants and human liver microsomes were used 
for the in vitro bioactivation of drugs like clozapine, acetaminophen and diclofenac to 
their corresponding reactive metabolites in order to study the ability of four allelic 
variants of hGSTP1-1, namely hGSTP1*A (Ile105/Ala114), hGSTP1*B 
(Val105/Ala114), hGSTP1*C (Val105/Val114) and hGSTP1*D (Ile105/Val114), to 
catalyze the GSH conjugation of the reactive metabolites. Differences in activity  
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between the proteins could not be attributed to a general decrease in catalytic 
efficiency. Rather, the differences reflected the effect of residue 105 and 114 specific 
for any given substrate. Single substitutions at residue 105 or 114 did affect the ability 
to catalyze GSH conjugation. However, when both residue 105 and 114 were 
substituted the effect could be enhanced or diminished. Based on the results in this 
chapter, we suggest that the binding orientation of substrates in the active site of 
GSTP1 mutants is changed and has effect on GSH conjugation.   
 
Chapter 7 describes the use of cytochrome P450 BM3 as a tool to bioactivate 
mefenamic acid (MFA) to reactive benzoquinoneimine intermediates and for the 
structural elucidation of the GSH conjugates. The high activity of BM3 mutant M11 
resulted in the convenient large scale production and isolation of the major GSH 
conjugate. The structure of the major conjugate was elucidated by NMR analysis and 
was found to be derived from MFA-1’,4’- quinoneimine followed by subsequent GSH 
conjugation at 6’ position. Two more minor conjugates were found to be derived from 
the MFA-2,5-quinoneimine pathway. MFA was incubated with fourteen different 
recombinant human CYPs to elucidate enzymes responsible for its bioactivation. 
While P450 mediated benzylic hydroxylation was catalyzed by CYP 2C9, the aromatic 
hydroxylation leading to the formation of 1’,4’-quinoneimine and the major GSH 
conjugate was catalyzed by both CYP 1A2 and CYP2C9. The formation of 5-OH-MFA 
and the minor GSH conjugates was mainly catalyzed by CYP1A2. Inhibition of 
metabolite formation by addition of selective inhibitors of individual CYP enzymes to 
human liver microsomes incubations confirmed these results. Since P450 BM3 could 
bioactivate MFA to the same human relevant intermediates, it was used as a tool to 
study the bioactivation and subsequent inactivation of the reactive quinoneimines by 
glutathione-S-transferases. The effects of a panel of seven major recombinant human 
GSTs on the formation of GSH conjugates of MFA were studied. The formation of the 
major GSH conjugate was not significantly increased by the addition of hGSTs. 
However, the formation of minor conjugates was catalyzed by hGSTs, in particular the 
addition of hGST P1-1 led to a ten-fold increase in the formation of one of the 
regioisomeric conjugates derived from 5-OH pathway.  
 
Conclusions  
 
During the last ten years, several labs around the world have worked on developing 
novel mutants of cytochrome P450 BM3 for a variety of applications (6). In the 
beginning, focus was laid on selective oxidation of small molecules and aromatics 
which over the years has shifted to exploit the catalytic potential of P450 BM3 
enzymes for pharmaceutical applications (12) and novel reactions like  
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cycloproponation and C-H amination not known thus far for P450s (13, 14). Figure 2 
summarizes the powerful tool of protein engineering used in context of P450 BM3 and 
the various novel applications of the engineered P450 BM3 variants. 
 
 
Figure 2. The figure shows protein engineering approach (top panel), and applications of 
engineered P450 BM3 mutants (bottom panel). Pictures depicting the various approaches to 
engineer P450s are taken from references (15-18). Pictures depicting the applications of the 
engineered variants were reproduced from references (13, 19-22). The general template of this 
figure is adapted from (18). 
 
 
Future prospectives based on this thesis 
 
Some aspects described in this thesis that be applied in future studies are discussed 
below. 
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Chimeragenesis as an approach for B or C ring steroid hydroxylation  
 
The regio- and stereoselectivity of P450-mediated reactions depends upon the 
orientation of the substrate relative to the reactive iron-oxo species, which is in turn 
determined by the active-site configuration of the P450 enzyme. (23). P450 BM3 
mutants engineered by combinatorial saturation mutagenesis or alanine scanning 
mutagenesis can perform only A or D ring hydroxylation of steroids (16, 24). It still 
remains a challenge to achieve B or C ring hydroxylation such as 6Ⱦ-hydroxy-
testosterone which is the major human metabolite of testosterone. These 
observations reiterate the fact that more rigorous methods may be required to re-
shape the active site to enable B or C ring hydroxylation. One approach is to create 
chimera of cytochrome P450s by domain swapping or by scanning chimeragenesis 
which has been successfully employed to for other substrates (15, 25). For example, in 
a recent study, the substrate recognition sites of insect CYP4C7, which hydroxylates 
farnesol at the terminal C12 position with high selectivity but low activity, were 
introduced into P450BM3 to yield successful chimeras capable of producing 12-
hydroxy-farnesol not observed with wild-type P450BM3(15). 
 
Computational and structural studies 
 
In chapters 2 and 4, we show that in silico docking studies can provide insights into 
the structural rationalization of the experimentally observed regio- and 
stereoselective hydroxylation  Ƚ-ionone and testosterone. In these studies, 
computational methods were used to identify critical residues involved in substrate 
recognition and to rationalize the experimentally observed selectivity. More recently, 
free energy calculations were applied to study the stereoselective hydroxylation of Ƚ-
ionone enantiomers by engineered BM3 mutants (26). In chapter 5 of this thesis, the 
regioselective benzylic and aromatic hydroxylation of fenamic acid NSAIDs is 
described. In silico modelling studies were used to get preliminary insights into the 
ring preference of fenamic acid hydroxylation by P450 BM3 mutants. In future studies, 
the observed benzylic and aromatic hydroxylation selectivity in different mutants can 
be further rationalized in extensive molecular dynamics (MD) simulation based 
studies by including protein plasticity and induced fit effects. This will be in line with 
the previous studies in which it was shown that predicting the effect of P450 BM3 
small active site mutations on regio-or stereoselectivity of substrates was found to be 
difficult based on (rigid) docking and scoring only (27). Moreover, crystallization of 
the selective P450 BM3 variants in the ligand bound and ligand free forms can 
potentially help to unravel the conformational changes caused by the mutation and 
get insights into the structural basis of selective oxidation. 
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Engineered P450 BM3 as a bioactivation tool in mammalian cellular studies 
 
The detection of the possible bioactivation pathways of drugs to reactive metabolites 
in early stage drug discovery is often difficult because of the problem of characterizing 
low levels of reactive metabolites. Therefore, efficient methods for the generation and 
characterization of reactive metabolites are necessary (28). In chapter 6 and 7, P450 
BM3 mutants are used as biocatalytic tools to generate high amounts of reactive 
intermediates. Recently, Boerma et.al used engineered P450 BM3 mutants to generate 
protein adducts resulting from the bioactivation of many drugs (29). Moreover, 
engineered P450 BM3 mutant F87V which metabolized arachidonic acid only to 14,15- 
epoxyeicosatrienoic acid (14,15-EET) was transfected in  pig renal epithelial cell lines 
(LLCPKcl4) as a tool to study the role of arachidonic acid epoxygenase pathway. The 
stable transfectants of of LLCPKcl4 cells with P450 BM3 mutant F87V as well as empty 
vector-transfected LLCPKcl4 cells were used to investigate the cell survival effects of 
endogenously produced 14,15-EET (20, 30). These studies exemplify the diverse 
applicability of engineered P450 BM3 which can be extended to mammalian cellular 
toxicity models in future. 
 
To summarize, engineered P450 BM3 mutants have been shown to have the potential 
as biocatalysts for metabolite production with possible applications ranging from 
biotechnology to toxicology. Combinatorial active site mutations have been effective 
to improve the selectivity of the reactions as well as to understand the structure-
function relationship of P450 BM3 reflected by the synergy between the experimental 
and computational studies. Moreover, the combination of P450 BM3 variants with 
other enzymes has led the development of a potential study system that can be 
applied for the large scale generation of reactive metabolites for structural elucidation 
as well as a versatile tool to study the interplay between Phase I and Phase II enzymes.  
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De toepassing van enzymen als biokatalysatoren in de chemische en farmaceutische 
industrie is door de jaren van steeds groter belang geworden. Enzymen kunnen 
uiteenlopende reacties katalyseren met hoge selectiviteit en onder milde 
omstandigheden. Oxidatieve biokatalysatoren zijn vooral van groot belang vanwege 
het gemak waarmee ze vele reacties kunnen katalyseren waaronder de selectieve 
oxidatie van niet geactiveerde C-H bindingen (1, 2). Regio- en stereoselectieve 
oxidaties van verbindingen zoals fijnchemicaliën en (kandidaat)geneesmiddelen met 
behulp van biokatalysatoren is van grote waarde voor de chemische industrie omdat 
deze reacties soms moeilijk toegankelijk zijn met organische synthese. Dit proefschrift 
beschrijft de mogelijkheden van cytochroom P450 BM3 mutanten voor 
metabolietproductie met verschillende toepassingen. 
 
Het belangrijkste doel van het onderzoek dat in dit proefschrift wordt beschreven is 
om het bacteriële cytochroom P450 BM3 enzym te optimaliseren voor regio- en 
stereoselectieve hydroxylering van fijnchemicaliën, steroïden en geneesmiddelen. 
Verschillende nieuwe mutanten specifiek voor verschillende toepassingen zijn 
ontwikkeld. Mutanten M01 en M11,  gegenereerd vóór deze studie (3), werden 
gebruikt als basis voor verdere mutagenese aan de hand van een computermodel van 
P450 BM3. P450 BM3 mutanten die de selectiviteit van menselijke levermicrosomen 
nabootsen werden gebruikt voor de synthese van metabolieten van geneesmiddelen 
voor toxicologisch onderzoek. Bovendien werden de ontwikkelde P450 BM3 
mutanten gebruikt voor de grootschalige productie van GSH-conjugaten, zodat de 
structuur hiervan kon worden opgehelderd met behulp van NMR.  Daarnaast werden 
deze mutanten gebruikt om het rol van humane glutathion-S-transferases in de 
inactivatie van reactieve metabolieten te bestuderen. 
 
Het werk beschreven in de hoofdstukken 2, 3 en 4 van dit proefschrift werd 
uitgevoerd in het kader van het NWO-IBOS project getiteld " Biocatalytic exploitation 
of monooxygenases" (BIOMOX). Het doel van dit project was het ontwerpen en 
karakteriseren P450 BM3 enzymen voor selectieve oxidatie van fijnchemicaliën en 
steroïden. De laatste 3 hoofdstukken (5, 6 en 7) beschrijven het gebruik van 
cytochroom P450 BM3 varianten voor de productie van geneesmiddelmetabolieten en 
de mogelijke toepassingen in toxicologische studies. 
 
Hoofdstuk 1 geeft een algemene inleiding op de verschillende onderdelen die in dit 
proefschrift worden beschreven. In dit hoofdstuk wordt het potentieel van oxidatieve 
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biokatalysatoren en in het bijzonder monooxygenases besproken. Cytochroom P450's 
vormen een klasse van heem-afhankelijke mono-oxygenasen die meer dan 75% van 
de geneesmiddelen op de markt metaboliseren. Hoewel de menselijke P450 algemeen 
bekend staan om rol in de biotransformatie van lipofiele lichaamsvreemde stoffen, is 
het gebruik van deze membraan-gebonden enzymen voor biosynthese op 
preparatieve schaal beperkt vanwege hun lage stabiliteit en relatief lage specifieke 
activiteit. Microbiële P450's zijn oplosbaar en gemakkelijker te expresseren en dus 
een aantrekkelijk alternatief voor metaboliet synthese vergeleken met hun menselijke 
tegenhangers (4). Eiwit optimalisatie van bacteriële P450's, en in het bijzonder P450 
BM3, heeft bewezen een uitstekend middel te zijn om het substraat gebied en 
specificiteit te verbreden en om de activiteiten te verbeteren. In dit hoofdstuk worden 
verschillende recente voorbeelden gegeven van selectieve oxidatieve biokatalysatoren 
die door middel van optimalisatie van bacteriële P450 zijn verkregen (5, 6). 
 
De synthese op preparatieve schaal en de isolatie van geneesmiddelmetabolieten is 
van groot belang in het licht van de recente richtlijnen van de FDA en EMA die 
voorschrijven dat ook geneesmiddel metabolieten op hun veiligheid worden getest 
(7). Er is verder een groeiende behoefte aan groene alternatieven voor de synthese 
van geneesmiddelmetabolieten (8). De optimalisatie van P450 BM3 voor de 
verbeterde productie van geneesmiddelmetabolieten wordt ook besproken in dit 
hoofdstuk. Naast het metabolisme van geneesmiddelen tot stabiele producten zijn 
P450's betrokken bij bioactiveringsreacties die leiden tot de vorming van zeer 
reactieve, potentieel toxische intermediairen. Deze reactieve metabolieten kunnen 
leiden tot covalente binding aan eiwitten hetgeen leidt tot bijwerkingen. Ontwikkeling 
van effectieve methoden voor detectie en structuuropheldering van reactieve 
metabolieten vroeg in de ontwikkeling van geneesmiddelen is belangrijk voor de 
ontwikkeling van veiligere geneesmiddelen (9). Verschillende strategieën die worden 
gebruikt voor de generatie van reactieve metabolieten en analyse van glutathion 
(GSH) conjugaten worden besproken in dit hoofdstuk. De conjugatie van een reactieve 
metaboliet met GSH kan spontaan plaatsvinden of gekatalyseerd worden door 
glutathion-S-transferases (GSTs) (10). Voorbeelden van de rol van menselijke GSTs in 
de detoxificatie van de reactieve metabolieten worden ook behandeld in dit hoofdstuk. 
 
Enzymen die in staat zijn tot selectieve oxidatie van fijne chemicaliën zijn van hoge 
waarde voor    ȋͳͳȌǤ Ƚ-Ionon en gehydroxyleerde varianten 
hebben organoleptische eigenschappen en zijn van commercieel belang in de smaak 
en geur-industrie. In het in Hoofdstuk 2 beschreven onderzoek werd een bibliotheek 
 ͶͷͲ ͵       Ƚ-ionon stereo- en 
regioǤ ´Ƚ-ionon bleek 
dat mutanten M01 A82W, M11 en ͳͳ ͺʹ ͺ͹ Ƚ-ionon regioselectief 
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hydroxyleren op de C-3 positie met trans stereoselectiviteit terwijl mutanten van M11 
met mutatie op positie 437 vrijwel gelijke hoeveelheden vormen van zowel cis en 
trans diastereomeren van 3-OH-Ƚ-ionon. Interessant is dat uit incubatie met 
afzonderlijke enantiomeren (6R)- en (6S)-Ƚ-ionon bleek dat de mutant M11 L437N 
tegengestelde stereoselectiviteit vertoonde resulterend in de vorming van (3S, 6R)-OH 
en (3S, 6S)-OH-Ƚ-ionone respectievelijk bij >90% d.e. M11 V87F L437N, een van de 
geteste mutanten, vertoonde matige selectiviteit (40%) voor de vorming van (3R, 6S)-
OH diastereomeer; deze mutant zou gebruikt kunnen worden als uitgangspunt voor 
verdere optimalisatie. Door middel van computational docking onderzoek werd het 
belang van residu 82 voor      Ƚ-ionon 
enantiomeren aangetoond. Deze P450 BM3 mutanten met hoge omzettingsgetallen 
         Ƚ-ionon op 
preparatieve schaal. 
 
In Hoofdstuk 3 werd het potentieel van Rhodococcus erythropolis als gastheer voor 
P450 BM3 gemedieerde hele cel biokatalyse onderzocht met norandrostenedione 
(nordione) als modelsubstraat. De wild-type stam van Rhodococcus erythropolis 
breekt steroïden af   ͻȽ-hydroxylase en 3-ketosteroid dehydrogenase 
activiteiten, wat het gebruik als gastheer voor steroid bioconversie belemmert. Door 
de genen die coderen voor deze katabole enzymen te ontregelen, zijn verschillende 
stammen van Rhodococcus erythropolis gegenereerd die niet meer in staat zijn 
steroïden te af te breken. Een van deze stammen, RG9, werd in dit hoofdstuk gebruikt 
om P450 BM3 mutant M02 heteroloog te expresseren en de biotransformatie van 
nordione te onderzoeken. Deze P450 BM3 mutant werd geselecteerd omdat het 
steroïden omzet met hoge regioselectiviteit; nordione wordt door deze mutant 
selectief gehydroxyleerd tot 16-Ⱦ-OH-nordione zijn. Door BM3 M02 heteroloog tot 
expressie te brengen in RG9 kon ongeveer 0,35 g/L van het product 16-Ⱦ-OH-
nordione in hele cellen werd gevormd. Deze studie toont aan dat de combinatie van 
een mutant Rhodococcus stam en een zeer actieve P450 BM3 variant een 
veelbelovende optie is voor de hele cel biokatalyse. 
 
In Hoofdstuk 4 werd een rationele benadering gebruikt om de belangrijke aminozuur 
residüen te identificeren die betrokken bij de binding en oriëntatie van testosteron in 
het katalytische centrum van P450 BM3. Residuen 72, 82, 87 en 437 bleken belangrijk 
te zijn voor de bindingsoriëntatie van testosteron. Een kleine bibliotheek bestaande 
uit enkele en combinaties van dubbele mutaties van deze residuen werd 
samengesteld. Ten tijde van dit onderzoek, waren alleen  P450 BM3 mutanten bekend 
die testosteron hydroxyleren aan  Ⱦ-zijde van de A of D ring. Screening van deze 
bibliotheek onthulde twee mutanten die een nieuw, niet eerder beschreven product 
vormen. Een van deze mutanten BM3 M01 A82W S72I werd gebruikt om dit product 
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op semipreparatieve schaal te produceren. Met behulp van NMR en door vergelijking 
met de chromatografische eigenschappen en massaspectrum van de referentie-
verbinding kon het nieuwe product werd geïdentificeerd  als 16-Ƚ-hydroxy-
testosteron, hetgeen de eerste keer is dat hydroxylering aan de Ƚ-zijde van testosteron 
is aangetoond. Hieruit blijkt dat door slechts een enkele aminozuur substitutie in M01 
A82W, dat C-ͳ͸   ͳͲͲΨ Ⱦ-enantioselectiviteit katalyseert, de 
stereoselectiviteit van testosteron 16-hydroxylering verandert van 16-Ⱦ- naar 16-Ƚ-
hydroxylering. Introductie van dezelfde mutatie in een ander 16-Ⱦ-hydroxylase, M11 
V87I, resulteerde ook in dezelfde verandering in enantioselectiviteit. In-silico studies 
gaven inzicht in welke aminozuur interacties mogelijk verantwoordelijk zijn voor deze 
verandering in selectiviteit. Door het polaire aminozuur serine te veranderen in het 
hydrofobe isoleucine op positie 72 werd een waterstofbrug met de A-ring carbonyl-
groep van testosteron, noodzakelijk voor 16 Ⱦ-hydroxylatie, verwijderd. Bovendien 
bleek er sprake van sterische hindering met de verschillende rotameren van 
isoleucine, wanneer testosteron is gebonden in de   ͳ͸ Ⱦ-
hydroxylatie. Deze studie toonde aan dat kleine verschillen in de belangrijkste 
residüen voor substraat interactie in P450 BM3 een groot effect op de 
stereoselectiviteit van hydroxylering kunnen hebben. 
 
In Hoofdstuk 5 werd de toepasbaarheid van de P450 BM3 mutanten voor de productie 
van de humaan relevante metabolieten van fenaminezuur NSAIDs bestudeerd. Een 
bibliotheek van mutanten werd gescreend met meclofenamic acid als substraat om 
katalytisch actieve en regioselectieve mutanten te identificeren. Mutanten van M11 
met isoleucine en fenylalanine op positie 87 bleken in staat tot selectieve 
hydroxylering op de benzylische en aromatische posities van meclofenamic acid. De 
meest geschikte P450 BM3 mutanten werden gebruikt voor opschaling van 
metaboliet-productie om structuuropheldering door middel van NMR mogelijk te 
maken. De geïsoleerde metabolieten bleken 3'-hydroxy-methyl, 4'-hydroxy en 5-
hydroxy-meclofenamic acid te zijn. Deze mutanten bleken ook in staat de structureel 
vergelijkbare verbindingen, mefenamic en tolfenamic acid,  met hoge selectiviteit en 
omzettingsnummers variërend van 4000-6000 te hydroxyleren. Computationele 
studies werden uitgevoerd om de waargenomen regioselectiviteit van de 
hydroxyleringsreacties van de P450 BM3 mutanten te rationaliseren. Deze 
enzymatisch geproduceerde metabolieten kunnen worden gebruikt voor 
toxicologische evaluaties in cellulaire studies. 
 
In Hoofdstuk 6 werden P450 BM3 mutanten en menselijke levermicrosomen gebruikt 
voor de in vitro bioactivatie van de geneesmiddelen clozapine, paracetamol en 
diclofenac naar hun overeenkomstige reactieve metabolieten.  Met behulp van deze 
bioactivatiesystemen werd het activiteit van vier allelische varianten van het 
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menselijke glutathione transferase GSTP1-1 in de inactivering van deze reactieve 
metabolieten onderzocht. De allelische varianten die werden onderzocht waren 
hGSTP1* A (Ile105 / Ala114), hGSTP1*B (Val105 / Ala114), hGSTP1*C (Val105 / 
Val114) en hGSTP1*D (Ile105 / Val114). Uit dit onderzoek bleek dat de verschillen in 
vermogen tot inactivatie van de reactieve metabolieten van de onderzochtte 
geneesmiddelen relatief beperkt waren. Uit het feit dat de mutaties tot verschillende 
verhoudingen van de regioisomeren van GSH-conjugaten leiden, blijkt dat 
bindingsoriëntatie van reactieve metabolieten in het katalytische centrum van GSTP1 
mutanten is veranderd. 
 
Hoofdstuk 7 beschrijft het gebruik van cytochroom P450 BM3 mutanten voor de 
bioactivatie van mefenamic acid (MFA) tot reactieve benzoquinoneïmine 
intermediairen en voor de structurele opheldering van de GSH-conjugaten. De meest 
actieve BM3 mutant M11 werd gebruikt voor de grootschalige productie en isolatie 
van het voornaamste GSH conjugaat. De structuur van dit conjugaat werd opgehelderd 
door NMR-analyse en bleek afkomstig te zijn van MFA-1',4'quinoneimine gevolgd door 
GSH conjugatie op de 6-positie. Twee kwantitatief minder belangrijke conjugaten 
bleken te zijn afgeleid uit de MFA-2,5-quinoneimine bioactivatie route. MFA werd 
geïncubeerd met veertien verschillende recombinante humane CYP enzymen om de 
enzymen die verantwoordelijk zijn voor zijn bioactivatie op te helderen. De P450 
gemedieerde benzylische hydroxylering bleek te worden gekatalyseerd door CYP 2C9, 
terwijl de aromatische hydroxylering die leidt tot de vorming van 1',4'-quinoneimine 
en grote GSH conjugaat werd gekatalyseerd door zowel CYP1A2 en CYP2C9. De 
vorming van 5-OH-MFA en de zijn GSH-conjugaten bleek voornamelijk te worden 
gekatalyseerd door CYP1A2. Remming van metabolietvorming door toevoeging van 
selectieve remmers van individuele CYP enzymen aan humane levermicrosomen 
incubaties bevestigden deze resultaten. Na identificatie van de bij bioactivatie 
betrokken humane P450s werd de activiteit van zeven recombinant humane GST’s in 
de inactivatie van de reactieve metabolieten van MFA bestudeerd. De vorming van de 
GSH-conjugaten die worden gevormd via de 5-OH-route,  bleek zeer sterk te worden 
gekatalyseerd door de GSTs.  Vervolgstudies zijn nodig om het belang van erfelijkheid 
van de beschermende GSTs in de incidenteel voorkomende levertoxiciteit van MFA te 
onderzoeken. 
 
Samengevat, P450 BM3 mutanten blijken potentieel te hebben als biokatalysatoren 
voor metabolietproductie met mogelijke toepassingen van biotechnologie tot 
toxicologie. Combinatorische mutaties in het katalytisch centrum zijn effectief om de 
selectiviteit van een reactie verbeteren, evenals om de structuur-functie relatie van 
P450 BM3 beter te begrijpen,  gereflecteerd door de synergie tussen de experimentele 
en computationele studies. Bovendien heeft de combinatie van P450 BM3 varianten 
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met andere enzymen geleid tot de ontwikkeling van een mogelijk nieuw onderzoek 
systeem dat kan worden toegepast voor de grootschalige productie van reactieve 
metabolieten voor structuuropheldering en als een veelzijdig instrument om de 
wisselwerking tussen fase I en fase II enzymen te bestuderen. 
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